Therapeutic	Format	Suffix	CH1 Isotype	VD LC	Highest_Clin_Trial (Jan '20)	Est. Status	Heavy Sequence	Light Sequence	Heavy Sequence (if bispec)	Light Sequence (if bispec)	100% SI Structure	99% SI Structure	95-98% SI Structure	Year Proposed	Year Recommended	Target	Companies	Conditions Approved	Conditions Active	Conditions Discontinued	Development Tech	Notes
Abagovomab	Whole mAb	-omab	G1	Kappa	Phase-III	Discontinued	QVKLQESGAELARPGASVKLSCKASGYTFTNYWMQWVKQRPGQGLDWIGAIYPGDGNTRYTHKFKGKATLTADKSSSTAYMQLSSLASEDSGVYYCARGEGNYAWFAYWGQGTTVTVSS	DIELTQSPASLSASVGETVTITCQASENIYSYLAWHQQKQGKSPQLLVYNAKTLAGGVSSRFSGSGSGTHFSLKIKSLQPEDFGIYYCQHHYGILPTFGGGTKLEIK			None	None	None	2006	2007.0	CA125	Menarini			Ovarian cancer;Pancreatic cancer 		
Abelacimab	Whole mAb	-imab	G1	Lambda	Unknown	Unknown	QVQLLESGGGLVQPGGSLRLSCAASGFTFSTAAMSWVRQAPGKGLEWVSGISGSGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRATAVYYCARELSYLYSGYYFDYWGQGTLVTVSS	QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNDVSWYQQLPGTAPKLLIYKNYNRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYAWDQRQFDVVFGGGTKLTVL			None	None	6r8x:CB	2018	2019.0	F11	Novartis		Thromboembolism			
Abituzumab	Whole mAb	-zumab	G2	Kappa	Phase-II	Active	QVQLQQSGGELAKPGASVKVSCKASGYTFSSFWMHWVRQAPGQGLEWIGYINPRSGYTEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCASFLGRGAMDYWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKAPKLLIYYTSKIHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQGNTFPYTFGQGTKVEIK			None	None	None	2013	2014.0	ITGAV	Merck		Systemic scleroderma 	Colorectal cancer;Ovarian cancer;Prostate cancer;Solid tumours 		4o02 claims to be abituzumab (17E6), but is not
Abrezekimab	Fab	-imab	G1	Kappa	Phase-I	Discontinued	QVTLKESGPVLVKPTETLTLTCTVSGFSLTNYHVQWIRQPPGKALEWLGVMWSDGDTSFNSVLKSRLTISRDTSKSQVVLTMTNMDPVATYYCARDGTIAAMDYFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCLASEDISNYLAWYQQKPGKAPKLLIYHTSRLQDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGYRFPLTFGGGTKVEIK			None	None	None	2017	2018.0	IL13	UCB			Asthma		
Abrilumab	Whole mAb	-umab	G2	Kappa	Phase-II	Discontinued	QVQLVQSGAEVKKPGASVKVSCKVSGYTLSDLSIHWVRQAPGKGLEWMGGFDPQDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLKSEDTAVYYCATGSSSSWFDPWGQGTLVTVSS	DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFANYYCQQANSFPWTFGQGTKVEIK			None	None	None	2014	2015.0	α4β7	Amgen;AstraZeneca			Crohn's disease;Ulcerative colitis 		
Acapatamab	Bispecific scFv	-amab	na;na	Kappa;Lambda	TBC	Active	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAIISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIK	EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS	QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL	None;None	None;None	None;None	2020		FOLH1;CD3E	TBC	TBC	TBC	TBC		
Actoxumab	Whole mAb	-umab	G1	Kappa	Phase-III	Active	QVQLVESGGGVVQPGRSLRLSCAASGFSFSNYGMHWVRQAPGKGLEWVALIWYDGSNEDYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWGMVRGVIDVFDIWGQGTVVTVSS	DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQHKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGQGTKVEIK			None	None	None	2012	2013.0	Toxin A	Bristol-Myers Squibb;Merck;University of Massachussets Medical School			Clostridium difficile	Medarex HuMAb Mouse	
Adalimumab	Whole mAb	-umab	G1	Kappa	Approved	Active	EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK			6cr1:HL/4nyl:AB:CD:EF:HL	3wd5:HL	None	1999	2000.0	TNFA	Abbvie;MedImmune	Ankylosing spondylitis;Behcet's syndrome;Crohn's disease;Hidradenitis suppurativa;Juvenile rheumatoid arthritis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis;Rheumatoid arthritis;Spondylarthritis;Ulcerative colitis;Uveitis 	Pyoderma 	Interstitial cystitis 	CAT Phage Display	
Adebrelimab	Whole mAb	-imab	G4	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGRIGPNSGFTSYNEKFKNRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGSSYDYFDYWGQGTTVTVSS	DIVLTQSPASLAVSPGQRATITCRASESVSIHGTHLMHWYQQKPGQPPKLLIYAASNLESGVPARFSGSGSGTDFTLTINPVEAEDTANYYCQQSFEDPLTFGQGTKLEIK			None	None	None	2019		PDL1	Jiangsu Hengrui Medicine		Solid tumours;Carcinoma			
Aducanumab	Whole mAb	-umab	G1	Kappa	Phase-III	Discontinued	QVQLVESGGGVVQPGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWFDGTKKYYTDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDRGIGARRGPYYMDVWGKGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK			6cnr:HL/6co3:HL	None	None	2013	2014.0	APP	Biogen;Neurimmune			Alzheimer's disease 		
Afasevikumab	Whole mAb	-umab	G1	Kappa	Phase-I	Active	EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGGFGEFYWNFGLWGRGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK			6ppg:HL:AB	None	None	2015	2016.0	IL17A	NovImmune;Genentech		Inflammation	Autoimmune disorders		
Afutuzumab	Whole mAb	-zumab	G1	Kappa	Approved	Active	QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS	DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK			3pp3:HL:IK/3pp4:HL	None	None	2008	2011.0	MS4A1	GLYCART Biotechnology;Biogen Idec;Chugai Pharmaceutical;Dana-Farber Cancer Institute;Genentech;Lymphoma Academic Research Organisation;Nippon Shinyaku;OHSU Knight Cancer Institute;Pharmacyclics;Polish Myeloma Consortium;Roche;Thomas Jefferson University;University of Heidelberg;University of Leeds	Chronic lymphocytic leukaemia;Follicular lymphoma;Non-Hodgkin's lymphoma	Diffuse large B cell lymphoma;CNS cancer;Graft-versus-host disease;Lupus nephritis;Mantle-cell lymphoma;Waldenstrom's macroglobulinaemia	Primary biliary cirrhosis	GlycoMAb Technology	Obinutuzumab and Afutuzumab are the same mAb
Alacizumab	di-Fab	-zumab		Kappa	Phase-II	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATITSGGSYTYYVDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCVRIGEDALDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDIAGSLNWLQQKPGKAIKRLIYATSSLDSGVPKRFSGSRSGSDYTLTISSLQPEDFATYYCLQYGSFPPTFGQGTKVEIK			None	None	None	2007	2008.0	KDR	UCB			Non-small cell lung cancer 		
Alemtuzumab	Whole mAb	-zumab	G1	Kappa	Approved	Active	QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIK			1bey:HL/1ce1:HL	None	None	2000	2001.0	CD52	Bayer HealthCare Pharmaceuticals Inc.;Dana-Farber Cancer Institute;German CLL Study Group;Ohio State University Comprehensive Cancer Center;Sanofi;Sanofi Oncology;University of Cologne;University of Cambridge	Chronic lymphocytic leukaemia;Multiple sclerosis 	Lymphoma;T-cell prolymphocytic leukaemia 	Rheumatoid arthritis;Diffuse large B cell lymphoma;Graft-versus-host disease;Sezary syndrome;T-cell lymphoma 		
Alirocumab	Whole mAb	-umab	G1	Kappa	Approved	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFNNYAMNWVRQAPGKGLDWVSTISGSGGTTNYADSVKGRFIISRDSSKHTLYLQMNSLRAEDTAVYYCAKDSNWGNFDLWGRGTLVTVSS	DIVMTQSPDSLAVSLGERATINCKSSQSVLYRSNNRNFLGWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTTPYTFGQGTKLEIK			None	None	None	2012	2013.0	PCSK9	Regeneron Pharmaceuticals;Sanofi;University Hospital Inselspital	Hypercholesterolaemia;Hyperlipoproteinaemia type IIa;Atherosclerosis	Coronary artery disease		VelocImmune Mouse	
Alnuctamab	Bispecific mAb with Domain Crossover	-amab	G1;G1	Kappa;Lambda	TBC	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSDNAMGWVRQAPGKGLEWVSAISGPGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVLGWFDYWGQGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSDEYLSWYQQKPGQAPRLLIHSASTRATGIPDRFSGSGSGTDFTLAISRLEPEDFAVYYCQQYGYPPDFTFGQGTKVEIK	EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS	QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL	None;None	None;None	None;None	2020		TNFRSF17;CD3E	TBC	TBC	TBC	TBC		
Alsevalimab	Whole mAb	-imab	G1	Kappa	Phase-I	Active	QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPSLRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNQFDPWGQGTLVTVSS	EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIK			None	None	None	2019		VTCN1	Five Prime Therapeutics		Solid tumours			
Amatuximab	Whole mAb	-ximab	G1	Kappa	Phase-II	Active	QVQLQQSGPELEKPGASVKISCKASGYSFTGYTMNWVKQSHGKSLEWIGLITPYNGASSYNQKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDYWGSGTPVTVSS	DIELTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPGRFSGSGSGNSYSLTISSVEAEDDATYYCQQWSKHPLTFGSGTKVEIK			None	4f33:BA:DC:FE:HG/4f3f:BA	None	2010	2011.0	MSLN	Eisai Co Ltd;Morphotek;National Cancer Institute (USA)		Mesothelioma	Pancreatic cancer;Solid tumours 		
Amivantamab	Bispecific mAb	-amab	G1	Kappa;Kappa	Phase-I	Active	QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS	AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK	QVQLVQSGAEVKKPGASVKVSCETSGYTFTSYGISWVRQAPGHGLEWMGWISAYNGYTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDLRGTNYFDYWGQGTLVTVSS	DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWFQHKPGKAPKLLIYAASSLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPITFGQGTRLEIK	None;None	None;None	None;None	2019	2020.0	EGFR;MET	Genmab;Janssen Research & Development		Non-small cell lung cancer			
Andecaliximab	Whole mAb	-ximab	G4	Kappa	Phase-III	Active	QVQLQESGPGLVKPSETLSLTCTVSGFSLLSYGVHWVRQPPGKGLEWLGVIWTGGTTNYNSALMSRFTISKDDSKNTVYLKMNSLKTEDTAIYYCARYYYGMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQDVRNTVAWYQQKPGKAPKLLIYSSSYRNTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYITPYTFGGGTKVEIK			5th9:HL:IM:JN	None	None	2016	2017.0	MMP9	Gilead Sciences		Gastric cancer;Solid tumours;Glioblastoma	Chronic obstructive pulmonary disease;Crohn's disease;Cystic fibrosis;Rheumatoid arthritis;Ulcerative colitis		
Anetumab	Whole mAb ADC	-umab	G1	Lambda	Phase-II	Active	QVELVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQAPGKGLEWMGIIDPGDSRTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGQLYGGTYMDGWGQGTLVTVSS	DIALTQPASVSGSPGQSITISCTGTSSDIGGYNSVSWYQQHPGKAPKLMIYGVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYDIESATPVFGGGTKLTVL			None	None	None	2013	2014.0	MSLN	Bayer HealthCare;ImmunoGen;MorphoSys;National Cancer Institute (USA) 		Lung cancer;Mesothelioma;Ovarian cancer;Pancreatic cancer;Solid tumours;Non-small cell lung cancer	Non-small cell lung cancer 	MorphoSys HuCAL Phage Display	
Anifrolumab	Whole mAb	-umab	G1	Kappa	Phase-III	Active	EVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLESMGIIYPGDSDIRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAWYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLTITRLEPEDFAVYYCQQYDSSAITFGQGTRLEIK			4qxg:HL	None	None	2013	2014.0	IFNAR1	Medarex;Medical University of Vienna;MedImmune		Systemic lupus erythematosus;Lupus nephritis;Rheumatoid arthritis	Scleroderma	Medarex UltiMAb Mouse	
Anrukinzumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGFTFISYAMSWVRQAPGKGLEWVASISSGGNTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLDGYYFGFAYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASESVDNYGKSLMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPWTFGGGTKVEIK			None	None	None	2007	2008.0	IL13	Pfizer;Wyeth			Asthma;Ulcerative colitis		
Apamistamab	Whole mAb Radiolabelled	-amab	G1	Kappa	Phase-III	Active	EVKLLESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPTSSTINFTPSLKDKVFISRDNAKNTLYLQMSKVRSEDTALYYCARGNYYRYGDAMDYWGQGTSVTVSS	DIALTQSPASLAVSLGQRATISCRASKSVSTSGYSYLHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPFTFGSGTKLEIK			None	None	None	2018	2019.0	PTPRC	Actinium Pharmaceuticals;Fred Hutchinson Cancer Research Center		Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma	Hodgkin's disease;Non-Hodgkin's lymphoma		
Apitegromab	Whole mAb	-omab	G4	Lambda	TBC	Active	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLLVRFLEWSHYYGMDVWGQGTTVTVSS	QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVHWYQQLPGTAPKLLIYSDNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGVFGGGTKLTVL			None	None	6umx:hl	2020		pro-GDF-8	TBC	TBC	TBC	TBC		
Aprutumab	Whole mAb ADC	-umab	G1	Lambda	Phase-I	Discontinued	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGTSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVRYNWNHGDWFDPWGQGTLVTVSS	QSVLTQPPSASGTPGQRVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYENYNRPAGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSSWDDSLNYWVFGGGTKLTVL			None	None	None	2016	2017.0	FGFR2	Bayer			Solid tumours		
Ascrinvacumab	Whole mAb	-umab	G2	Kappa	Phase-II	Active	QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGEYYWNWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARESVAGFDYWGQGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGTSSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGQGTRLEIK			None	None	None	2015	2016.0	ACVRL1	Duke University Medical Center;Fondazione IRCCS Istituto Nazionale dei Tumori;Pfizer;Suzhou Kintor Pharmaceuticals		Age-related macular degeneration;Cancer;Liver Cancer	Colorectal cancer;Liver cancer;Solid tumours;Urogenital cancer		
Astegolimab	Whole mAb	-imab	G2	Kappa	Phase-II	Active	EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIYPGNSDTRFSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHGTSSDYYGLDVWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQDDNFPLTFGGGTKVEIK			None	None	None	2019	2020.0	IL1RL1	Amgen;Genentech;University of Leicester		Allergic asthma;Asthma;Atopic dermatitis;Chronic obstructive pulmonary disease			
Atezolizumab	Whole mAb	-zumab	G1	Kappa	Approved	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK			5x8l:FK:HM:GL:JO:SN	5xxy:HL	None	2014	2015.0	CD274	Amgen;ARCAGY/GINECO Group;BioLineRx;Chugai Pharmaceutical;Clovis Oncology;Dana-Farber Cancer Institute;Duke University;European Organisation for Research and Treatment of Cancer;Exelixis;Fondazione Michelangelo;GEICO (Spanish Ovarian Cancer Research Group);Genentech;GERCOR;Gradalis;H. Lee Moffitt Cancer Center and Research Institute;Immune Design;Incyte Corporation;Johns Hopkins University;Kaiser Permanente;M. D. Anderson Cancer Center;Memorial Sloan-Kettering Cancer Center;National Cancer Center (Korea);National Cancer Institute (USA);Netherlands Cancer Institute;Roche;Sanofi;Seattle Genetics;University Hospital Southampton NHS Foundation Trust;University Medical Center Groningen;University of California;University of California at San Francisco;University of Oklahoma;Yale University	Non-small cell lung cancer;Urogenital cancer;Breast cancer;Small cell lung cancer	Bladder cancer;Cervical cancer;Colorectal cancer;Fallopian tube cancer;Head and neck cancer;Liver cancer;Malignant melanoma;Ovarian cancer;Peritoneal cancer;Prostate cancer;Renal cell carcinoma;Anal cancer;Brain metastases;Chronic lymphocytic leukaemia;Cutaneous T-cell lymphoma;Diffuse large B cell lymphoma;Endometrial cancer;Gastric cancer;Gynaecological cancer;Mantle-cell lymphoma;Marginal zone B-cell lymphoma;Oesophageal cancer;Soft tissue sarcoma;Solid tumours;Thyroid cancer;Waldenstrom's macroglobulinaemia;Acute myeloid leukaemia;Follicular lymphoma;Glioblastoma;Pancreatic cancer;Haematological malignancies;Multiple myeloma;Non-Hodgkin's lymphoma	Hodgkin's disease;Myelodysplastic syndromes	Human Phage Display	
Atidortoxumab	Whole mAb	-umab	G1	Kappa	Phase-II	Discontinued	EVQLQESGPGLVRPSETLSLTCAVSGYSISSGMGWGWIRQPPGKGLEWIGSIDQRGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDAGHAVDMDVWGKGTTVTVSS	DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYVFPLTFGGGTKVEIK			None	None	None	2017	2018.0	Toxin A	Adimab;Arsanis;X4 Pharmaceuticals			Staphylococcal infections		
Atinumab	Whole mAb	-umab	G4	Kappa	Phase-I	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMSWVRQAPGKGLEWVATIKQDGSQKNYVDSVKGRFTISRDNAKNSLYLRLNSLRAEDTAVYYCATELFDLWGRGSLVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTKLEIK			None	None	None	2010	2011.0	RTN4	Novartis			Spinal cord injuries		
Atoltivimab	Whole mAb	-imab	G1	Kappa	Preregistration	Discontinued	QVQLVESGGGVVQPGRSLRLSCAASGFTFNNYGMHWVRQAPGMGLEWVAVIWHDGSDKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARNWNLFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRITITCRASQSISTYLHWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSTPPINFGQGTKLEIK			None	None	None	2018		Zaire Ebolavirus GP	Regeneron Pharmaceuticals			Ebola virus infections		
Avdoralimab	Whole mAb	-imab	G1	Kappa	Phase-I	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMHWVRQATGKGLEWVSAIDTGGGTYYADSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDYYYYASGSYYKAFDIWGQGTMVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSSRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSPLTFGQGTKLEIK			None	None	None	2019	2020.0	C5AR1	Novo Nordisk;Innate Pharma		Solid tumours	Rheumatoid arthritis		
Avelumab	Whole mAb	-umab	G1	Lambda	Approved	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS	QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL			4nki:HL/5grj:HL	None	None	2015	2016.0	CD274	AIO Studien gGmbH;Array BioPharma;Chong Kun Dang;Dana-Farber Cancer Institute;Debiopharm;eFFECTOR Therapeutics;EMD Serono;Forty Seven;Fred Hutchinson Cancer Research Center;Gachon University Gil Medical Center;Hellenic Cooperative Oncology Group;Hospices Civils de Lyon;Johannes Gutenberg-University Mainz;M. D. Anderson Cancer Center;Merck KGaA;National Cancer Institute (USA);National Cancer Institute Slovakia;Netherlands Cancer Institute;Pfizer;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syndax Pharmaceuticals;Transgene;University College London;University of Birmingham;University of California San Diego;University of Iowa;Vaccinex;Vanderbilt-Ingram Cancer Center;VAXIMM;Verastem Oncology;Washington University School of Medicine	Merkel cell carcinoma;Urogenital cancer;Renal cell carcinoma	Breast cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Bladder cancer;Endometrial cancer;Fallopian tube cancer;Germ cell and embryonal neoplasms;Gestational trophoblastic disease;Glioblastoma;Haemangiosarcoma;Intestinal cancer;Leiomyosarcoma;Nasopharyngeal cancer;Neuroendocrine tumours;Osteosarcoma;Peripheral T-cell lymphoma;Peritoneal cancer;Prostate cancer;Recurrent respiratory papillomatosis;Small cell lung cancer;Solid tumours;Squamous cell cancer;Thymoma;Liposarcoma;Lymphoma;Oropharyngeal cancer;Pancreatic cancer;Acute myeloid leukaemia;Follicular lymphoma;Hodgkin's disease;Liver cancer;Meningioma		Human Phage Display	Avelumab and Bintrafusp have identical V domains
Avizakimab	Whole mAb	-imab	G1	Kappa	Phase-I/II	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYWMHWVRQAPGQGLEWMGTIDPSDQYTIYSQNFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYGFAMDYWGQGTLVTVSS	DIQLTQSPSSLSASVGDRVTITCRASQDISNFLNWYQQKPGKAVKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGHTLPRTFGGGTKVEIK			None	None	None	2019	2020.0	IL21	MedImmune;Boston Pharmaceuticals		Systemic lupus erythematosus;Autoimmune disorders			
Axatalimab	Whole mAb	-imab	G4	Kappa	Unknown	Active	EVTLKESGPALVKPTQTLTLTCTFSGFSLTTYGMGVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIGPIKYPTAPYRYFDFWGQGTMVTVSS	DIQMTQSPSSLSASVGDRVTITCLASEDIYDNLAWYQQKPGKAPKLLIYYASSLQDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQDSEYPWTFGGGTKVEIK			None	None	None	2019	2020.0	CSF1R						
Azintuxizumab	Whole mAb ADC	-xizumab	G1	Kappa	Phase-I	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMAWVRQAPGKGLEWVASINYDGSSTYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRGYYFDYWGQGTTVTVSS	DVVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPPFTFGGGTKVEIK			None	None	None	2016	2017.0	SLAMF7	AbbVie			Multiple myeloma		
Balstilimab	Whole mAb	-imab	G4	Kappa	Phase-II	Active	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASNGDHWGQGTLVTVSS	EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPRTFGQGTKVEIK			None	None	None	2018	2019.0	PDCD1	Agenus;Ludwig Institute for Cancer Research		Cervial cancer;Solid tumours			
Bapineuzumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Discontinued	EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRYDHYSGSSDYWGQGTLVTVSS	DVVMTQSPLSLPVTPGEPASISCKSSQSLLDSDGKTYLNWLLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPRTFGQGTKVEIK			None	None	4ojf:HL/4hix:HL	2005	2006.0	APP	JANSSEN Alzheimer Immunotherapy;Pfizer;Wyeth;Elan Corporation			Alzheimer's disease		"Jain paper: ""Conflicting literature sequences in FR3 of VH - AKNTLYLQMNSLRAEDTAV vs. AKNSLYLQMNSLRAEDTAL"""
Bapotulimab	Whole mAb	-imab	G2	Kappa	TBC	Active	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGRLPYGDFWDSWGQGTLVTVSS	DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKLEIR			None	None	None	2020		ILDR2	TBC	TBC	TBC	TBC		
Barecetamab	Whole mAb	-amab	G1	Lambda	TBC	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYDMSWVRQAPGKGLEWVSTIDLDSGSIYYADSVQGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDLHMGPEGPFDYWGQGTLVTVSS	QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNSVSWYQQLPGTAPKLLIYSDNHRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQGWDTSLSGHVFGGGTKLTVL			None	None	None	2020		ERBB3	TBC	TBC	TBC	TBC		
Basiliximab	Whole mAb	-ximab	G1	Kappa	Approved	NFD	QVQLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSS	QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIK			1mim:HL/3iu3:AB:CD:HL	None	None	1996	1997.0	IL2RA	Cerimon Pharmaceuticals;Novartis	Renal transplant rejection;Transplant rejection		Ulcerative colitis;Uveitis		
Batoclimab	Whole mAb	-imab	G1	Lambda	Phase-II	Active	QLLLQESGPGLVKPSETLSLTCTVSGGSLSSSFSYWVWIRQPPGKGLEWIGTIYYSGNTYYNPSLKSRLTISVDTSKNHFSLKLSSVTAADTAVYYCARRAGILTGYLDSWGQGTLVTVSS	SYVLTQSPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSASNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL			None	None	None	2019	2020.0	FCGRT	Immunovant Sciences		Graves’ Ophtalmopathy;Myasthenia gravis;Autoimmune disorders;Neuromyelitis optica;Idiopathic thrombocytopenic purpura			
Bavituximab	Whole mAb	-ximab	G1	Kappa	Phase-III	Active	EVQLQQSGPELEKPGASVKLSCKASGYSFTGYNMNWVKQSHGKSLEWIGHIDPYYGDTSYNQKFRGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCVKGGYYGHWYFDVWGAGTTVTVSS	DIQMTQSPSSLSASLGERVSLTCRASQDIGSSLNWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYVSSPPTFGAGTKLELK			None	None	None	2006	2007.0	Phosphatidylserine	Avid Bioservices;IMV;Massachusetts General Hospital;Merck Sharp & Dohme;Peregrine Pharmaceuticals;University of Arizona;University of Texas Southwestern Medical Center;University of Texas M. D. Anderson Cancer Center		Non-small cell lung cancer;Glioblastoma;Liver cancer;Solid tumours	Breast cancer;Malignant melanoma;Pancreatic cancer;Brain cancer;Hepatitis C;HIV infections;Rectal cancer;Viral haemorrhagic fevers;Influenza virus infections;Prostate cancer		
Bedinvetmab	Canine Whole mAb	-vetmab	G2	Lambda	Unknown	Active	EVQLVESGGDLVKPGGSLRLSCVASGFTFSSHGMHWVRQSPGKGLQWVAVINSGGSSTYYTDAVKGRFTISRDNAKNTVYLQMNSLRAEDTAMYYCAKESVGGWEQLVGPHFDYWGQGTLVIVSS	QSVLTQPTSVSGSLGWRVTISCSGSTNNIGILGASWYQLFPGKAPKLLVYGNGNRPSGVPDRFSGADSGDSVTLTITGLQAEDEADYYCQSFDTTLGAHVFGGGTHLTVL			None	None	None	2018	2019.0	Canine NGFB			Canine lupus familiaris			
Befovacimab	Whole mAb	-imab	G2	Lambda	Phase-II	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMDWVRQAPGKGLEWVSSIRGSRGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLYRYWFDYWGQGTLVTVSS	SYELTQPPSVSVSPGQTARITCSGDNLPKYYAHWYQQKPGQAPVVVIFYDVNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWWSSTPVFGGGTKLTVL			None	None	None	2019	2020.0	TFPI			Haemophilia			
Begelomab	Whole mAb	-omab	G2b	Kappa	Phase-II/III	Active	QVQLQQSGAELVKPGASVKLSCKASGYTFRSYDINWVRQRPEQGLEWIGWIFPGDGSTKYNEKFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCARWTVVGPGYFDVWGAGTTVTVSS	QIVLTQSPAIMSASPGEKVTITCSASSSVSYMNWFQQKPGTSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSYPNTFGGGTKLEIK			None	None	None	2014	2015.0	DPP4	ADIENNE		Graft-versus-host disease			
Belantamab	Whole mAb ADC	-amab	G1	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLDNWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKLLIYYTSNLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIK			None	None	None	2017	2018.0	TNFRSF17	GlaxoSmithKline		Multiple myeloma			
Belimumab	Whole mAb	-umab	G1	Lambda	Approved	Active	QVQLQQSGAEVKKPGSSVRVSCKASGGTFNNNAINWVRQAPGQGLEWMGGIIPMFGTAKYSQNFQGRVAITADESTGTASMELSSLRSEDTAVYYCARSRDLLLFPHHALSPWGRGTMVTVSS	SSELTQDPAVSVALGQTVRVTCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCSSRDSSGNHWVFGGGTELTVL			5y9k:HL/5y9j:HL/6fxn:OP:QR:MN:FG:HI:DE	None	6erx:HI:DE:QR:MN:FG:OP	2003	2004.0	TNFSF13B	Assistance Publique Hopitaux de Paris;Cancer Trials Australia;GlaxoSmithKline;Hospital for Special Surgery;Human Genome Sciences;North Shore-Long Island Jewish Health System;University of Alabama at Birmingham;University of Pennsylvania;University of Wisconsin-Madison;Washington University School of Medicine;Cambridge Antibody Technology	Systemic lupus erythematosus	Anti-neutrophil cytoplasmic antibody-associated vasculitis;Lupus nephritis;Myositis;Emphysema;Membranous glomerulonephritis;Myasthenia gravis;Renal transplant rejection;Sjogren's syndrome;Systemic scleroderma;Graft-versus-host disease	Waldenstrom's macroglobulinaemia;Rheumatoid arthritis	CAT Phage Display	
Bemarituzumab	Whole mAb	-zumab	G1	Kappa	Phase-III	Active	QVQLVQSGAEVKKPGSSVKVSCKASGYIFTTYNVHWVRQAPGQGLEWIGSIYPDNGDTSYNQNFKGRATITADKSTSTAYMELSSLRSEDTAVYYCARGDFAYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQGVSNDVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHSTTPYTFGQGTKLEIK			None	None	None	2017	2018.0	FGFR2	Five Prime Therapeutics;ZAI Lab		Gastric cancer;Oesophageal cancer;Solid tumours		POTELLIGENT Technology	
Benralizumab	Whole mAb	-zumab	G1	Kappa	Approved	Active	EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCGTSEDIINYLNWYQQKPGKAPKLLIYHTSRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYTLPYTFGQGTKVEIK			None	None	None	2009	2010.0	IL5RA	AstraZeneca;Cincinnati Children's Hospital Medical Center;Kyowa Hakko;Kyowa Hakko Kirin;McMaster University;MedImmune;National Jewish Medical and Research Center;BioWa	Asthma	Chronic obstructive pulmonary disease;Nasal polyps;Atopic dermatitis;Churg-Strauss syndrome;Hypereosinophilic syndrome;Rhinosinusitis;Eosinophilic gastroenteritis;Skin disorders		POTELLIGENT Technology	
Bentracimab	Whole mAb	-imab	G1	Lambda	TBC	Active	QVQLQESGAEVKKPGSSVRVSCKASGGTFDSYSIHWVRQAPGQGLEWMGGIIPAFGTLSSAQDFQARVTISADKSTSTAYMELSGLRSEDTAVYYCARGSFDYYFWSASHPPNDALAIWGQGTLVTVSS	QSVVTQPPSVSAAPGQKVTISCSGSNSDIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLAITGLQAGDEADYYCGTWLYDRAVGLFGGGTKVTVL			5alb:HL	None	5alc:HL	2020		AR-C124910XX	TBC	TBC	TBC	TBC		
Benufutamab	Whole mAb	-amab	G1	Kappa	Phase-I/II	Active	EVQLQQSGAEVVKPGASVKLSCKASGFNIKDTFIHWVKQAPGQGLEWIGRIDPANTNTKYDPKFQGKATITTDTSSNTAYMELSSLRSEDTAVYYCVRGLYTYYFDYWGQGTLVTVSS	EIVMTQSPATLSVSPGERATLSCRASQSISNNLHWYQQKPGQAPRLLIKFASQSITGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQGNSWPYTFGQGTKLEIK			None	None	None	2019	2020.0	TNFRSF10B	Genmab;VU University Medical Center;iDD Biotech		Solid tumours;Multiple myeloma			
Bepranemab	Whole mAb	-emab	G4	Kappa	Phase-I	Active	EVQLQESGPGLVKPSETLSLTCTVSGFSLTSNDIAWIRQPPGKGLEWMGTIWTDGSTNYNTAVQSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHRLYYGAFDYWGQGTMVTVSS	DIVMTQTPLSLSVTPGQPASISCRSSQSLEYSDGYTYLEWYLQKPGQSPQLLIYEVSNRFSGVPDRFSGSGSGTDDFTLKISRVEAEDVGVYYCFQATHNPYTFGQGTKLEIK			None	None	None	2019		MAPT	UCB BioPharma		Progressive supranuclear palsy (PSP)			
Berlimatoxumab	Whole mAb	-umab	G1	Kappa	Phase-II	Discontinued	ELQLQESGPGLVKPSETLSLTCTVSGGSISSGSYYWDWIRQPPGKGLEWIGNIYKSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARERGMHYMDVWGKGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQSINSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQFDPPFTFGGGTKVEIK			5k59:HL:EF	None	None	2017	2018.0	Toxin A	Adimab;Arsanis;X4 Pharmaceuticals			Staphylococcal infections		
Bermekimab	Whole mAb	-imab	G1	Kappa	Preregistration	Active	QVQLVESGGGVVQPGRSLRLSCTASGFTFSMFGVHWVRQAPGKGLEWVAAVSYDGSNKYYAESVKGRFTISRDNSKNILFLQMDSLRLEDTAVYYCARGRPKVVIPAPLAHWGQGTLVTFSS	DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYEASNLETGVPSRFSGSGSGSDFTLTISSLQPEDFATYYCQQTSSFLLSFGGGTKVEHK			None	None	None	2018	2019.0	IL1A	XBiotech Inc.		Colorectal cancer;Cachexia;Atopic dermatitis;Acne vulgaris;Hidradenitis suppurativa;Non-small cell lung cancer;Plaque psoriasis;Systemic scleroderma;Type 2 diabetes mellitus;Vascular restenosis	Haematological malignancies		
Bersanlimab	Whole mAb	-imab	G1	Lambda	Phase-II	Discontinued	EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVAFIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYSGWYFDYWGQGTLVTVSS	QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYDNNNRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQSYDSSLSAWLFGGGTKLTVL			None	None	None	2017	2018.0	ICAM1	BioInvent International			Multiple myeloma	n-CoDeR	
Bevacizumab	Whole mAb	-zumab	G1	Kappa	Approved	Active	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK			1bj1:HL:KJ	None	6bft:AB:HL/1cz8:HL:YX	2000	2001.0	VEGFA	All Ireland Cooperative Oncology Research Group;ARCAGY/GINECO Group;Austrian Breast & Colorectal Cancer Study Group;Bayer;Beth Israel Deaconess Medical Center;Breast Cancer Research Foundation;Brigham and Women's Hospital;Bristol-Myers Squibb;Cancer and Leukemia Group B;Cancer Research UK;Chugai Pharmaceutical;Cincinnati Children's Hospital Medical Center;Dana-Farber Cancer Institute;Duke University;European Organisation for Research and Treatment of Cancer;European Thoracic Oncology Platform;Genentech;Hackensack University Medical Center;Hoosier Cancer Research Network;Indiana University School of Medicine;Japan Breast Cancer Research Group;M. D. Anderson Cancer Center;Massachusetts General Hospital;Medical University of South Carolina;Melanoma Research Foundation Breakthrough Consortium;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);National Comprehensive Cancer Network;NCIC Clinical Trials Group;North Central Cancer Treatment Group;NSABP Foundation;Ohio State University Medical Center;Peter MacCallum Cancer Centre;Roche;Royal Marsden NHS Foundation Trust;Sanofi;Sarcoma Alliance for Research through Collaboration;SCRI Development Innovations;South Eastern European Research Oncology Group;Spanish Cooperative Group for Digestive Tumour Therapy;Spanish Lung Cancer Group;Stanford University School of Medicine;SWOG;The Catalan Institute of Oncology;UNICANCER;University College London;University of Alabama at Birmingham;University of Arkansas System;University of California Davis;University of Iowa;University of Oklahoma;University of Tennessee;University of Texas M. D. Anderson Cancer Center;US Oncology Research;West German Study Group;Xijing Hospital	Breast cancer;Cervical cancer;Colorectal cancer;Glioblastoma;Glioma;Non-small cell lung cancer;Ovarian cancer;Renal cell carcinoma;Fallopian tube cancer;Peritoneal cancer	Head and neck cancer;Biliary cancer;Brain metastases;Endometrial cancer;Ewing's sarcoma;Gynaecological cancer;Hodgkin's disease;Intestinal cancer;Liver cancer;Liver metastases;Malignant melanoma;Meningioma;Multiple myeloma;Neuroblastoma;Neurofibromatoses;Rectal cancer;Soft tissue sarcoma;Solid tumours;Urogenital cancer;Neoplastic meningitis;Sarcoma	Carcinoid tumour;Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Eye disorders;Gastric cancer;Gastrointestinal stromal tumours;Mesothelioma;Oesophageal cancer;Pancreatic cancer;Prostate cancer;Small cell lung cancer		
Bexmarilimab	Whole mAb	-imab	G4	Kappa	Phase-I/II	Active	QVTLKESGPTLVKPTQTLTLTCSFSGFSLSTSGMGIGWIRQPPGKALEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARHYGYDPYYAMDYWGQGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCTASSSVSSSYLHWYQQKPGKAPKLLIYRTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCHQYHRSPPTFGQGTKLEIK			None	None	None	2019		STAB1	Faron Pharmaceuticals		Solid tumours			
Bezlotoxumab	Whole mAb	-umab	G1	Kappa	Approved	NFD	EVQLVQSGAEVKKSGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIFYPGDSSTRYSPSFQGQVTISADKSVNTAYLQWSSLKASDTAMYYCARRRNWGNAFDIWGQGTMVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSTWTFGQGTKVEIK			4np4:HL:IM	None	None	2012	2013.0	Toxin A	Medarex;University of Massachusetts Medical School;Merck & Co;Merck Sharp & Dohme	Clostridium difficile			Medarex HuMAb Mouse	
Bifikafusp	Whole mAb Fusion	-fusp	E	Kappa	Phase-III	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK			None	None	None	2010	2011.0	FN extra domain B	Philogen		Cancers;Pancreatic cancer;Metastatic melanoma	Brain cancer;Non-small cell lung cancer;Solid tumours		Radretumab+Bifikafusp+Onfekafusp have identical V domains
Bimagrumab	Whole mAb	-umab	G1	Lambda	Phase-II	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSSYINWVRQAPGQGLEWMGTINPVSGSTSYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWFDYWGQGTLVTVSS	QSALTQPASVSGSPGQSITISCTGTSSDVGSYNYVNWYQQHPGKAPKLMIYGVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCGTFAGGSYYGVFGGGTKLTVL			5nhr:HL:AB	5nhw:HL/5nh3:HL:IM/5ngv:HL	None	2012	2013.0	ACVR2B	MorphoSys;Novartis		Cachexia;Muscular atrophy;Type 2 diabetes mellitus	Inclusion body myositis	MorphoSys HuCAL Phage Display	
Bimekizumab	Whole mAb	-zumab	G1	Kappa	Phase-III	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYNMAWVRQAPGKGLEWVATITYEGRNTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPPQYYEGSIYRLWFAHWGQGTLVTVSS	AIQLTQSPSSLSASVGDRVTITCRADESVRTLMHWYQQKPGKAPKLLIYLVSNSEIGVPDRFSGSGSGTDFRLTISSLQPEDFATYYCQQTWSDPWTFGQGTKVEIK			None	None	None	2013	2014.0	IL17A	UCB		Ankylosing spondylitis;Plaque psoriasis;Psoriatic arthritis;Hidradenitis suppurativa;Rheumatoid arthritis;Ulcerative colitis	Psoriasis		
Bintrafusp	Whole mAb Fusion	-fusp	G1	Lambda	Approved	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS	QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL			4nki:HL/5grj:HL	None	None	2015	2016.0	CD274	AIO Studien gGmbH;Array BioPharma;Chong Kun Dang;Dana-Farber Cancer Institute;Debiopharm;eFFECTOR Therapeutics;EMD Serono;Forty Seven;Fred Hutchinson Cancer Research Center;Gachon University Gil Medical Center;Hellenic Cooperative Oncology Group;Hospices Civils de Lyon;Johannes Gutenberg-University Mainz;M. D. Anderson Cancer Center;Merck KGaA;National Cancer Institute (USA);National Cancer Institute Slovakia;Netherlands Cancer Institute;Pfizer;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syndax Pharmaceuticals;Transgene;University College London;University of Birmingham;University of California San Diego;University of Iowa;Vaccinex;Vanderbilt-Ingram Cancer Center;VAXIMM;Verastem Oncology;Washington University School of Medicine	Merkel cell carcinoma;Urogenital cancer	Renal cell carcinoma;Breast cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Bladder cancer;Endometrial cancer;Fallopian tube cancer;Germ cell and embryonal neoplasms;Gestational trophoblastic disease;Glioblastoma;Haemangiosarcoma;Intestinal cancer;Leiomyosarcoma;Nasopharyngeal cancer;Neuroendocrine tumours;Osteosarcoma;Peripheral T-cell lymphoma;Peritoneal cancer;Prostate cancer;Recurrent respiratory papillomatosis;Small cell lung cancer;Solid tumours;Squamous cell cancer;Thymoma;Liposarcoma;Lymphoma;Oropharyngeal cancer;Pancreatic cancer;Acute myeloid leukaemia;Follicular lymphoma;Hodgkin's disease;Liver cancer;Meningioma		Human Phage Display	Avelumab and Bintrafusp have identical V domains
Birtamimab	Whole mAb	-imab	G1	Kappa	Phase-III	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMYWIRQAPGKGLEWVARIRSKSNNYAIYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARPYSDSFAYWGQGTLVTVSS	DVVMTQSPLSLPVTPGEPASISCRSSQSLVHSTGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPFTFGGGTKVEIK			None	None	None	2018	2019.0	SAA1	Neotope Biosciences;Onclave Therapeutics;Prothena			Amyloid light-chain amyloidosis		
Bleselumab	Whole mAb	-umab	G4	Kappa	Phase-II	Active	QLQLQESGPGLLKPSETLSLTCTVSGGSISSPGYYGGWIRQPPGKGLEWIGSIYKSGSTYHNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCTRPVVRYFGWFDPWGQGTLVTVSS	AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPTFGQGTKVEIK			None	None	None	2015	2016.0	CD40	Kirin Brewery;Astellas Pharma;Kyowa Hakko Kirin		Focal segmental glomerulosclerosis;Renal transplant rejection	Transplant rejection;Plaque psoriasis		
Blinatumomab	Bispecific T-Cell Engager	-omab		Kappa;Kappa	Approved	Active	QVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSS	DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIK	DIKLQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS	DIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK	None;None	None;None	None;None	2008	2009.0	CD19;CD3E	Amgen;Astellas Pharma;M. D. Anderson Cancer Center;Merck & Co;Micromet Inc;National Cancer Institute (USA);University of California Davis	Precursor B-cell lymphoblastic leukaemia-lymphoma	Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma	Chronic lymphocytic leukaemia	BiTE Technology	
Blontuvetmab	Canine Whole mAb	-vetmab	G2	Kappa	Unknown	Active	QVQLQQSRAELVRPGASVTLSCKPSGYTFTDYEVHWVKQTPVHGLEWIGAIDPETGGTADNQKFKGKAILTADKSSSTAYMELRSLTSEDSAVYYCTNFVDVWGTGTTVTVSS	DVVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSGNQKNYLAWYQQKPGQSPRLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVFYCQQYYNYPLTFGGGTHL			None	None	None	2015	2016.0	MS4A1	Aratana Pharmaceuticals		Canine B-cell lymphoma			
Blosozumab	Whole mAb	-zumab	G4	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGASVKVSCKVSGFPIKDTFQHWVRQAPGKGLEWMGWSDPEIGDTEYASKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGDTTYKFDFWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQDVHTAVAWYQQKPGKAPKLLIYWASTRWTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSDYPWTFGGGTKVEIK			None	None	None	2011	2012.0	SOST	Eli Lilly		Postmenopausal osteoporosis			
Bococizumab	Whole mAb	-zumab	G2	Kappa	Phase-III	Discontinued	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGEISPFGGRTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARERPLYASDLWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQRYSLWRTFGQGTKLEIK			3sqo:HL	None	None	2013	2014.0	PCSK9	Halozyme Therapeutics;Pfizer			Cardiovascular disorders;Hypercholesterolaemia;Hyperlipidaemia		
Brazikumab	Whole mAb	-umab	G2	Lambda	Phase-II/III	Active	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNEYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGYTSSWYPDAFDIWGQGTMVTVSS	QSVLTQPPSVSGAPGQRVTISCTGSSSNTGAGYDVHWYQQVPGTAPKLLIYGSGNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTRLTVL			None	None	None	2016	2017.0	IL23A	Allergan;Amgen;AstraZeneca		Crohn's disease;Ulcerative colitis	Psoriasis		
Brentuximab	Whole mAb ADC	-ximab	G1	Kappa	Approved	Active	QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCANYGNYWFAYWGQGTQVTVSA	DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPKVLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK			None	None	None	2010	2011.0	TNFRSF8	Bristol-Myers Squibb;Celgene Corporation;Dana-Farber Cancer Institute;Fondazione Italiana Linfomi;Fox Chase Cancer Center;Immune Tolerance Network;Lymphoma Academic Research Organisation;Massachusetts General Hospital;National Cancer Institute (USA);National Institute of Allergy and Infectious Diseases;Seattle Genetics;Stanford University;Takeda;Takeda Oncology;UNC Lineberger Comprehensive Cancer Center;Washington University School of Medicine	Anaplastic large cell lymphoma;Cutaneous T-cell lymphoma;Hodgkin's disease;Mycosis fungoides;T-cell lymphoma	Adult T-cell leukaemia-lymphoma;Diffuse large B cell lymphoma;Germ cell and embryonal neoplasms;Mastocytosis;Mesothelioma;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma;Sezary syndrome;Diffuse scleroderma	Graft-versus-host disease;Leukaemia;Multiple myeloma;Solid tumours;Systemic lupus erythematosus		
Briakinumab	Whole mAb	-umab	G1	Lambda	Preregistration (w)	Discontinued	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSS	QSVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPGTAPKLLIYYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGTKVTVL			5n2k:LK:BA:PO:DC:NM:FE	None	None	2009	2010.0	IL12B	Cambridge Antibody Technology;Abbott GmbH & Co. KG			Plaque psoriasis;Crohn's disease;Multiple sclerosis;Rheumatoid arthritis		
Brodalumab	Whole mAb	-umab	G2	Kappa	Approved	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTRYGISWVRQAPGQGLEWMGWISTYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRQLYFDYWGQGTLVTVSS	EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWFQQKPGQAPRPLIYDASTRATGVPARFSGSGSGTDFTLTISSLQSEDFAVYYCQQYDNWPLTFGGGTKVEIK			None	None	None	2011	2012.0	IL17RA	Amgen;AstraZeneca;Bausch Health Companies;Kyowa Hakko Kirin;LEO Pharma	Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis;Psoriasis	Spondylarthritis;Systemic scleroderma	Asthma;Crohn's disease;Rheumatoid arthritis	Abgenix XenoMouse	
Brolucizumab	scFv	-zumab		Kappa	Approved	Active	EVQLVESGGGLVQPGGSLRLSCTASGFSLTDYYYMTWVRQAPGKGLEWVGFIDPDDDPYYATWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGGDHNSGWGLDIWGQGTLVTVSS	EIVMTQSPSTLSASVGDRVIITCQASEIIHSWLAWYQQKPGKAPKLLIYLASTLASGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCQNVYLASTNGANFGQGTKLTVL			None	None	None	2014	2015.0	VEGFA	ESBATech;Alcon	Wet age-related macular degeneration	Diabetic macular oedema;Retinal vein occlusion			
Brontictuzumab	Whole mAb	-zumab	G2	Lambda	Phase-I	Active	QVQLVQSGAEVKKPGASVKISCKVSGYTLRGYWIEWVRQAPGKGLEWIGQILPGTGRTNYNEKFKGRVTMTADTSTDTAYMELSSLRSEDTAVYYCARFDGNYGYYAMDYWGQGTTVTVSS	QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWFQQKPGQAPRTLIGGTNNRAPGVPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNHWVFGGGTKLTVL			None	None	None	2014	2015.0	NOTCH1	OncoMed Pharmaceuticals;University of Texas M. D. Anderson Cancer Center		Colorectal cancer	Adenoid cystic carcinoma;Solid tumours;Haematological malignancies		
Budigalimab	Whole mAb	-imab	G1	Kappa	Phase-I	Active	EIQLVQSGAEVKKPGSSVKVSCKASGYTFTHYGMNWVRQAPGQGLEWVGWVNTYTGEPTYADDFKGRLTFTLDTSTSTAYMELSSLRSEDTAVYYCTREGEGLGFGDWGQGTTVTVSS	DVVMTQSPLSLPVTPGEPASISCRSSQSIVHSHGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPVTFGQGTKLEIK			None	None	None	2018	2019.0	PDCD1	AbbVie		Colorectal cancer;Ovarian cancer;Small cell lung cancer;Solid tumours 			
Burosumab	Whole mAb	-umab	G1	Kappa	Approved	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHYMHWVRQAPGQGLEWMGIINPISGSTSNAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDIVDAFDFWGQGTMVTVSS	AIQLTQSPSSLSASVGDRVTITCRASQGISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNDYFTFGPGTKVDIK			None	None	None	2016	2017.0	FGF23	Kyowa Hakko Kirin;Ultragenyx Pharmaceutical 	X-linked dominant hypophosphataemic rickets	Osteomalacia;Nevus			
Cabiralizumab	Whole mAb	-zumab	G4	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVRQAPGQGLEWMGDINPYNGGTTFNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARESPYFSNLYVMDYWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCKASQSVDYDGDNYMNWYQQKPGQAPRLLIYAASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHLSNEDLSTFGGGTKVEIK			None	None	None	2015	2016.0	CSF1R	Apexigen;Bristol-Myers Squibb;Five Prime Therapeutics;University of Chicago;Yale University		Pancreatic cancer;Pigmented villonodular synovitis;Cancer;Malignant melanoma;Non-small cell lung cancer;Renal cell carcinoma;Solid tumours 	Rheumatoid arthritis		
Camidanlumab	Whole mAb ADC	-umab	G1	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRYIINWVRQAPGQGLEWMGRIIPILGVENYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARKDWFDYWGQGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK			None	None	None	2017	2018.0	IL2RA	ADC Therapeutics;Genmab		Hodgkin's disease;Non-Hodgkin's lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma;Solid tumours	Acute myeloid leukaemia		
Camrelizumab	Whole mAb	-zumab	G4	Kappa	Approved	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYMMSWVRQAPGKGLEWVATISGGGANTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLYYFDYWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCLASQTIGTWLTWYQQKPGKAPKLLIYTATSLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVYSIPWTFGGGTKVEIK			None	None	None	2016	2017.0	PDCD1	Chinese PLA General Hospital;Hangzhou Cancer Hospital;Incyte Corporation;Jiangsu Hengrui Medicine Co.;Nanjing Medical University;Peking University People's Hospital;Sun Yat-Sen University	Hodgkin's disease	Nasopharyngeal cancer;Non-small cell lung cancer;Oesophageal cancer;Liver cancer;Biliary cancer;Cervical cancer;Cholangiocarcinoma;Colorectal cancer;Endometrial cancer;Fallopian tube cancer;Gastric cancer;Osteosarcoma;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Renal cell carcinoma;Solid tumours;Urogenital cancer;Diffuse large B cell lymphoma;Breast cancer;Malignant melanoma			
Canakinumab	Whole mAb	-umab	G1	Kappa	Approved	Active	QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSS	EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIK			None	4g5z:HL/5bvj:HG:FE:BA:DC/4g6j:HL/5bvp:HL	None	2007	2008.0	IL1B	Charite - Universitatsmedizin Berlin;Novartis;Triemli hospital;University Hospital Tubingen;University Hospital Zurich	Adult-onset Still's disease;Cryopyrin-associated periodic syndromes;Familial autosomal dominant periodic fever;Familial Mediterranean fever;Gouty arthritis;Juvenile rheumatoid arthritis;Peroxisomal disorders	Cardiovascular disorders;Behcet's syndrome;Non-small cell lung cancer;Abdominal aortic aneurysm;Atherosclerosis;Malignant melanoma;Osteoarthritis;Peripheral arterial occlusive disorders;Pulmonary sarcoidosis;Schnitzler syndrome;Sickle cell anaemia;Breast cancer	Chronic obstructive pulmonary disease;Asthma;Diabetic retinopathy;Polymyalgia rheumatica;Rheumatoid arthritis;Type 1 diabetes mellitus;Type 2 diabetes mellitus	Medarex UltiMAb Mouse	
Cantuzumab	Whole mAb ADC	-zumab	G1	Kappa	Phase-II	Discontinued	QVQLVQSGAEVKKPGETVKISCKASDYTFTYYGMNWVKQAPGQGLKWMGWIDTTTGEPTYAQKFQGRIAFSLETSASTAYLQIKSLKSEDTATYFCARRGPYNWYFDVWGQGTTVTVSS	DIVMTQSPLSVPVTPGEPVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLVSGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCLQHLEYPFTFGPGTKLELK			None	None	None	2003	2004.0	MUC1	ImmunoGen;GlaxoSmithKline			Gastric cancer;Solid tumours		
Caplacizumab	Nanobody	-zumab			Approved	NFD	EVQLVESGGGLVQPGGSLRLSCAASGRTFSYNPMGWFRQAPGKGRELVAAISRTGGSTYYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAAAGVRAEDGRVRTLPSEYTFWGQGTQVTVSS				None	None	None	2011	2012.0	VWF	Ablynx	Thrombotic thrombocytopenic purpura		Thrombosis	Nanobody Technology	
Carlumab	Whole mAb	-umab	G1	Kappa	Phase-II	Discontinued	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDGIYGELDFWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSDAYLAWYQQKPGQAPRLLIYDASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYIQLHSFTFGQGTKVEIK			None	4dn3:HL/4dn4:HL	None	2010	2011.0	CCL2	MorphoSys;Janssen Biotech			Idiopathic pulmonary fibrosis;Ovarian cancer;Prostate cancer;Solid tumours	Human Phage Display	
Carotuximab	Whole mAb	-ximab	G1	Kappa	Phase-II	Active	EVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAEIRSKASNHATYYAESVKGRFTISRDDSKSSVYLQMNSLRAEDTGIYYCTRWRRFFDSWGQGTTLTVSS	QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWSSNPLTFGAGTKLELK			None	None	None	2015	2016.0	ENG	National Cancer Institute (USA);Santen Pharmaceutical;TRACON Pharmaceuticals;University of Alabama at Birmingham;University of Minnesota;Roswell Park Cancer Institute		Wet age-related macular degeneration	Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Haemangiosarcoma;Choriocarcinoma;Glioblastoma;Liver cancer;Renal cell carcinoma;Soft tissue sarcoma;Breast cancer;Non-small cell lung cancer;Acute myeloid leukaemia;Colorectal cancer;Precursor B-cell lymphoblastic leukaemia-lymphoma		
Cemiplimab	Whole mAb	-imab	G4	Kappa	Approved	Active	EVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYFADSVKGRFTISRDNSKNTLYLQMNSLKGEDTAVYYCVKWGNIYFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPSRFSGSGSGTDFTLTIRTLQPEDFATYYCQQSSNTPFTFGPGTVVDFR			None	None	None	2018	2019.0	PDCD1	Inovio Pharmaceuticals;ISA Pharmaceuticals;Regeneron Pharmaceuticals;Sanofi;Sidney Kimmel Cancer Center;SillaJen Biotherapeutics;University of Texas M. D. Anderson Cancer Center	Squamous cell cancer	Cervical cancer;Non-small cell lung cancer;Basal cell cancer;Oropharyngeal cancer;Prostate cancer;Fallopian tube cancer;Glioblastoma;Multiple myeloma;Ovarian cancer;Peritoneal cancer;Solid tumours;B-cell lymphoma;Cancer;Head and neck cancer;Malignant melanoma;Renal cell carcinoma			
Cendakimab	Whole mAb	-imab	G1	Kappa	Phase-II	Active	EVTLRESGPGLVKPTQTLTLTCTLYGFSLSTSDMGVDWIRQPPGKGLEWLAHIWWDDVKRYNPALKSRLTISKDTSKNQVVLKLTSVDPVDTATYYCARTVSSGYIYYAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTISCRASQDIRNYLNWYQQKPGKAPKLLIFYTSKLHSGVPSRFSGSGSGTDYTLTISSLQPEDIATYYCQQGNTLPLTFGGGTKVEIK			None	None	None	2018	2019.0	IL13	Abbott Laboratories;AbbVie;Receptos		Eosinophilic oesophagitis	Allergic asthma		
Cergutuzumab	Whole mAb Fusion	-zumab	G1	Kappa	Phase-I	Discontinued	QVQLVQSGAEVKKPGASVKVSCKASGYTFTEFGMNWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARWDFAYYVEAMDYWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCKASAAVGTYVAWYQQKPGKAPKLLIYSASYRKRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYYTYPLFTFGQGTKLEIK			None	None	None	2015	2016.0	CEACAM5	Roche			Solid tumours		
Certolizumab	Fab	-zumab	G1	Kappa	Approved	Active	EVQLVESGGGLVQPGGSLRLSCAASGYVFTDYGMNWVRQAPGKGLEWMGWINTYIGEPIYADSVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRSYAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQNVGTNVAWYQQKPGKAPKALIYSASFLYSGVPYRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGTKVEIK			5wuv:HL/5wux:HL:AB:CD	None	None	2004	2004.0	TNFA	UCB	Ankylosing spondylitis;Crohn's disease;Plaque psoriasis;Psoriatic arthritis;Rheumatoid arthritis;Spondylitis;Non-radiographic axial spondyloarthritis	Interstitial cystitis;Juvenile rheumatoid arthritis	Cognition disorders		
Cetrelimab	Whole mAb	-imab	G4	Kappa	Phase-II/III	Active	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFDTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARPGLAAAYDTGSLDYWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRNYWPLTFGQGTKVEIK			None	None	None	2017	2018.0	PDCD1	Janssen Research & Development 		Multiple myeloma;Prostate cancer;Solid tumours;Urogenital cancer			
Cetuximab	Whole mAb	-ximab	G1	Kappa	Approved	Active	QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSA	DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK			6au5:DC:BA/6axp:BA:DC/6ayn:BA:DC/6azk:DC:BA/6azl:BA:DC	5i76:DC:BA/1yy8:DC:BA/5th2:DC:BA/5f88:DC:BA/5hyq:DC:BA/5ir1:DC:BA/5ivz:DC:BA/5iv2:DC:BA/5t1k:DC:BA/5t1l:DC:BA/5id0:DC:BA/5id1:DC:BA/5euk:DC:BA/5ff6:DC:BA/5iop:DC:BA/5icy:DC:BA/5itf:DC:BA/5etu:DC:BA/5t1m:DC:BA/5esq:DC:BA/5icz:DC:BA/5i2i:DC:BA/5icx:DC:BA/5hpm:DC:BA/4gw5:DC:BA/4gw1:DC:BA/1yy9:DC/4krp:DC/4kro:DC	5gz0:BA:DC/6arp:BA:DC/6aru:CB	1999	2000.0	EGFR	Array BioPharma;Bristol-Myers Squibb;Celldex Therapeutics Inc;Centre Jean Perrin;Eli Lilly;Merck KGaA;New York University School of Medicine;Novartis;Pierre Fabre;Roche;University Hospital Ghent;University of California;University of Heidelberg;University of Michigan Comprehensive Cancer Center	Colorectal cancer;Head and neck cancer	Non-small cell lung cancer;Bladder cancer;Breast cancer;Gastric cancer;Mesothelioma;Rectal cancer;Squamous cell cancer;Adenoid cystic carcinoma;Oesophageal cancer	Pancreatic cancer;Prostate cancer		
Cevostamab	Bispecific mAb	-amab	G1	Kappa;Kappa	Phase-I	Active	EVQLVESGPGLVKPSETLSLTCTVSGFSLTRFGVHWVRQPPGKGLEWLGVIWRGGSTDYNAAFVSRLTISKDNSKNQVSLKLSSVTAADTAVYYCSNHYYGSSDYALDNWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQDVRNLVVWFQQKPGKAPKLLIYSGSYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSPPYTFGQGTKVEIK	EVQLVQSGAEVKKPGASVKVSCKASGFTFTSYYIHWVRQAPGQGLEWIGWIYPENDNTKYNEKFKDRVTITADTSTSTAYLELSSLRSEDTAVYYCARDGYSRYYFDYWGQGTLVTVSS	DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIYWTSTRKSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSFILRTFGQGTKVEIK	None;None	None;None	None;None	2019		FCRL5;CD3	Genentech		Multiple myeloma			
Cibisatamab	Bispecific mAb with Domain Crossover	-amab	G1	Kappa;Lambda	Phase-I/II	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTEFGMNWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARWDFAYYVEAMDYWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCKASAAVGTYVAWYQQKPGKAPKLLIYSASYRKRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYYTYPLFTFGQGTKLEIK	QVQLVQSGAEVKKPGASVKVSCKASGYTFTEFGMNWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARWDFAYYVEAMDYWGQGTTVTVSS	QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL	None;None	None;None	None;None	2017	2018.0	CEACAM5&CD3E;CD3E	Roche		Non-small cell lung cancer;Colorectal cancer;Solid tumours			
Cinpanemab	Whole mAb	-emab	G1	Lambda	Phase-II	Active	EVQLVESGGGLVEPGGSLRLSCAVSGFDFEKAWMSWVRQAPGQGLQWVARIKSTADGGTTSYAAPVEGRFIISRDDSRNMLYLQMNSLKTEDTAVYYCTSAHWGQGTLVTVSS	SYELTQPPSVSVSPGQTARITCSGEALPMQFAHWYQQRPGKAPVIVVYKDSERPSGVPERFSGSSSGTTATLTITGVQAEDEADYYCQSPDSTNTYEVFGGGTKLTVL			6ct7:HL:AB	None	None	2018	2019.0	SNCA	Neurimmune Therapeutics;Biogen		Parkinson's disease			
Citatuzumab	Fab Fusion	-zumab	G1	Kappa	Phase-I	Active	EVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDYWGQGTLLTVSS	DIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELK			None	None	None	2008	2009.0	EPCAM	Viventia Biotech;Sesen Bio		Solid tumours			
Cixutumumab	Whole mAb	-umab	G1	Lambda	Phase-II	Discontinued	EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARAPLRFLEWSTQDHYYYYYMDVWGKGTTVTVSS	SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCKSRDGSGQHLVFGGGTKLTVL			None	None	None	2008	2009.0	IGF1R	Eli Lilly;ImClone Systems;M. D. Anderson Cancer Center;National Cancer Institute (USA) 			Breast cancer;Colorectal cancer;Head and neck cancer;Liver cancer;Neuroendocrine tumours;Non-small cell lung cancer;Oesophageal cancer;Pancreatic cancer;Prostate cancer;Rhabdomyosarcoma;Sarcoma;Soft tissue sarcoma;Solid tumours;Thymoma	Dyax Human Phage Display	
Claudiximab	Whole mAb	-ximab	G1	Kappa	Phase-III	Active	QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWINWVKQRPGQGLEWIGNIYPSDSYTNYNQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCTRSWRGNSFDYWGQGTTLTVSS	DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPFTFGSGTKLEIK			None	None	None	2017	2018.0	CLDN18	Ganymed Pharmaceuticals		Gastric cancer;Oesophageal cancer;Pancreatic cancer;Solid tumours			Zolbetuximab and Claudiximab are the same mAb
Clazakizumab	Whole mAb	-zumab	G1	Kappa	Phase-III	Active	EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYYVTWVRQAPGKGLEWVGIIYGSDETAYATSAIGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDSSDWDAKFNLWGQGTLVTVSS	AIQMTQSPSSLSASVGDRVTITCQASQSINNELSWYQQKPGKAPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQGYSLRNIDNAFGGGTKVEIK			None	None	None	2012	2013.0	IL6	Alder Biopharmaceuticals;Cedars-Sinai Medical Center;Medical University of Vienna;Vitaeris		Inflammation;Psoriatic arthritis;Renal transplant rejection;Rheumatoid arthritis	Anaemia;Cachexia;Fatigue;Stomatitis;Crohn's disease;Graft-versus-host disease		
Clervonafusp	di-Fab Fusion	-fusp	G1	Kappa	Phase-I/II	Active	EVQLQESGGGVVQPGGSLRLSCAASGFTFSNYGMHWIRQAPGKGLEWVSYISSGSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRSEDTAVYYCARRGLLLDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTISCRASKSVSTSSYSYMHWYQQKPEKALIKYASYLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQHSRETFGAGTKLELK			None	None	None	2018	2019.0	SLC29A2	Valerion Therapeutics		Glycogen storage disease type II			
Clivatuzumab	Whole mAb Radiolabelled	-zumab	G1	Kappa	Phase-III	Discontinued	QVQLQQSGAEVKKPGASVKVSCEASGYTFPSYVLHWVKQAPGQGLEWIGYINPYNDGTQYNEKFKGKATLTRDTSINTAYMELSRLRSDDTAVYYCARGFGGSYGFAYWGQGTLVTVSS	DIQLTQSPSSLSASVGDRVTMTCSASSSVSSSYLYWYQQKPGKAPKLWIYSTSNLASGVPARFSGSGSGTDFTLTISSLQPEDSASYFCHQWNRYPYTFGGGTRLEIK				None	None	2009	2010.0	MUC1	Immunomedics			Pancreatic cancer		
Cobolimab	Whole mAb	-imab	G4	Kappa	Phase-II	Active	EVQLLESGGGLVQPGGSLRLSCAAASGFTFSSYDMSWVRQAPGKGLDWVSTISGGGTYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASMDYWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQSIRRYLNWYHQKPGKAPKLLIYGASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQSHSAPLTFGGGTKVEIK			None	None	None	2018	2019.0	HAVCR2	AnaptysBio;GlaxoSmithKline;TESARO		Non-small cell lung cancer;Solid tumours			
Codrituzumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPGQGLEWMGALDPKTGDTAYSQKFKGRVTLTADKSTSTAYMELSSLTSEDTAVYYCTRFYSYTYWGQGTLVTVSS	DVVMTQSPLSLPVTPGEPASISCRSSQSLVHSNRNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQNTHVPPTFGQGTKLEIK			None	None	None	2013	2014.0	GPC3	Perseus Proteomics;Chugai Pharmaceutical;Roche		Liver cancer			
Cofetuzumab	Whole mAb ADC	-zumab	G1	Kappa	Phase-I	Active	QVQLVQSGPEVKKPGASVKVSCKASGYTFTDYAVHWVRQAPGKRLEWIGVISTYNDYTYNNQDFKGRVTMTRDTSASTAYMELSRLRSEDTAVYYCARGNSYFYALDYWGQGTSVTVSS	EIVLTQSPATLSLSPGERATLSCRASESVDSYGKSFMHWYQQKPGQAPRLLIYRASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSNEDPWTFGGGTKLEIK			None	None	None	2017	2018.0	PTK7	Stemcentrx;Indiana University;Pfizer;Stemcentrx		Breast cancer;Solid tumours			
Coltuximab	Whole mAb ADC	-ximab	G1	Kappa	Phase-II	Active	QVQLVQPGAEVVKPGASVKLSCKTSGYTFTSNWMHWVKQAPGQGLEWIGEIDPSDSYTNYNQNFQGKAKLTVDKSTSTAYMEVSSLRSDDTAVYYCARGSNPYYYAMDYWGQGTSVTVSS	EIVLTQSPAIMSASPGERVTMTCSASSGVNYMHWYQQKPGTSPRRWIYDTSKLASGVPARFSGSGSGTDYSLTISSMEPEDAATYYCHQRGSYTFGGGTKLEIK			6ani:HL:IM	None	None	2013	2014.0	CD19	ImmunoGen		Diffuse large B cell lymphoma	Precursor cell lymphoblastic leukaemia-lymphoma		
Conatumumab	Whole mAb	-umab	G1	Kappa	Phase-II	Discontinued	QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYFWSWIRQLPGKGLEWIGHIHNSGTTYYNPSLKSRVTISVDTSKKQFSLRLSSVTAADTAVYYCARDRGGDYYYGMDVWGQGTTVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQGISRSYLAWYQQKPGQAPSLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGSSPWTFGQGTKVEIK			None	None	None	2008	2009.0	TNFRSF10B	Amgen;Takeda			Colorectal cancer;Lymphoma;Non-small cell lung cancer;Pancreatic cancer;Sarcoma;Solid tumours	Abgenix XenoMouse	
Concizumab	Whole mAb	-zumab	G4	Kappa	Phase-III	Active	EVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWVRQTPEKRLEWVATISRSGSYSYFPDSVQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGGYDEGDAMDSWGQGTTVTVSS	DIVMTQTPLSLSVTPGQPASISCKSSQSLLESDGKTYLNWYLQKPGQSPQLLIYLVSILDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQATHFPQTFGGGTKVEIK			4dtg:HL	None	None	2012	2013.0	TFPI	Novo Nordisk		Haemophilia			
Coprelotamab	Whole mAb	-amab	G1	Kappa	TBC	Active	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK			1fvc:DC:BA/4hkz:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD	1fve:BA:DC/4x4x:AB:CD/6bgt:BA	5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL	2020		ERBB2	TBC	TBC	TBC	TBC	Coprelotamab is a biosimilar of Trastuzumab and Timigutuzumab with an identical Variable region. Cinrebafusp have identical V domain.	
Cosfroviximab	Whole mAb	-ximab	G1	Kappa	Phase-II	Active	DVKLLESGGGLVQPGGSLKLSCAASGFSLSTSGVGVGWFRQPSGKGLEWLALIWWDDDKYYNPSLKSQLSISKDFSRNQVFLKISNVDIADTATYYCARRDPFGYDNAMGYWGQGTSVTVSS	DIVMTQSPLSLSTSVGDRVSLTCKASQNVGTAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADYFCQQYSSYPLTFGAGTKLELR			None	None	None	2016	2017.0	Zaire Ebolavirus GP	Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases		Ebola virus infections 		Zmapp Technology	
Cosibelimab	Whole mAb	-imab	G1	Lambda	Phase-I	Active	EVQLVQSGAEVKKPGSSVKVSCKASGGTFSRSAISWVRQAPGQGLEWMGVIIPAFGEANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGRQMFGAGIDFWGQGTLVTVSS	NFMLTQPHSVSESPGKTVTISCTRSSGSIDSNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSNNRHVIFGGGTKLTVL			None	None	None	2019	2020.0	PDL1	Dana-Farber Cancer Institute;Checkpoint Therapeutics;TG Therapeutics Inc		Cancer;Lymphoma			
Crenezumab	Whole mAb	-zumab	G4	Kappa	Phase-III	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLELVASINSNGGSTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASGDYWGQGTTVTVSS	DIVMTQSPLSLPVTPGEPASISCRSSQSLVYSNGDTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK			5vzx:HL:EI/5vzy:HL	5kmv:HL:EI	None	2011	2012.0	APP	AC Immune;Genentech;Universidad de Antioquia		Alzheimer's disease			
Crizanlizumab	Whole mAb	-zumab	G2	Kappa	Approved	Active	QVQLVQSGAEVKKPGASVKVSCKVSGYTFTSYDINWVRQAPGKGLEWMGWIYPGDGSIKYNEKFKGRVTMTVDKSTDTAYMELSSLRSEDTAVYYCARRGEYGNYEGAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGHSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSDENPLTFGGGTKVEIK			None	None	None	2016	2017.0	SELP	Selexys Pharmaceuticals;Novartis	Vaso-occlusive crisis	Priapism;Myelofibrosis			
Crotedumab	Whole mAb	-umab	G4	Kappa	Phase-I	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYLMNWVRQAPGKGLEWLANIQEDGIEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREPSHYDILTGYDYYYGMDVWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTEFILTVSSLQPEDFATYYCLQYNSNPFTFGPGTKVDIK			None	None	None	2015	2016.0	GCGR	Regeneron Pharmaceuticals;Sanofi			Type 2 diabetes mellitus		
Crovalimab	Whole mAb	-imab	G1	Kappa	Phase-I/II	Active	QVQLVESGGGLVQPGRSLRLSCAASGFTVHSSYYMAWVRQAPGKGLEWVGAIFTGSGAEYKAEWAKGRVTISKDTSKNQVVLTMTNMDPVDTATYYCASDAGYDYPTHAMHYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQGISSSLAWYQQKPGKAPKLLIYGASETESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNTKVGSSYGNTFGGGTKVEIK			5b71:DC:BA	None	None	2018	2019.0	C5	Chugai Pharmaceutical;Roche		Paroxysmal nocturnal haemoglobinuria			
Cudarolimab	Whole mAb	-imab	G1	Kappa	Phase-I	Active	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGRPWYSETGTSAFDIWGQGTMVTVSS	DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQSDHYPTFGGGTKVEIK			None	None	None	2019		TNFRSF4	Innovent Biologics		Solid tumours			
Cusatuzumab	Whole mAb	-zumab	G1	Lambda	Phase-II	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSVYYMNWVRQAPGKGLEWVSDINNEGGTTYYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAVYYCARDAGYSNHVPIFDSWGQGTLVTVSS	QAVVTQEPSLTVSPGGTVTLTCGLKSGSVTSDNFPTWYQQTPGQAPRLLIYNTNTRHSGVPDRFSGSILGNKAALTITGAQADDEAEYFCALFISNPSVEFGGGTQLTVL			None	None	None	2017	2018.0	CD70	arGEN-X		Cutaneous T-cell lymphoma;Acute myeloid leukaemia;Haematological malignancies;Myelodysplastic syndromes;Solid tumours;Autoimmune disorders	Nasopharyngeal cancer	POTELLIGENT Technology;SIMPLE Antibody Technology	
Dacetuzumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSYNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIK			None	None	None	2007	2008.0	CD40	Seattle Genetics			Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Multiple myeloma;Non-Hodgkin's lymphoma		
Daclizumab	Whole mAb	-zumab	G1	Kappa	Approved	Active	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTLVTVSS	DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGQGTKVEVK			3nfs:HL/3nfp:HL:AB	None	None	1994	1998.0	IL2RA	AbbVie;Biogen;Dana-Farber Cancer Institute;National Cancer Institute (USA);PDL BioPharma	Renal transplant rejection	Multiple sclerosis	Asthma;Graft-versus-host disease;Haematological malignancies;Immune-mediated uveitis;Liver transplant rejection;Psoriasis;Tropical spastic paraparesis;Type 1 diabetes mellitus;Ulcerative colitis	GS Gene Expression System	
Dafsolimab	Whole mAb	-imab	G2b	Kappa	TBC	Active	QVQLQQSGAELARPGASVKMSCKASGYTFTSYTMHWVKQRPGQGLEWIGYINPSSGYTNYIQRFKDKATLTADKSSSTAYMQVSSLTSEDSAVYYCARGSRYDYYGMDYWGQGTSVTVSS	QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK			None	None	None	2020		CD3E	TBC	TBC	TBC	TBC		
Dalotuzumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Active	QVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTLVTVSS	DIVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPWTFGQGTKVEIK			None	None	None	2009	2010.0	IGF1R	Pierre Fabre;Merck & Co		Breast cancer;Colorectal cancer;Pancreatic cancer	Multiple myeloma;Neuroendocrine tumours;Non-small cell lung cancer;Solid tumours		"Jain paper: ""Entries in WHO-INN documents (PL102 and RL64) have errors"""
Dapirolizumab	Fab	-zumab	G1	Kappa	Phase-II	Active	EVQLVESGGGLVQPGGSLRLSCAVSGFSSTNYHVHWVRQAPGKGLEWMGVIWGDGDTSYNSVLKSRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARQLTHYYVLAAWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASEDLYYNLAWYQRKPGKAPKLLIYDTYRLADGVPSRFSGSGSGTDYTLTISSLQPEDFASYYCQQYYKFPFTFGQGTKVEIK			None	None	None	2013	2014.0	CD40LG	Biogen;Biogen Idec;UCB		Systemic lupus erythematosus			
Daratumumab	Whole mAb	-umab	G1	Kappa	Approved	Active	EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIK			None	None	None	2009	2010.0	CD38	Boston Medical Center;Bristol-Myers Squibb;Dana-Farber Cancer Institute;French Innovative Leukemia Organisation;Genentech;Genmab;Janssen Biotech;Janssen Research & Development;M. D. Anderson Cancer Center;Syros Pharmaceuticals	Multiple myeloma	Amyloid light-chain amyloidosis;Acute myeloid leukaemia;Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Follicular lymphoma;Mantle-cell lymphoma;Myelodysplastic syndromes;Precursor B-cell lymphoblastic leukaemia-lymphoma;Precursor T-cell lymphoblastic leukaemia-lymphoma;Prostate cancer;T-cell lymphoma;Waldenstrom's macroglobulinaemia;Solid tumours	Non-small cell lung cancer	Medarex HuMAb Mouse	
Datopotamab	Whole mAb	-amab	G1	Kappa	Phase-I	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTTAGMQWVRQAPGQGLEWMGWINTHSGVPKYAEDFKGRVTISADTSTSTAYLQLSSLKSEDTAVYYCARSGFGSSYWYFDVWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGQGTKLEIK			None	None	None	2019		TACSTD2	Daiichi Sankyo		Cancers;Non-small cell lung cancer			
Daxdilimab	Whole mAb	-imab	G1	Lambda	Phase-I	Active	QVQLQQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTIDTSTSTAYMELRSLRSDDTAVYYCARNGLWGWDSDAFDIWGRGTLVTVSS	QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTVVFGGGTKVTVL			None	None	None	2020		LILRA4	Viela Bio		Cutaneous lupus erythematosus;Dermatomyositis;Polymyositis;Sjogren's syndrome;Systemic lupus erythematosus;Systemic scleroderma			
Dectrekumab	Whole mAb	-umab	G1	Kappa	Phase-II	Discontinued	EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLWFGDLDAFDIWGQGTMVTVSS	EIVLTQSPATLSLSPGERAILSCRAGQSVSSYLVWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSSWPPVYTFGQGTKLEIK			None	None	None	2014	2015.0	IL13	Novartis			Asthma;Idiopathic pulmonary fibrosis;Keloids;Oesophagitis;Rectal fistula;Seasonal allergic rhinitis		
Demcizumab	Whole mAb	-zumab	G2	Kappa	Phase-I	Discontinued	QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIHWVKQAPGQGLEWIGYISSYNGATNYNQKFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVGMDYWGQGTLVTVSS	DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIK			None	None	None	2012	2013.0	DLL4	Celgene Corporation;OncoMed Pharmaceuticals			Colorectal cancer;Fallopian tube cancer;Non-small cell lung cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Solid tumours		
Demupitamab	Whole mAb	-amab	G1	Kappa	Phase-I	Active	QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS	DIQMTQSPSTLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK			None	5sx4:HL:JI/5sx5:HL:JK	None	2019		EGFR	Sinocelltech		Cancers			Likely to be a Panitumumab biosimilar
Denintuzumab	Whole mAb ADC	-zumab	G1	Kappa	Phase-II	Discontinued	QVQLQESGPGLVKPSQTLSLTCTVSGGSISTSGMGVGWIRQHPGKGLEWIGHIWWDDDKRYNPALKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARMELWSYYFDYWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPRLLIYDTSKLASGIPARFSGSGSGTDFTLTISSLEPEDVAVYYCFQGSVYPFTFGQGTKLEIK			None	None	None	2014	2015.0	CD19	Seattle Genetics			Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma		
Denosumab	Whole mAb	-umab	G2	Kappa	Approved	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIK			None	None	6ghg:HL	2005	2006.0	TNFSF11	Amgen;Daiichi Sankyo Company;European Thoracic Oncology Platform;GlaxoSmithKline;Jules Bordet Institute;Melbourne Health;University Health Network	Bone cancer;Bone disorders;Bone metastases;Corticosteroid-induced osteoporosis;Male osteoporosis;Malignant hypercalcaemia;Osteoporosis;Postmenopausal osteoporosis;Rheumatoid arthritis	Breast cancer;Non-small cell lung cancer;Osteogenesis imperfecta;Malignant melanoma	Multiple myeloma 	Abgenix XenoMouse	
Depatuxizumab	Whole mAb ADC	-xizumab	G1	Kappa	Phase-III	Discontinued	QVQLQESGPGLVKPSQTLSLTCTVSGYSISSDFAWNWIRQPPGKGLEWMGYISYSGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTAGRGFPYWGQGTLVTVSS	DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK			None	None	None	2016	2017.0	EGFR	Ludwig Institute for Cancer Research;AbbVie			Solid tumours		
Depemokimab	Whole mAb	-imab	G1	Kappa	TBC	Active	QVTLRESGPALVKPTQTLTLTCTVSGFSLTGSSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSGLLRLDYWGRGTLVTVSS	DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIK			None	None	None	2020		IL5	TBC	TBC	TBC	TBC		
Derlotuximab	Whole mAb Radiolabelled	-ximab	G1	Kappa	Approved	Active	QVQLKESGPGLVAPSQSLSITCTVSGFSLTDYGVRWIRQPPGKGLEWLGVIWGGGSTYYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAKEKRRGYYYAMDYWGQGTSVTVSS	ENVLTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFGGGTKLEIK			None	None	None	2015	2016.0	DNA/H1 Complex	Avid Bioservices;MediPharm Biotech	Lung cancer	Glioblastoma			
Dezamizumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGSSVKVSCKASGFTFATYNMHWVRQAPGQGLEWMGYIYPGDGNANYNQQFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGDFDYDGGYYFDSWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASENIYSYLAWYQQKPGKAPKLLIHNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGAPLTFGQGTKLEIK			None	None	None	2016	2017.0	APCS	Pentraxin Therapeutics;GlaxoSmithKline		Amyloidosis			
Dilpacimab	Bispecific mAb	-imab	G1	Kappa;Kappa	Phase-II	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFPMAWVRQAPGKGLEWVATISSSDGTTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGYYNSPFAYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASEDIYSNLAWYQQKPGKAPKLLIYDTNNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPPTFGQGTKLEIK	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK	None;1bj1:HL:KJ	None;None	None;6bft:HL:AB/1cz8:HL:YX	2018	2019.0	DLL4;VEGFA	AbbVie		Colorectal cancer;Solid tumours			
Dinutuximab	Whole mAb	-ximab	G1	Kappa	Approved	Active	EVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSSSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVSS	EIVMTQSPATLSVSPGERATLSCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK			None	None	4tuj:CD:AB/4tul:HL/4trp:HL/4tuo:AB:CD/4tuk:HL	2013	2014.0	Ganglioside GD2	National Cancer Institute (USA);New Approaches to Neuroblastoma Therapy Consortium;St. John of God Foundation;United Therapeutics Corporation	Neuroblastoma	Small cell lung cancer	Malignant melanoma		
Diridavumab	Whole mAb	-umab	G1	Lambda	Phase-II	Active	EVQLVESGAEVKKPGSSVKVSCKASGGPFRSYAISWVRQAPGQGPEWMGGIIPIFGTTKYAPKFQGRVTITADDFAGTVYMELSSLRSEDTAMYYCAKHMGYQVRETMDVWGKGTTVTVSS	QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNDYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEANYYCATWDRRPTAYVVFGGGTKLTVL			3gbn:HL/3gbm:HL:IM/5c0s:HL	None	4evn:AB:CD:IJ:OP:KL:EF:GH:MN	2014	2015.0	Influenza A HA2	National Institute of Allergy and Infectious Diseases;Crucell		Influenza A virus infections			
Disitamab	Whole mAb ADC	-amab	G1	Kappa	Phase-II	Active	EVQLVQSGAEVKKPGATVKISCKVSGYTFTDYYIHWVQQAPGKGLEWMGRVNPDHGDSYYNQKFKDKATITADKSTDTAYMELSSLRSEDTAVYFCARNYLFDHWGQGTLVTVSS	DIQMTQSPSSVSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASIRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQFATYTFGGGTKVEIK			None	None	None	2018	2019.0	ERBB2	Yantai Rongchang Biological Engineering		Breast cancer;Gastric cancer;Urogenital cancer;Solid tumours			
Divozilimab	Whole mAb	-imab	G1	Kappa	TBC	Active	EVQLVQPGAEVVKPGASVKVSCKASGYTFTSYNMHWVRQAPGRGLEWMGAIYPGNGDTSYNQKFKGRVTMTRDKSTSTVYMELSSLRSEDTAVYYCARSTYYGGDWYFNVWGQGTLVTVSS	QIVLSQSPAILSASPGERVTLTCRASSSVSYIHWFQQKPGKAPKPLIYATSNLASGVPSRFSGSGSGTDFSLTISRVEPEDFAVYYCQQWTSNPPTFGGGTKVEIK			None	None	None	2020		MS4A1	TBC	TBC	TBC	TBC		
Docaravimab	Whole mAb (Mouse)	-imab	G2b	Kappa	Phase-I	Active	QVQLKESGPGLLAPSQSLSITCTVSGFSLTGHGVNWVRQPPGKGLEWLGIIWADGTTNYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTASYYCAREGDISGYYFDYWGQGTTLTVSS	DVQMTQTTSSLSASLGDRVTITCRPSQDINNYLSWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPPTFGGGTKLEIK			None	None	None	2019		Rabies Virus Strain ERA GP Ectodomain Epitope G-III	Candila Healthcare		Rabies post-exposure			Mouse antibody
Domagrozumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSTISSGGSYTSYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKQDYAMNYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFGGGTKVEIK			None	5f3h:EF:GH:AB:CD	None	2015	2016.0	MSTN	Kennedy Krieger Institute;Pfizer		Duchenne muscular dystrophy;Limb girdle muscular dystrophies			
Donanemab	Whole mAb	-emab	G1	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGSSVKVSCKASGYDFTRYYINWVRQAPGQGLEWMGWINPGSGNTKYNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCAREGITVYWGQGTTVTVSS	DIVMTQTPLSLSVTPGQPASISCKSSQSLLYSRGKTYLNWLLQKPGQSPQLLIYAVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCVQGTHYPFTFGQGTKLEIK			None	None	None	2018	2019.0	APP	Eli Lilly		Alzheimer's disease			
Dostarlimab	Whole mAb	-imab	G4	Kappa	Phase-III	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASPYYAMDYWGQGTTVTVSS	DIQLTQSPSFLSAYVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTLHTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQHYSSYPWTFGQGTKLEIK			None	None	None	2018	2019.0	PDCD1	AnaptysBio;European Network of Gynaecological Oncological Trial Groups;GlaxoSmithKline;TESARO		Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Endometrial cancer;Non-small cell lung cancer;Solid tumours			
Dovanvetmab	Feline Whole mAb	-vetmab	G1	Kappa	Unknown	Active	QVLLVQSGAEVRTPGASVKIFCKASGYSFTSYTIHWLRQAPAQGLEWMGNINPTSGYTENNQRFKDRLTLTADTSTNTAYMELSSLRSADTAMYYCARWGFKYDGEWSFDVWGAGTTVTVSS	EIQMTQSPSSLSASPGDRVTITCRASQGISIWLSWYQQKPGNIPKVLINKASNLHIGVPSRFSGSGSGTDFTLTISSLEPEDAATYYCLQSQTYPLTFGGGTKLEIK			None	None	None	2019	2020.0	IL31 (Feline)						
Drozitumab	Whole mAb	-umab	G1	Lambda	Phase-II	Discontinued	EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSGINWQGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDYWGKGTTVTVSS	SELTQDPAVSVALGQTVRITCSGDSLRSYYASWYQQKPGQAPVLVIYGANNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSADSSGNHVVFGGGTKLTVL			4od2:BA	None	None	2010	2011.0	TNFRSF10B	Genentech			Chondrosarcoma;Colorectal cancer;Non-Hodgkin's lymphoma;Non-small cell lung cancer		
Duligotuzumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGFTLSGDWIHWVRQAPGKGLEWVGEISAAGGYTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARESRVSFEAAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQNIATDVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSEPEPYTFGQGTKVEIK			None	None	3p0v:HL:IM/3p0y:HL/3p11:HL	2012	2014.0	ERBB3	Genentech;Roche			Solid tumours;Colorectal cancer;Head and neck cancer		
Dupilumab	Whole mAb	-umab	G4	Kappa	Approved	Active	EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSS	DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQALQTPYTFGQGTKLEIK			None	None	None	2012	2013.0	IL4R	Aimmune Therapeutics;Regeneron Pharmaceuticals;Sanofi	Asthma;Atopic dermatitis	Nasal polyps;Chronic obstructive pulmonary disease;Eosinophilic oesophagitis;Grass pollen hypersensitivity;Peanut hypersensitivity;Urticaria;Allergic asthma		VelocImmune Mouse	
Durvalumab	Whole mAb	-umab	G1	Kappa	Approved	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIK			5xj4:HL/5x8m:BC	None	None	2014	2015.0	CD274	Advaxis;AIO Studien gGmbH;AstraZeneca;Big Ten Cancer Research Consortium;Canadian Cancer Trials Group;Case Comprehensive Cancer Center;Celgene International SARL;Centre hospitalier de l'Universite de Montreal;Centre Leon Berard;Charite - Universitatsmedizin Berlin;Childrens Hospital Los Angeles;Dana-Farber Cancer Institute;Eli Lilly;Fondazione IRCCS Istituto Nazionale dei Tumori;GlaxoSmithKline;Gradalis;Grand Hopital de Charleroi;Grupo Espanol de Tumores Neuroendocrinos;Gustave Roussy;Immunocore;Innate Pharma;Institut Claudius Regaud;Juno Therapeutics;Kyoto Breast Cancer Research Network;Ludwig Institute for Cancer Research;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;Mirati Therapeutics;Myriad Genetic Laboratories;National Cancer Institute (USA);National Health and Medical Research Council;Northwestern University;Pharmacyclics;Plexxikon;Radboud University;Samsung Medical Center;Spanish Oncology Genito-Urinary Group;Swiss Group for Clinical Cancer Research;UNC Lineberger Comprehensive Cancer Center;UNICANCER;University College London;University of Colorado at Denver;University of Kansas Medical Center;University of Maryland Greenbaum Cancer Center;University of Southern California;University of Sydney;University of Texas M. D. Anderson Cancer Center;VentiRx Pharmaceuticals;Washington University School of Medicine;Yale University;Yonsei University College of Medicine	Non-small cell lung cancer;Urogenital cancer	Biliary cancer;Bladder cancer;Cervical cancer;Fallopian tube cancer;Head and neck cancer;Liver cancer;Ovarian cancer;Peritoneal cancer;Renal cell carcinoma;Small cell lung cancer;Solid tumours;Breast cancer;Gynaecological cancer;Pancreatic cancer;Acute myeloid leukaemia;Brain metastases;Cholangiocarcinoma;Colorectal cancer;Diffuse large B cell lymphoma;Endometrial cancer;Gallbladder cancer;Gastric cancer;Germ cell and embryonal neoplasms;Glioblastoma;Mesothelioma;Multiple myeloma;Myelodysplastic syndromes;Neuroendocrine tumours;Oesophageal cancer;Oropharyngeal cancer;Prostate cancer;Sarcoma;Soft tissue sarcoma;Chronic lymphocytic leukaemia;Cutaneous T-cell lymphoma;Haematological malignancies;Lung cancer;Lymphoma;Malignant melanoma;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma;Renal cancer;CNS cancer;Gastrointestinal cancer;Lymphoproliferative disorders;Myelofibrosis;Thyroid cancer;Vulvovaginal cancer		Abgenix XenoMouse	
Dusigitumab	Whole mAb	-umab	G2	Lambda	Phase-II	Discontinued	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGNTGYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARDPYYYYYGMDVWGQGTTVTVSS	QSVLTQPPSVSAAPGQKVTISCSGSSSNIENNHVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCETWDTSLSAGRVFGGGTKLTVL			None	None	None	2012	2013.0	IGF1&IGF2	MedImmune			Breast cancer;Liver cancer;Solid tumours		
Duvortuxizumab	Bispecific scFv with Crossover	-xizumab		Kappa;Lambda	Phase-I	Discontinued	QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGKALEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVFLTMTNMDPVDTATYYCARMELWSYYFDYWGQGTTVTVSS	ENVLTQSPATLSVTPGEKATITCRASQSVSYMHWYQQKPGQAPRLLIYDASNRASGVPSRFSGSGSGTDHTLTISSLEAEDAATYYCFQGSVYPFTFGQGTKLEIK	EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS	QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL	None;None	None;None	None;None	2016	2017.0	CD19;CD3E	Janssen Biotech;MacroGenics			Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma	Dual-Affinity Re-Targeting Technology	
Ebronucimab	Whole mAb	-imab	G1	Lambda	TBC	Active	EVQLVESGGGLVQPGRSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSGISSSSSYISYADSVQGRFTISRDNGKNSLYLQMNSLRAEDTALYFCAREYDFWSAYYDAFDVWGQGTMVTVSS	QSELTQPRSVSGSPGQSVTISCTGTSRNIGGGNDVHWYQQHPGKAPKLLISGVIERSSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCQSFDGSLSGSVFGTGTDVTVL			None	None	None	2020		PCSK9	TBC	TBC	TBC	TBC		
Eculizumab	Whole mAb	-zumab	G2	Kappa	Approved	Active	QVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK			5i5k:HL:XY	None	None	2002	2003.0	C5	Alexion Pharmaceuticals;Brigham and Womens Hospital;Chiba University;Handok Inc	Haemolytic uraemic syndrome;Myasthenia gravis;Paroxysmal nocturnal haemoglobinuria	Neuromyelitis optica;Delayed graft function;Guillain-Barre syndrome;Renal transplant rejection	Antiphospholipid syndrome;Heart transplant rejection;Adult respiratory distress syndrome;Age-related macular degeneration;Allergic asthma;Autoimmune haemolytic anaemia;Bullous pemphigoid;Dermatomyositis;Glomerulonephritis;Idiopathic thrombocytopenic purpura;Lupus nephritis;Membranous glomerulonephritis;Motor neuron disease;Psoriasis;Rheumatoid arthritis;Systemic lupus erythematosus	GS Gene Expression System	
Edrecolomab	Whole mAb	-omab	G2a	Kappa	Approved (w)	Discontinued	QVQLQQSGAELVRPGTSVKVSCKASGYAFTNYLIEWVKQRPGQGLEWIGVINPGSGGTNYNEKFKGKATLTADKSSSTAYMQLSSLTSDDSAVYFCARDGPWFAYWGQGTLVTVSA	NIVMTQSPKSMSMSVGERVTLTCKASENVVTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQGYSYPYTFGGGTKLEIK			None	None	None	1995	1996.0	EPCAM	Ajinomoto;Centocor Inc	Colorectal cancer 		Adenocarcinoma;Pancreatic cancer		
Efalizumab	Whole mAb	-zumab	G1	Kappa	Approved	NFD	EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGMIHPSDSETRYNQKFKDRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARGIYFYGTTYFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIK			3eo9:HL/3eoa:HL:BA/3eob:HL:BA	None	None	2001	2002.0	ITGAL	Genentech;Merck Serono;XOMA	Psoriasis		Psoriatic arthritis;Type 1 diabetes mellitus		
Efungumab	scFv	-umab		Kappa	Phase-III	Discontinued	EVQLVESGAEVKKPGESLRISCKGSGCIISSYWISWVRQMPGKGLEWMGKIDPGDSYINYSPSFQGHVTISADKSINTAYLQWNSLKASDTAMYYCARGGRDFGDSFDYWGQGTLVTVSS	DVVMTQSPSFLSAFVGDRITITCRASSGISRYLAWYQQAPGKAPKLLIYAASTLQTGVPSRFSGSGSGTEFTLTINSLQPEDFATYYCQHLNSYPLTFGGGTKVDIK			None	None	None	2006	2007.0	Heat Shock Protein 90 Homolog	NeuTec Pharma			Breast cancer;Candidiasis		
Eldelumab	Whole mAb	-umab	G1	Kappa	Phase-II	Discontinued	QMQLVESGGGVVQPGRSLRLSCTASGFTFSNNGMHWVRQAPGKGLEWVAVIWFDGMNKFYVDSVKGRFTISRDNSKNTLYLEMNSLRAEDTAIYYCAREGDGSGIYYYYGMDVWGQGTTVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPIFTFGPGTKVDIK			None	None	None	2013	2014.0	CXCL10	Bristol-Myers Squibb;Medarex			Crohn's disease;Ulcerative colitis;Multiple sclerosis;Rheumatoid arthritis;Spinal cord injuries	Medarex UltiMAb Mouse	
Elezanumab	Whole mAb	-umab	G1	Lambda	Phase-II	Active	EVQLVQSGAEVKKPGASVKVSCKASGYTFTSHGISWVRQAPGQGLDWMGWISPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELSSLRSEDTAVYYCARVGSGPYYYMDVWGQGTLVTVSS	QSALTQPRSVSGSPGQSVTISCTGTSSSVGDSIYVSWYQQHPGKAPKLMLYDVTKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCYSYAGTDTLFGGGTKVTVL			None	None	None	2016	2017.0	RGMA	AbbVie		Multiple sclerosis;Spinal cord injuries			
Elgemtumab	Whole mAb	-umab	G1	Kappa	Phase-I/II	Discontinued	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINSQGKSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWGDEGFDIWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSFPTTFGQGTKVEIK			None	None	4p59:HL	2014	2015.0	ERBB3	MorphoSys;Novartis;Memorial Sloan-Kettering Cancer Center;Novartis Oncology			Breast cancer;Gastric cancer;Head and neck cancer;Oesophageal cancer;Solid tumours	Medarex HuMAb Mouse	
Elipovimab	Whole mAb	-imab	G1	Lambda	Phase-I	Active	QMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLTGVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGTGTQVTVSS	SDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSRPGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVL			None	None	4fq1:HL/4jy4:BA/4fqc:HL	2018	2019.0	HIV-1 gp120	Gilead Sciences		HIV infections			
Elotuzumab	Whole mAb	-zumab	G1	Kappa	Approved	NFD	EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLLIYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQQYSSYPYTFGQGTKVEIK			None	None	None	2008	2009.0	SLAMF7	AbbVie;Australasian Leukaemia & Lymphoma Group;Bristol-Myers Squibb;PDL BioPharma	Multiple myeloma				
Eluvixtamab	Bispecific scFv	-amab	na;na	Kappa;Lambda	TBC	Active	QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVKQAPGQGLEWMGWINTYTGEPTYADKFQGRVTMTTDTSTSTAYMEIRNLGGDDTAVYYCARWSWSDGYYVYFDYWGQGTSVTVSS	DIVMTQSPDSLTVSLGERTTINCKSSQSVLDSSTNKNSLAWYQQKPGQPPKLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSPQPEDSATYYCQQSAHFPITFGQGTRLEIK	EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS	QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL	None;None	None;None	None;None	2020		CD33;CD3E	TBC	TBC	TBC	TBC		
Emactuzumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWMGVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDQRLYFDVWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCRASEDVNTYVSWYQQKPGKAPKLLIYAASNRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSYPTFGQGTKLEIK			4liq:HL	None	None	2014	2015.0	CSF1R	Roche;University of Texas M. D. Anderson Cancer Center		Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Solid tumours	Giant cell tumour of tendon sheath;Pigmented villonodular synovitis		
Emapalumab	Whole mAb	-umab	G1	Lambda	Approved	NFD	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGSSGWYVPHWFDPWGQGTLVTVSS	NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDGSNRWMFGGGTKLTVL			None	None	None	2016	2017.0	IFNG	NovImmune SA;Swedish Orphan Biovitrum	Haemophagocytic lymphohistiocytosis				
Emerfetamab	Bispecific scFv	-amab	na;na	Kappa;Lambda	TBC	Active	QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVKQAPGQCLEWMGWINTYTGEPTYADKFQGRVTMTTDTSTSTAYMEIRNLGGDDTAVYYCARWSWSDGYYVYFDYWGQGTSVTVSS	DIVMTQSPDSLTVSLGERTTINCKSSQSVLDSSTNKNSLAWYQQKPGQPPKLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSPQPEDSATYYCQQSAHFPITFGCGTRLEIK	EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS	QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL	None;None	None;None	None;None	2020		CD33;CD3E	TBC	TBC	TBC	TBC		
Emicizumab	Bispecific mAb	-zumab	G4;G4	Kappa;Kappa	Approved	NFD	QVQLVQSGSELKKPGASVKVSCKASGYTFTDNNMDWVRQAPGQGLEWMGDINTRSGGSIYNEEFQDRVIMTVDKSTDTAYMELSSLRSEDTATYHCARRKSYGYYLDEWGEGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASRNIERQLAWYQQKPGQAPELLIYQASRKESGVPDRFSGSRYGTDFTLTISSLQPEDIATYYCQQYSDPPLTFGGGTKVEIK	QVQLVESGGGLVQPGGSLRLSCAASGFTFSYYDIQWVRQAPGKGLEWVSSISPSGQSTYYRREVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRTGREYGGGWYFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASRNIERQLAWYQQKPGQAPELLIYQASRKESGVPDRFSGSRYGTDFTLTISSLQPEDIATYYCQQYSDPPLTFGGGTKVEIK	None;None	None;None	None;None	2015	2016.0	F9;F10	Chugai Pharmaceutical;Roche	Haemophilia A				
Emibetuzumab	Whole mAb	-zumab	G4	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGRVNPNRRGTTYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARANWLDYWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCSVSSSVSSIYLHWYQQKPGKAPKLLIYSTSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQVYSGYPLTFGGGTKVEIK			None	None	None	2014	2015.0	MET	Eli Lilly		Gastric cancer;Non-small cell lung cancer;Cancer			
Enapotamab	Whole mAb ADC	-amab	G1	Kappa	Phase-II	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSTTSGSGASTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKIWIAFDIWGQGTMVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKLEIK			None	None	None	2017	2018.0	AXL	Genmab		Solid tumours			
Enavatuzumab	Whole mAb	-zumab	G1	Kappa	Phase-I	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAEIRLKSDNYATHYAESVKGRFTISRDDSKNSLYLQMNSLRAEDTAVYYCTGYYADAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQSVSTSSYSYMHWYQQKPGKAPKLLIKYASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSWEIPYTFGGGTKVEIK			None	None	None	2010	2011.0	TNFRSF12A	PDL BioPharma;Abbott Laboratories			Solid tumours		
Encelimab	Whole mAb	-imab	G4	Kappa	Phase-I	Active	EVQLVQSGAEVKKPGATVKISCKASGFSIKDDYIHWVQQAPGKGLEWMGWIDAMNDDSQYSSKFQGRVTITVDTSTNTAYMKLSSLRSEDTAVYYCTYAFGGYWGQGTTVTVSS	DIVMTQTPLSLSVTPGQPASISCRSSQSLVHSDSNTYLHWYLQKPGQSPQLLIYLVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCGQSTHVPYAFGGGTKVEIK			None	None	None	2019	2020.0	LAG3	Anaptys Bio;TESARO		Solid tumours			
Enfortumab	Whole mAb ADC	-umab	G1	Kappa	Approved	NFD	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYNMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLSLQMNSLRDEDTAVYYCARAYYYGMDVWGQGTTVTVSS	DIQMTQSPSSVSASVGDRVTITCRASQGISGWLAWYQQKPGKAPKFLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPPTFGGGTKVEIK			None	None	None	2013	2014.0	PVRL4	Agensys;Seattle Genetics		Urogenital cancer			
Enibarcimab	Whole mAb	-imab	G1	Kappa	TBC	Active	QVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWIEWVRQAPGQGLEWIGEILPGSGSTNYNQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCTEGYEYDGFDYWGQGTTVTVSS	DVVLTQSPLSLPVTLGQPASISCRSSQSIVYSNGNTYLEWYLQRPGQSPRLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPYTFGGGTKLEIK			None	None	None	2020		ADM	TBC	TBC	TBC	TBC		
Enoblituzumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSDSSAIYYADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTVSS	DIQLTQSPSFLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPFTFGQGTKLEIK			None	None	None	2015	2017.0	CD276	MacroGenics;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins		Prostate cancer;Solid tumours;Malignant melanoma;Non-small cell lung cancer;Squamous cell cancer;Urogenital cancer			
Enokizumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Discontinued	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSYYWIEWVRQAPGQGLEWMGEILPGSGTTNPNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARADYYGSDYVKFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQHVITHVTWYQQKPGKAPKLLIYGTSYSYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYEYPLTFGGGTKVEIK			None	None	None	2010	2011.0	IL9	Genaera Corporation;Ludwig Institute for Cancer Research;MedImmune			Asthma		
Enoticumab	Whole mAb	-umab	G1	Kappa	Phase-I	Discontinued	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVSFLWYDGTNKNYVESVKGRFTISRDNSKNMLYLEMNSLRAEDTAVYYCARDHDFRSGYEGWFDPWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHRSNWPPTFGGGTKVEIK			None	None	None	2012	2013.0	DLL4	Regeneron Pharmaceuticals;Sanofi			Solid tumours	VelocImmune Mouse	
Ensituximab	Whole mAb	-ximab	G1	Kappa	Phase-II	Active	QVQLKESGPDLVAPSQSLSITCTVSGFSLSKFGVNWVRQPPGKGLEWLGVIWGDGSTSYNSGLISRLSISKENSKSQVFLKLNSLQADDTATYYCVKPGGDYWGHGTSVTVSS	QVVLTQSPVIMSASPGEKVTMTCSASSSISYMYWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISNMEAGDAATYYCHQRDSYPWTFGGGTNLEIK			None	None	None	2010	2011.0	MUC5AC	Neogenix Oncology;Duke University Medical Center;H. Lee Moffitt Cancer Center and Research Institute;Johns Hopkins Medical Institutions;Montefiore Medical Center;National Cancer Institute (USA);Precision Biologics;University of North Carolina;University of Texas Southwestern Medical Center;Yale University School of Medicine		Colorectal cancer;Pancreatic cancer			
Envafolimab	Single Domain Variable Fragment;H	-imab	G1		Phase-III	Active	QVQLVESGGGLVQPGGSLRLSCAASGKMSSRRCMAWFRQAPGKERERVAKLLTTSGSTYLADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAADSFEDPTCTLVTSS				None	None	None	2018	2019.0	PDL1	Alphamab;3D Medicines;Sun Yat-Sen University		Biliary cancer;Breast cancer;Solid tumours			
Epcoritamab	Bispecific mAb	-amab	G1	Lambda;Kappa	Phase-I/II	Active	EVKLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKSSLYLQMNNLKTEDTAMYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS	QAVVTQEPSFSVSPGGTVTLTCRSSTGAVTTSNYANWVQQTPGQAFRGLIGGTNKRAPGVPARFSGSLIGDKAALTITGAQADDESIYFCALWYSNLWVFGGGTKLTVL	EVQLVESGGGLVQPDRSLRLSCAASGFTFHDYAMHWVRQAPGKGLEWVSTISWNSGTIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK	None;None	None;None	None;3giz:HL	2019	2020.0	CD3E;MS4A1	Genmab		Haematological malignancies			Second Fv closely related to Ofatumumab
Epratuzumab	Whole mAb	-zumab	G1	Kappa	Phase-III	Discontinued	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIGYINPRNDYTEYNQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCARRDITTFYWGQGTTVTVSS	DIQLTQSPSSLSASVGDRVTMSCKSSQSVLYSANHKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYLSSWTFGGGTKLEIK			None	5vkk:AB:HL/5vl3:EF:AB:HL:CD	None	1999	2000.0	CD22	Charite - Universitatsmedizin Berlin;Children's Oncology Group;Immunomedics;National Cancer Institute (USA);UCB			Precursor cell lymphoblastic leukaemia-lymphoma;Systemic lupus erythematosus;Non-Hodgkin's lymphoma;Cachexia		
Eptinezumab	Whole mAb	-zumab	G1	Kappa	Preregistration	Active	EVQLVESGGGLVQPGGSLRLSCAVSGIDLSGYYMNWVRQAPGKGLEWVGVIGINGATYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVTVSS	QVLTQSPSSLSASVGDRVTINCQASQSVYHNTYLAWYQQKPGKVPKQLIYDASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLGSYDCTNGDCFVFGGGTKVEIK			None	None	None	2016	2017.0	CALCA&CALCB	Alder Biopharmaceuticals		Migraine			
Erenumab	Whole mAb	-umab	G2	Lambda	Approved	NFD	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSIKYSVDSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCARDRLNYYDSSGYYHYKYYGMAVWGQGTTVTVSS	QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSTTLGITGLQTGDEADYYCGTWDSRLSAVVFGGGTKLTVL			6umh:HL/6umi:HL/6umj:HL	None	None	2016	2017.0	CALCRL	Amgen;Novartis	Migraine		Hot flashes	Abgenix XenoMouse	
Etaracizumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Discontinued	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVAKVSSGGGSTYYLDTVQGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHLHGSFASWGQGTTVTVSS	EIVLTQSPATLSLSPGERATLSCQASQSISNFLHWYQQRPGQAPRLLIRYRSQSISGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSGSWPLTFGGGTKVEIK			None	None	None	2008	2009.0	ITGAV_ITGB3	Applied Molecular Evolution;MedImmune			Colorectal cancer;Malignant melanoma;Prostate cancer;Psoriasis;Rheumatoid arthritis		
Etevritamab	Bispecific scFv	-amab	na;na	Kappa;Lambda	TBC	Active	QVQLVESGGGVVQSGRSLRLSCAASGFTFRNYGMHWVRQAPGKCLEWVAVIWYDGSDKYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGYDILTGNPRDFDYWGQGTLVTVSS	DTVMTQTPLSSHVTLGQPASISCRSSQSLVHSDGNTYLSWLQQRPGQPPRLLIYRISRRFSGVPDRFSGSGAGTDFTLEISRVEAEDVGVYYCMQSTHVPRTFGCGTKVEIK	EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS	QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL	None;None	None;None	None;None	2020		EGFR;CD3E	TBC	TBC	TBC	TBC		
Etigilimab	Whole mAb	-imab	G1	Kappa	Phase-I	Active	QVQLQESGPGLVKPSETLSLTCAVSGYSITSDYAWNWIRQPPGKGLEWIGYISYSGSTSYNPSLRSRVTISRDTSKNQFFLKLSSVTAADTAVYYCARRQVGLGFAYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHYSTPWTFGQGTKVEIK			None	None	None	2017	2018.0	TIGIT	OncoMed Pharmaceuticals		Solid tumours			
Etokimab	Whole mAb	-imab	G1	Kappa	Phase-II	Active	QVQLMQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGTIYPRNSNTDYNQKFKARVTMTRDTSTSTVYMELSSLRSEDTAVYYCARPLYYYLTSPPTLFWGQGTLVTVSS	DIQLTQSPSFLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQAKTYPFTFGSGTKLEIK			None	None	None	2018	2019.0	IL13	AnaptysBio		Asthma;Atopic dermatitis;Peanut hypersensitivity;Rhinosinusitis			
Etrolizumab	Whole mAb	-zumab	G1	Kappa	Phase-III	Active	EVQLVESGGGLVQPGGSLRLSCAASGFFITNNYWGWVRQAPGKGLEWVGYISYSGSTSYNPSLKSRFTISRDTSKNTFYLQMNSLRAEDTAVYYCARTGSSGYFDFWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASESVDDLLHWYQQKPGKAPKLLIKYASQSISGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGNSLPNTFGQGTKVEIK			None	None	None	2010	2011.0	ITGA4_ITGB7&ITGAE_ITGB7	Genentech;Roche		Crohn's disease;Ulcerative colitis			
Evinacumab	Whole mAb	-umab	G4	Kappa	Phase-III	Active	EVQLVESGGGVIQPGGSLRLSCAASGFTFDDYAMNWVRQGPGKGLEWVSAISGDGGSTYYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAFFYCAKDLRNTIFGVVIPDAFDIWGQGTMVTVSS	DIQMTQSPSTLSASVGDRVTITCRASQSIRSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSYTFGQGTKLEIK			None	None	None	2014	2015.0	ANGPTL3	Regeneron Pharmaceuticals;Sanofi		Hypercholesterolaemia;Hyperlipoproteinaemia type IIa;Hypertriglyceridaemia			
Evolocumab	Whole mAb	-umab	G2	Lambda	Approved	Active	EVQLVQSGAEVKKPGASVKVSCKASGYTLTSYGISWVRQAPGQGLEWMGWVSFYNGNTNYAQKLQGRGTMTTDPSTSTAYMELRSLRSDDTAVYYCARGYGMDVWGQGTTVTVSS	ESALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTSTSMVFGGGTKLTVL			None	None	None	2012	2013.0	PCSK9	Amgen;Amgen Astellas BioPharma;University Hospital Inselspital	Coronary disorders;Hypercholesterolaemia;Hyperlipoproteinaemia type IIa;Myocardial infarction;Stroke	Hyperlipidaemia		Abgenix XenoMouse	
Ezabenlimab	Whole mAb	-imab	G4	Kappa	Phase-I	Active	EVMLVESGGGLVQPGGSLRLSCTASGFTFSKSAMSWVRQAPGKGLEWVAYISGGGGDTYYSSSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHSNYNYYAMDYWGQGTLVTVSS	EIVLTQSPATLSLSPGERATMSCRASENIDVSGISFMNWYQQKPGQAPKLLIYVASNQGSGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCQQSKEVPQTFGQGTKLEIK			None	None	None	2019		PDCD1	Boehringer Ingelheim		Cancers;Non-small cell lung cancer;Solid tumours;Lymphoma			
Faricimab	Bispecific mAb	-imab	G1	Kappa;Lambda	Phase-III	Active	EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS	DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSPNPYYYDSSGYYYPGAFDIWGQGTMVTVSS	SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVL	1cz8:HL:YX;None	None;None	1bj1:HL:KJ/6bft:AB:HL;4iml:AB:HL/4imk:AD:BC	2017	2018.0	VEGFA;ANGPT2	Chugai Pharmaceutical;Roche		Diabetic macular oedema;Wet age-related macular degeneration		Dual-Affinity Re-Targeting Technology	
Farletuzumab	Whole mAb	-zumab	G1	Kappa	Phase-III	Active	EVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQAPGKGLEWVAMISSGGSYTYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDPAWFAYWGQGTPVTVSS	DIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPGKAPKPWIYGTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSYPYMYTFGQGTKVEIK			None	None	None	2008	2009.0	FOLR1	Ludwig Institute for Cancer Research;Morphotek;Eisai Co Ltd		Ovarian cancer;Non-small cell lung cancer	Solid tumours		
Fasinumab	Whole mAb	-umab	G4	Kappa	Phase-III	Active	QVQLVQSGAEVKKPGASVKVSCKVSGFTLTELSIHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELTSLRSEDTAVYYCSTIFGVVTNFDNWGQGTLVTVSS	DIQMTQSPSSLSASAGDRVTITCRASQAIRNDLGWYQQKPGKAPKRLIYAAFNLQSGVPSRFSGSGSGTEFTLTISSLQPEDLASYYCQQYNRYPWTFGQGTKVEIK			None	None	None	2012	2013.0	NGFB	Mitsubishi Tanabe Pharma Corporation;Regeneron Pharmaceuticals;Teva Pharmaceutical Industries;Sanofi		Back pain;Pain		VelocImmune Mouse	
Feladilimab	Whole mAb	-imab	G4	Kappa	Phase-I/II	Active	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYAMHWVRQAPGQGLEWMGLISIYSDHTNYNQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCGRNNYGNYGWYFDVWGQGTTVTVSS	EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPRLLIYDTSKLASGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCFQGSGYPYTFGQGTKLEIK			None	None	None	2019		ICOS	GlaxoSmithKline		Solid tumours			
Felzartamab	Whole mAb	-amab	G1	Lambda	Phase-I/II	Active	QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQGTLVTVSS	DIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTGGASLVFGGGTKLTVL			None	None	None	2019		CD38	MorphoSys		Multiple myeloma			
Fezakinumab	Whole mAb	-umab	G1	Lambda	Phase-I	Discontinued	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWVGWINPYTGSAFYAQKFRGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREPEKFDSDDSDVWGRGTLVTVSS	QAVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYGVHWYQQLPGTAPKLLIYGDSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDNSLSGYVFGGGTQLTVL			None	None	None	2009	2010.0	IL22	Pfizer;Wyeth			Psoriasis;Rheumatoid arthritis		
Fianlimab	Whole mAb	-imab	G4	Kappa	Phase-I	Active	QVQLVESGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAIIWYDGSNKYYADSVKGRFTISRDNSKNTQYLQMNSLRAEDTAVYYCASVATSGDFDYYGMDVWGQGTTVTVSS	EIVLTQSPATLSLSPGERTTLSCRASQRISTYLAWYQQKPGQAPRLLIYDASKRATGIPARFSGSGSGTGFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK			None	None	None	2019	2020.0	LAG3	Regeneron Pharmaceuticals		Cancer			
Fibatuzumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYWMNWVRQAPGQGLEWMGDIYPGSGNTNYDEKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGYYEDFDSWGQGTTVTVSS	DIQMTQSPSFLSASVGDRVTITCRASQGIISYLAWYQQKPEKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCGQYANYPYTFGQGTKLEIK			None	None	None	2015	2017.0	EPHA3	Ludwig Institute for Cancer Research;Humanigen;Olivia Newton-John Cancer Research Institute		Acute myeloid leukaemia;Myelodysplastic syndromes;Myelofibrosis;Glioblastoma		POTELLIGENT Technology;Humaneering Technology	Fibatuzumab and Ifabotuzumab are the same mAb
Ficlatuzumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Active	QVQLVQPGAEVKKPGTSVKLSCKASGYTFTTYWMHWVRQAPGQGLEWIGEINPTNGHTNYNQKFQGRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNYVGSIFDYWGQGTLLTVSS	DIVMTQSPDSLAMSLGERVTLNCKASENVVSYVSWYQQKPGQSPKLLIYGASNRESGVPDRFSGSGSATDFTLTISSVQAEDVADYHCGQSYNYPYTFGQGTKLEIK			None	None	None	2011	2012.0	HGF	AVEO Oncology;AVEO Pharmaceuticals;Dana-Farber Cancer Institute;University of Arizona Cancer Center;University of California at San Francisco		Head and neck cancer;Non-small cell lung cancer;Acute myeloid leukaemia;Pancreatic cancer	Lymphoma;Multiple myeloma;Solid tumours;Glioblastoma		
Figitumumab	Whole mAb	-umab	G2	Kappa	Phase-I	Discontinued	EVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMNWVRQAPGKGLEWVSAISGSGGTTFYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDLGWSDSYYYYYGMDVWGQGTTVTVSS	DIQMTQFPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASRLHRGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPCSFGQGTKLEIK			None	None	None	2008	2009.0	IGF1R	Pfizer			Breast cancer;Colorectal cancer;Gastrointestinal cancer;Gynaecological cancer;Multiple myeloma;Non-small cell lung cancer;Prostate cancer;Rheumatoid arthritis;Sarcoma;Small cell lung cancer;Solid tumours		
Firivumab	Whole mAb	-umab	G1	Kappa	Preclinical	Discontinued	QVQLVQSGAEVKMPGSSVKVSCKTSGVFFSSHAISWVRQAPGQGLEWMGGISPMFGTTHYAQKFQGRVTITADQSTTTAYMELTSLTSEDTAVYYCARDGAGSYYPLNWFDPWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASENIWNNLAWYQQKPGQAPRLLISGASTGATGVPSRFRGSGSRTEFTLTISSLQSEDFAIYFCQQYNSWPRTFGPGTKVEIK			None	None	None	2014	2015.0	Influenza A HA	Celltrion			Influenza A virus H1N1 subtype;Influenza A virus H5N1 subtype;Influenza virus infections		Firivumab and Navivumab are the same mAb
Flanvotumab	Whole mAb	-umab	G1	Kappa	Phase-I	Discontinued	QVQLVQSGSELKKPGASVKISCKASGYTFTSYAMNWVRQAPGQGLESMGWINTNTGNPTYAQGFTGRFVFSMDTSVSTAYLQISSLKAEDTAIYYCAPRYSSSWYLDYWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWLMYTFGQGTKLEIK			None	None	None	2011	2012.0	TYRP1	ImClone Systems;Eli Lilly			Malignant melanoma		
Fletikumab	Whole mAb	-umab	G4	Kappa	Phase-II	Discontinued	QVQLVQSGAEVKRPGASVKVSCKASGYTFTNDIIHWVRQAPGQRLEWMGWINAGYGNTQYSQNFQDRVSITRDTSASTAYMELISLRSEDTAVYYCAREPLWFGESSPHDYYGMDVWGQGTTVTVSS	AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK			None	None	None	2013	2014.0	IL20	ZymoGenetics;Novo Nordisk			Psoriasis;Rheumatoid arthritis		
Flotetuzumab	Bispecific scFv with Crossover	-zumab		Kappa;Lambda	Phase-I/II	Active	EVQLVQSGAELKKPGASVKVSCKASGYTFTDYYMKWVRQAPGQGLEWIGDIIPSNGATFYNQKFKGRVTITVDKSTSTAYMELSSLRSEDTAVYYCARSHLLRASWFAYWGQGTLVTVSS	DFVMTQSPDSLAVSLGERVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGQGTKLEIK	EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS	QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL	None;None	None;None	None;None	2017	2018.0	CD3E;IL3RA	MacroGenics;Servier		Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma		Dual-Affinity Re-Targeting Technology	
Fontolizumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Discontinued	QVQLVQSGAELKKPGSSVKVSCKASGYIFTSSWINWVKQAPGQGLEWIGRIDPSDGEVHYNQDFKDKATLTVDKSTNTAYMELSSLRSEDTAVYYCARGFLPWFADWGQGTLVTVSS	DIQMTQSPSTLSASVGDRVTITCKASENVDTYVSWYQQKPGKAPKLLIYGASNRYTGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCGQSYNYPFTFGQGTKVEVK			None	1t3f:BA/1t04:DC:BA	None	2002	2003.0	IFNG	PDL BioPharma			Autoimmune disorders;Crohn's disease;Psoriasis;Rheumatoid arthritis		
Foralumab	Whole mAb	-umab	G1	Kappa	Phase-I/II	Active	QVQLVESGGGVVQPGRSLRLSCAASGFKFSGYGMHWVRQAPGKGLEWVAVIWYDGSKKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQMGYWHFDLWGRGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPLTFGGGTKVEIK			None	None	None	2010	2011.0	CD3E	Medarex;NovImmune SA;Harvard Medical School;Tiziana Life Sciences		Crohn's disease;Neurodegenerative disorders;Primary biliary cirrhosis;Inflammatory bowel diseases;Non-alcoholic steatohepatitis;Type 2 diabetes mellitus	Transplant rejection;Type 1 diabetes mellitus		
Foravirumab	Whole mAb	-umab	G1	Kappa	Phase-II	Discontinued	QVQLVESGGGAVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVILYDGSDKFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVAVAGTHFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPPTFGGGTKVEIK			None	None	None	2008	2009.0	RV Antigenic Site III	Crucell;Sanofi Pasteur			Rabies	Human Phage Display	
Fremanezumab	Whole mAb	-zumab	G2	Kappa	Approved	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWISWVRQAPGKGLEWVAEIRSESDASATHYAEAVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLAYFDYGLAIQNYWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCKASKRVTTYVSWYQQKPGQAPRLLIYGASNRYLGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCSQSYNYPYTFGQGTKLEIK			None	None	None	2016	2017.0	CALCA&CALCB	Rinat Neuroscience;Teva Pharmaceutical Industries	Migraine	Headache	Cluster headache		
Fresolimumab	Whole mAb	-umab	G4	Kappa	Phase-I	Active	QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCASTLGLVLDAMDYWGQGTLVTVSS	ETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIK			None	3eo0:DC:BA/4kxz:JI:HL:NM:QP/4kv5:EF:GK:HL:JI/3eo1:BA:ED:KJ:HG	None	2009	2010.0	TGFB	Cambridge Antibody Technology;Baylor College of Medicine;Genzyme Corporation;Sanofi Genzyme		Osteogenesis imperfecta	Fibrosis;Malignant melanoma;Pulmonary fibrosis;Renal cancer;Focal segmental glomerulosclerosis	CAT Phage Display	
Frovocimab	Whole mAb	-imab	G4	Kappa	Phase-II	Active	EVQLVESGGGLVKPGGSLRLSCAASGFPFSKLGMVWVRQAPGKGLEWVSTISSGGGYTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGISFQGGTYTYVMDYWGQGTLVTVSS	DIVMTQSPLSLPVTPGEPASISCRSSKSLLHRNGITYSYWYLQKPGQSPQLLIYQLSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCYQNLELPLTFGQGTKVEIK			None	None	None	2018	2019.0	PCSK9	Eli Lilly		Hypercholesterolaemia			
Frunevetmab	Feline Whole mAb	-vetmab	G1	Kappa	Unknown	Active	QVQLVESGAELVQPGESLRLTCAASGFSLTNNNVNWVRQAPGKGLEWMGGVWAGGATDYNSALKSRLTITRDTSKNTVFLQMHSLQSEDTATYYCARDGGYSSSTLYAMDAWGQGTTVTVSA	DIEMTQSPLSLSVTPGESVSISCRASEDIYNALAWYLQKPGRSPRLLIYNTDTLHTGVPDRFSGSGSGTDFTLKISRVQTEDVGVYFCQHYFHYPRTFGQGTKLELK			None	None	None	2016	2017.0	NGFB	Nexvet		Feline osteoarthritis		PETization Technology	
Fulranumab	Whole mAb	-umab	G2	Kappa	Phase-III	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGFTLRSYSMNWVRQAPGKGLEWVSYISRSSHTIFYADSVKGRFTISRDNAKNSLYLQMDSLRDEDTAMYYCARVYSSGWHVSDYFDYWGQGILVTVSS	AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK			None	4m6o:HL	None	2010	2011.0	NGFB	Janssen Pharmaceuticals;Janssen Research & Development;Takeda;Amgen			Pain;Back pain;Cancer pain;Musculoskeletal pain;Neuropathic pain	Abgenix XenoMouse	
Futuximab	Whole mAb	-ximab	G1	Kappa	Phase-II	Active	EVQLQQPGSELVRPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGNIYPGSRSTNYDEKFKSKATLTVDTSSSTAYMQLSSLTSEDSAVYYCTRNGDYYVSSGDAMDYWGQGTSVTVSS	DIQMTQTTSSLSASLGDRVTISCRTSQDIGNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDFSLTINNVEQEDVATYFCQHYNTVPPTFGGGTKLEIK			None	None	None	2012	2013.0	EGFR	Symphogen;Merck		Colorectal cancer;Glioma;Non-small cell lung cancer	Head and neck cancer;Oesophageal cancer		Futuximab and Zatuximab are the same mAb
Galcanezumab	Whole mAb	-zumab	G4	Kappa	Approved	Active	QVQLVQSGAEVKKPGSSVKVSCKASGYTFGNYWMQWVRQAPGQGLEWMGAIYEGTGKTVYIQKFADRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSDYVSGFGYWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCRASKDISKYLNWYQQKPGKAPKLLIYYTSGYHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDALPPTFGGGTKVEIK			None	None	None	2015	2016.0	CALCA&CALCB	Eli Lilly	Migraine	Cluster headache	Musculoskeletal pain		
Galiximab	Whole mAb	-ximab	G1	Lambda	Phase-II	Discontinued	QVQLQESGPGLVKPSETLSLTCAVSGGSISGGYGWGWIRQPPGKGLEWIGSFYSSSGNTYYNPSLKSQVTISTDTSKNQFSLKLNSMTAADTAVYYCVRDRLFSVVGMVYNNWFDVWGPGVLVTVSS	ESALTQPPSVSGAPGQKVTISCTGSTSNIGGYDLHWYQQLPGTAPKLLIYDINKRPSGISDRFSGSKSGTAASLAITGLQTEDEADYYCQSYDSSLNAQVFGGGTRLTVL			None	None	None	2003	2004.0	CD80	Biogen;Biogen Idec			Autoimmune disorders;Non-Hodgkin's lymphoma;Psoriasis		
Gancotamab	scFv	-amab		Lambda	Phase-II	Discontinued	QVQLVESGGGLVQPGGSLRLSCAASGFTFRSYAMSWVRQAPGKGLEWVSAISGRGDNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKMTSNAFAFDYWGQGTLVTVSS	QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYGVHWYQQLPGTAPKLLIYGNTNRPSGVPDRFSGFKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL			None	None	None	2018	2019.0	ERBB2	Merrimack Pharmaceuticals;HERMES BioSciences			Breast cancer		
Ganitumab	Whole mAb	-umab	G1	Kappa	Phase-III	Active	QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARWTGRTDAFDIWGQGTMVTVSS	DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGQGTKVEIK			None	None	None	2010	2011.0	IGF1R	Amgen;Millennium;NantWorks;National Cancer Institute (USA);Novartis;Takeda;Takeda Oncology;UCLAs Jonsson Comprehensive Cancer Center		Ewing's sarcoma;Solid tumours;Rhabdomyosarcoma	Breast cancer;Colorectal cancer;Sarcoma;Small cell lung cancer;Non-small cell lung cancer;Pancreatic cancer;Prostate cancer		
Gantenerumab	Whole mAb	-umab	G1	Kappa	Phase-III	Active	QVELVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINASGTRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVRYFDVWGQGTLVTVSS	DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCLQIYNMPITFGQGTKVEIK			5csz:HL:AB	None	None	2012	2008.0	APP	MorphoSys;Chugai Pharmaceutical;Roche		Alzheimer's disease			
Garadacimab	Whole mAb	-imab	G4	Lambda	Phase-II	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSKYIMQWVRQAPGKGLEWVSGIDIPTKGTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARALPRSGYLISPHYYYYALDVWGQGTTVTVSS	QSVLTQPPSASGTPGQRVTISCSGSSSNIGRNYVYWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDASLRGVFGGGTKLTVL			None	None	None	2018	2019.0	F12	CSL Behring		Hereditary angioedema			
Garetosmab	Whole mAb	other	G4	Kappa	Phase-II	Active	QVQLQESGPGLVKPSETLSLTCTVSGGSFSSHFWSWIRQPPGKGLEWIGYILYTGGTSFNPSLKSRVSMSVGTSKNQFSLKLSSVTAADTAVYYCARARSGITFTGIIVPGSFDIWGQGTMVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK			None	None	None	2018	2019.0	INHBA	Regeneron Pharmaceuticals		Fibrodysplasia ossificans progressiva;Musculoskeletal disorders			
Garivulimab	Whole mAb	-imab	G1	Kappa	TBC	Active	EVQLVESGGGLVQPGGSLRLSCAVSGFSLTSYGVHWVRQAPGKGLEWVAVIWAGGSTNYADSVKGRFTISKDTSKNTVYLQMNSLRAEDTAVYYCAKPYGTSAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQDVGIVVAWYQQKPGKAPKLLIYWASIRHTGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYSNYPLYTFGQGTKVEIK			None	None	None	2020		CD274	TBC	TBC	TBC	TBC		
Gatipotuzumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Active	EVQLVESGGGLVQPGGSMRLSCVASGFPFSNYWMNWVRQAPGKGLEWVGEIRLKSNNYTTHYAESVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTRHYYFDYWGQGTLVTVSS	DIVMTQSPLSNPVTPGEPASISCRSSKSLLHSNGITYFFWYLQKPGQSPQLLIYQMSNLASGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGQGTKVEIK			None	None	None	2016	2017.0	MUC1	NEMOD Biotherapeutics;Glycotope		Ovarian cancer;Solid tumours		GlycoExpress Technology	Gatipotuzumab and PankoMab are the same mAb
Gatralimab	Whole mAb	-imab	G1	Kappa	Phase-I	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGFPFSNYWMNWVRQAPGKGLEWVGQIRLKSNNYATHYAESVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTPIDYWGQGTTVTVSS	DIVMTQTPLSLSVTPGQPASISCKSSQSLLYSNGKTYLNWVLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCVQGSHFHTFGQGTKLEIK			6obd:HL	None	None	2019	2020.0	CD52	Sanofi			Multiple sclerosis		
Gedivumab	Whole mAb	-umab	G1	Kappa	Phase-II	Active	EVQLVESGGGVVQPGKSLRLSCAASGLTFSSYAVHWVRQAPGKGLEWVTLISYDGANQYYADSVKGRFTISRDNSKNTVYLQMNSLRPEDTAVYYCAVPGPVFGIFPPWSYFDNWGQGILVTVSS	EIVLTQSPATLSVSPGERATLSCRASQVISHNLAWYQQKPGQAPRLLIYGASTRASGIPARFSGSGSGTDYTLTITSLQSEDFAVYYCQHYSNWPPRLTFGGGTKVEIK			None	None	4kvn:HL	2016	2017.0	Influenza A HA	Genentech		Influenza A virus infections			
Gemtuzumab	Whole mAb ADC	-zumab	G4	Kappa	Approved	NFD	EVQLVQSGAEVKKPGSSVKVSCKASGYTITDSNIHWVRQAPGQSLEWIGYIYPYNGGTDYNQKFKNRATLTVDNPTNTAYMELSSLRSEDTAFYYCVNGNPWLAYWGQGTLVTVSS	DIQLTQSPSTLSASVGDRVTITCRASESLDNYGIRFLTWFQQKPGKAPKLLMYAASNQGSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQTKEVPWSFGQGTKVEVK						2016	2017.0	CD33	UCB;Celgene Corporation;Pfizer;University of California San Diego	Acute myeloid leukaemia				
Geptanolimab	Whole mAb	-imab	G4	Kappa	TBC	Active	QIQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLKWMGWISGYTREPTYAADFKGRFVISLDTSVSTAYLQISSLKAEDTAVYYCARDVFDYWGQGTLVTVSS	DIVLTQSPASLAVSPGQRATITCRASESVDNYGYSFMNWFQQKPGQPPKLLIYRASNLESGVPARFSGSGSRTDFTLTINPVEADDTANYYCQQSNADPTFGQGTKLEIK			None	None	None	2020		PDCD1	TBC	TBC	TBC	TBC		
Gevokizumab	Whole mAb	-zumab	G2	Kappa	Phase-III	Active	QVQLQESGPGLVKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDGDESYNPSLKSRLTISKDTSKNQVSLKITSVTAADTAVYFCARNRYDPPWFVDWGQGTLVTVSS	DIQMTQSTSSLSASVGDRVTITCRASQDISNYLSWYQQKPGKAVKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQQEDFATYFCLQGKMLPWTFGQGTKLEIK			4g6k:HL/4g6m:HL	None	None	2010	2011.0	IL1B	IRIS;National Eye Institute;North Shore-Long Island Jewish Health System;Novartis;Servier;University of Zurich;XOMA		Uveitis;Acne vulgaris;Acute coronary syndromes;Diabetic nephropathies;Giant cell arteritis;Labyrinthitis;Myositis;Osteoarthritis;Schnitzler syndrome;Scleritis;Colorectal cancer;Renal cell carcinoma	Rheumatoid arthritis;Cancer;Gout;Juvenile rheumatoid arthritis;Type 1 diabetes mellitus;Type 2 diabetes mellitus;Pyoderma		
Giloralimab	Whole mAb	-imab	G1	Kappa	Phase-I	Active	EVQLQESGPGLVKPSETLSLTCTVSGYSITSNYYWNWIRQPPGKGLEWMGYIRYDGSNNYNPSLKNRVTISRDTSKNQFSLKLSSVTAADTAVYYCARLDYWGQGTTVTVSS	DIVMTQTPLSLSVTPGQPASISCRSSQSLENTNGNTFLNWYLQKPGQSPQLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQVTHVPFTFGQGTKLEIK			None	None	None	2019		CD40	AbbVie		Solid tumours			
Gilvetmab	Canine Whole mAb	-vetmab	G2	Kappa	Unknown	Active	EVQLVQSGGDLVKPGGSVRLSCVASGFNIKNTYMHWVRQAPGKGLQWIGRIAPANVDTKYAPKFQGKATISADTAKNTAYMQLNSLRAEDTAVYYCVLIYYDYDGDIDVWGQGTLVTVSS	DIVMTQTPLSLSVSLGEPASISCHASQNINVWLSWYRQKPGQIPQLLIYKASHLHTGVPDRFSGSGSGTDFTLRISRVEADDAGVYYCQQGQSWPLTFGQGTKVEIK						2016	2017.0	PDCD1 (Canine)	Merck		Canine Cancers			
Gimsilumab	Whole mAb	-umab	G1	Kappa	Phase-I	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGFTFSRHWMHWLRQVPGKGPVWVSRINGAGTSITYADSVRGRFTISRDNANNTLFLQMNSLRADDTALYFCARANSVWFRGLFDYWGQGTPVTVSS	EIVLTQSPVTLSVSPGERVTLSCRASQSVSTNLAWYQQKLGQGPRLLIYGASTRATDIPARFSGSGSETEFTLTISSLQSEDFAVYYCQQYDKWPDTFGQGTKLEIK			None	None	None	2017	2018.0	CSF2	Ludwig Institute for Cancer Research;Morphotek			Cancer;Rheumatoid arthritis	MORPHODOMA Technology	
Girentuximab	Whole mAb Radiolabelled	-ximab	G1	Kappa	Phase-III	Discontinued	DVKLVESGGGLVKLGGSLKLSCAASGFTFSNYYMSWVRQTPEKRLELVAAINSDGGITYYLDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALFYCARHRSGYFSMDYWGQGTSVTVSS	DIVMTQSQRFMSTTVGDRVSITCKASQNVVSAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADFFCQQYSNYPWTFGGGTKLEIK			None	None	None	2009	2010.0	CA9	Centocor Inc;Heidelberg Pharma AG			Renal cancer		
Glembatumumab	Whole mAb ADC	-umab	G2	Kappa	Phase-III	Discontinued	QVQLQESGPGLVKPSQTLSLTCTVSGGSISSFNYYWSWIRHHPGKGLEWIGYIYYSGSTYSNPSLKSRVTISVDTSKNQFSLTLSSVTAADTAVYYCARGYNWNYFDYWGQGTLVTVSS	EIVMTQSPATLSVSPGERATLSCRASQSVDNNLVWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK			None	None	None	2015	2016.0	GPNMB	CuraGen Corporation;Celldex Therapeutics Inc;National Cancer Institute (USA)			Brain cancer;Breast cancer;Malignant melanoma;Osteosarcoma;Squamous cell cancer;Uveal melanoma		
Glenzocimab	Fab	-imab	G1	Kappa	Phase-I	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGGIYPGNGDTSYNQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGTVVGDWYFDVWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRSSQSLENSNGNTYLNWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGRDFTFTISSLQPEDIATYYCLQLTHVPWTFGQGTKVEIT			None	None	None	2018	2019.0	GP6	Acticor Biotech		Stroke			
Glofitamab	Bispecific mAb with Domain Crossover	-amab	G1	Lambda;Kappa	Phase-I	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS	QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL	QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS	DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK	None;3pp3:HL/3pp4:HL	None;None	None;None	2019	2020.0	CD3E;MS4A1	Roche		Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma			
Golimumab	Whole mAb	-umab	G1	Kappa	Approved	Active	QVQLVESGGGVVQPGRSLRLSCAASGFIFSSYAMHWVRQAPGNGLEWVAFMSYDGSNKKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGIAAGGNYYYYGMDVWGQGTTVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVYSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK			5yoy:RO:IF:QN:GD:HE:PM	None	None	2004	2005.0	TNFA	Centocor;Centocor Ortho Biotech;Janssen Biotech;Merck & Co;Mitsubishi Tanabe Pharma Corporation;Medarex	Ankylosing spondylitis;Juvenile rheumatoid arthritis;Non-radiographic axial spondyloarthritis;Psoriatic arthritis;Rheumatoid arthritis;Ulcerative colitis	Hearing disorders;Type 1 diabetes mellitus	Asthma;Cardiovascular disorders;Sarcoidosis;Uveitis	Medarex UltiMAb Mouse	
Gomiliximab	Whole mAb	-ximab	G1	Kappa	Phase-II	Discontinued	EVQLVESGGGLAKPGGSLRLSCAASGFRFTFNNYYMDWVRQAPGQGLEWVSRISSSGDPTWYADSVKGRFTISRENANNTLFLQMNSLRAEDTAVYYCASLTTGSDSWGQGVLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDIRYYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTVSSLQPEDFATYYCLQVYSTPRTFGQGTKVEIK			None	3fzu:HL:CD	None	2004	2004.0	FCER2	Biogen Idec			Allergic asthma;Allergic rhinitis;Chronic lymphocytic leukaemia		Lumiliximab and Gomiliximab are the same mAb
Gontivimab	Bispecific Single Domains (VH-VH'-VH’)	-imab			Phase-II	Discontinued	DVQLVESGGGLVQAGGSLSISCAASGGSLSNYVLGWFRQAPGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYLQMNSLAPDDTAVYYCGAGTPLNPGAYIYDWSYDYWGRGTQVTVSS		EVQLVESGGGLVQAGGSLSISCAASGGSLSNYVLGWFRQAPGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYLQMNSLAPDDTAVYYCGAGTPLNPGAYIYDWSYDYWGRGTQVTVSS		None;None	None;None	None;None	2019		RSV gpF	Ablynx			Respiratory syncytial virus infections		
Gosuranemab	Whole mAb	-emab	G4	Kappa	Phase-II	Active	EVHLVESGGALVKPGGSLRLSCAASGFSFSKYGMSWVRQAPGKGLEWVATISSSGSRTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCSISWDGAMDYWGQGTTVTVSS	DVVMTQSPLSLPVTLGQPASISCKSSQSIVHSNGNTYLEWYLQKPGQSPQLLVYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGTYYCFQGSLVPWAFGGGTKVEIK			None	None	None	2018	2019.0	MAPT	Biogen;Bristol-Myers Squibb;iPierian		Alzheimer's disease;Progressive supranuclear palsy;Neurodegenerative disorders	Cardiovascular disorders;Metabolic disorders		
Gremubamab	Bispecific mAb	-amab	G1	Kappa;Kappa	Phase-II	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSAITMSGITAYYTDDVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEEFLPGTHYYYGMDVWGQGTTVTVSS	AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYSASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYCLQDYNYPWTFGQGTKVEIK	QVQLQESGPGLVKPSETLSLTCTVSGGSISPYYWTWIRQPPGKCLELIGYIHSSGYTDYNPSLKSRVTISGDTSKKQFSLKLSSVTAADTAVYYCARADWDRLRALDIWGQGTMVTVSS	DIQLTQSPSSLSASVGDRVTITCRASQSIRSHLNWYQQKPGKAPKLLIYGASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTGAWNWFGCGTKVEIK	None;None	None;None	None;None	2019	2020.0	PcrV type III secretion system;Polysaccharide synthesis locus (Pseudomonas)	MedImmune		Nosocomial pneumonia			
Grisnilimab	Whole mAb	-imab	G2a	Lambda	TBC	Active	QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLMWLGWINTYTGEPTYADDFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARWAYFYGSSPYFFDYWGQGTTLTVSS	QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWCSNHLVFGGGTKLTVL			None	None	None	2020		CD7	TBC	TBC	TBC	TBC		
Guselkumab	Whole mAb	-umab	G1	Lambda	Approved	Active	EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS	QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVL			4m6m:HL/4m6n:HL	None	None	2013	2014.0	IL23A	Janssen Biotech;MorphoSys;Taiho Pharmaceutical	Erythrodermic psoriasis;Palmoplantar pustulosis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis 	Crohn's disease;Hidradenitis suppurativa;Rheumatoid arthritis;Ulcerative colitis;Familial adenomatous polyposis		MorphoSys HuCAL Phage Display	
Ianalumab	Whole mAb	-umab	G1	Kappa	Phase-II/III	Active	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWGWIRQSPGRGLEWLGRIYYRSKWYNSYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARYQWVPKIGVFDSWGQGTLVTVSS	DIVLTQSPATLSLSPGERATLSCRASQFILPEYLSWYQQKPGQAPRLLIYGSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQFYSSPLTFGQGTKVEIK			None	None	None	2017	2018.0	TNFRSF13C	H. Lee Moffitt Cancer Center and Research Institute;MorphoSys;Novartis		Autoimmune hepatitis;Idiopathic pulmonary fibrosis;Multiple sclerosis;Pemphigus vulgaris;Rheumatoid arthritis;Sjogren's syndrome;Systemic lupus erythematosus;Chronic lymphocytic leukaemia		POTELLIGENT Technology	
Ibalizumab	Whole mAb	-zumab	G4	Kappa	Approved	NFD	QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSS	DIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYRTFGGGTKLEIK			3o2d:HL	None	None	2007	2008.0	CD4	Biogen Idec;TaiMed Biologics;Theratechnologies	HIV-1 infections				
Icatolimab	Whole mAb	-imab	G4	Kappa	Phase-I	Active	QVQLVQSGAEVKKPGASVKLSCKASGYNFKHTYAHWVRQAPGQGLEWIGRIDPANGNTKYDPKFQGRATMTADTASNTAYLELSSLRSEDTAVYYCVADHYGSSLLDYWGQGTLVTVSS	DVVMTQTPLSLSVTPGQPASISCKSSQSLLDSDGKTYLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTYFPYTFGQGTKLEIK			None	None	None	2019		BTLA	Shanghai Junshi Biosciences		Solid tumours			Chimeric
Icrucumab	Whole mAb	-umab	G1	Kappa	Phase-II	Active	QAQVVESGGGVVQSGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVRGRFTISRDNSENTLYLQMNSLRAEDTAVYYCARDHYGSGVHHYFYYGLDVWGQGTTVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK			None	None	None	2010	2011.0	FLT1	ImClone Systems		Breast cancer	Colorectal cancer;Urogenital cancer		
Idactamab	Whole mAb	-amab	G1	Kappa	TBC	Active	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEIHHSGGANYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGQGKNWHYDYFDYWGQGTLVTVSS	DIQMTQSPSTLSASVGDRVTITCRASQSIRSWLAWYQQKPGKAPKLLIYKASILKIGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYYSYSRTFGQGTKVEIK			None	None	None	2020		SLC1A5	TBC	TBC	TBC	TBC		
Idarucizumab	Fab	-zumab	G1	Kappa	Approved	NFD	QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYIVDWIRQPPGKGLEWIGVIWAGGSTGYNSALRSRVSITKDTSKNQFSLKLSSVTAADTAVYYCASAAYYSYYNYDGFAYWGQGTLVTVSS	DVVMTQSPLSLPVTLGQPASISCKSSQSLLYTDGKTYLYWFLQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQSTHFPHTFGGGTKVEIK			4jn2:HL:BA/4jn1:HL	None	None	2013	2014.0	Dabigatran	Boehringer Ingelheim	Blood coagulation disorders				
Ieramilimab	Whole mAb	-imab	G4	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGASVKVSCKASGFTLTNYGMNWVRQARGQRLEWIGWINTDTGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARNPPYYYGTNNAEAMDYWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCSSSQDISNYLNWYLQKPGQSPQLLIYYTSTLHLGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYYNLPWTFGQGTKVEIK			None	None	None	2018	2019.0	CD223	Immutep Limited;Novartis		Breast cancer;Diffuse large B cell lymphoma;Malignant melanoma;Solid tumours			
Ifabotuzumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYWMNWVRQAPGQGLEWMGDIYPGSGNTNYDEKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGYYEDFDSWGQGTTVTVSS	DIQMTQSPSFLSASVGDRVTITCRASQGIISYLAWYQQKPEKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCGQYANYPYTFGQGTKLEIK			None	None	None	2015	2017.0	EPHA3	Ludwig Institute for Cancer Research;Humanigen;Olivia Newton-John Cancer Research Institute		Acute myeloid leukaemia;Myelodysplastic syndromes;Myelofibrosis;Glioblastoma		POTELLIGENT Technology;Humaneering Technology	Fibatuzumab and Ifabotuzumab are the same mAb
Iladatuzumab	Whole mAb ADC	-zumab	G1	Kappa	Phase-I	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS	DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIK			None	None	None	2017	2019.0	CD79B	Roche			Non-Hodgkin's lymphoma		
Imalumab	Whole mAb	-umab	G1	Kappa	Phase-II	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSIYSMNWVRQAPGKGLEWVSSIGSSGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGSQWLYGMDVWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCRSSQRIMTYLNWYQQKPGKAPKLLIFVASHSQSGVPSRFRGSGSETDFTLTISGLQPEDSATYYCQQSFWTPLTFGGGTKVEIK			6foe:HL:AB	None	None	2014	2015.0	MIF	Cytokine PharmaSciences;Baxalta;Shire;Takeda		Colorectal cancer;Malignant ascites	Solid tumours;Lupus nephritis		
Imaprelimab	Whole mAb	-imab	G1	Kappa	Phase-I	Discontinued	QVTLKESGPVLVKPTETLTLTCTVSGFSLTSNAVSWVRQPPGKALEWIAAISSGGTTYYNSAFKSRLTISRDTSKSQVVLTMTNMDPVDTATYYCARRYGYGWYFDFWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTINCKASQNIYNSLAWYQQKPGKAPKVLIFNANSLQTGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYSGYTFGQGTKLEIK			None	None	None	2017	2018.0	MCAM	Neotope Biosciences;Onclave Therapeutics;Prothena;Prothena Corporation			Cancer;Inflammation;Psoriasis		
Imgatuzumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Discontinued	QVQLVQSGAEVKKPGSSVKVSCKASGFTFTDYKIHWVRQAPGQGLEWMGYFNPNSGYSTYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSPGGYYVMDAWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQGINNYLNWYQQKPGKAPKRLIYNTNNLQTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSFPTFGQGTKLEIK			None	None	None	2012	2013.0	EGFR	GLYCART Biotechnology;Roche			Colorectal cancer;Head and neck cancer;Non-small cell lung cancer	GlycoMAb Technology	
Inclacumab	Whole mAb	-umab	G4	Kappa	Phase-II	Discontinued	EVQLVESGGGLVRPGGSLRLSCAASGFTFSNYDMHWVRQATGKGLEWVSAITAAGDIYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARGRYSGSGSYYNDWFDPWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK			None	None	None	2011	2012.0	SELP	Genmab;Roche;Global Blood Therapeutics			Acute coronary syndromes;Myocardial infarction;Peripheral vascular disorders	Medarex UltiMAb Mouse	
Indatuximab	Whole mAb ADC	-ximab	G4	Kappa	Phase-II	Active	QVQLQQSGSELMMPGASVKISCKATGYTFSNYWIEWVKQRPGHGLEWIGEILPGTGRTIYNEKFKGKATFTADISSNTVQMQLSSLTSEDSAVYYCARRDYYGNFYYAMDYWGQGTSVTVSS	DIQMTQSTSSLSASLGDRVTISCSASQGINNYLNWYQQKPDGTVELLIYYTSTLQSGVPSRFSGSGSGTDYSLTISNLEPEDIGTYYCQQYSKLPRTFGGGTKLEIK			None	None	None	2011	2012.0	SDC1	Biotest AG		Bladder cancer;Breast cancer;Multiple myeloma			
Indusatumab	Whole mAb ADC	-umab	G1	Kappa	Phase-II	Discontinued	QVQLQQWGAGLLKPSETLSLTCAVFGGSFSGYYWSWIRQPPGKGLEWIGEINHRGNTNDNPSLKSRVTISVDTSKNQFALKLSSVTAADTAVYYCARERGYTYGNFDHWGQGTLVTVSS	EIVMTQSPATLSVSPGERATLSCRASQSVSRNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTIGSLQSEDFAVYYCQQYKTWPRTFGQGTNVEIK			None	None	None	2014	2015.0	GUCY2C	Millennium;Takeda Oncology			Colorectal cancer;Gastrointestinal cancer;Pancreatic cancer		
Inebilizumab	Whole mAb	-zumab	G1	Kappa	Preregistration	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSSWMNWVRQAPGKGLEWVGRIYPGDGDTNYNVKFKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARSGFITTVRDFDYWGQGTLVTVSS	EIVLTQSPDFQSVTPKEKVTITCRASESVDTFGISFMNWFQQKPDQSPKLLIHEASNQGSGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQSKEVPFTFGGGTKVEIK			None	None	None	2015	2016.0	CD19	Cellective Therapeutics;MedImmune		Neuromyelitis optica;Chronic lymphocytic leukaemia;B-cell lymphoma;Follicular lymphoma;Multiple myeloma;Multiple sclerosis;Autoimmune disorders;Myasthenia gravis;Renal transplant rejection	 Systemic scleroderma;Diffuse large B cell lymphoma	POTELLIGENT Technology	
Infliximab	Whole mAb	-ximab	G1	Kappa	Approved	NFD	EVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYAESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGTTLTVSS	DILLTQSPAILSVSPGERVSFSCRASQFVGSSIHWYQQRTNGSPRLLIKYASESMSGIPSRFSGSGSGTDFTLSINTVESEDIADYYCQQSHSWPFTFGSGTNLEVK			5vh3:HL:AB/5vh4:HL:AB/4g3y:HL/6ugs:HL:AB/6ugv:HL:AB/6ugt:HL:AB/6ugu:HL:AB	None	None	1997	1998.0	TNFA	Centocor;Janssen Biotech;Merck & Co;Mitsubishi Tanabe Pharma Corporation;National Jewish Medical and Research Center;Xian-Janssen	Ankylosing spondylitis;Behcet's syndrome;Crohn's disease;Mucocutaneous lymph node syndrome;Plaque psoriasis;Psoriasis;Psoriatic arthritis;Rheumatoid arthritis;Ulcerative colitis		Berylliosis;Hepatitis C;Pyoderma		
Inotuzumab	Whole mAb ADC	-zumab	G4	Kappa	Approved	Active	EVQLVQSGAEVKKPGASVKVSCKASGYRFTNYWIHWVRQAPGQGLEWIGGINPGNNYATYRRKFQGRVTMTADTSTSTVYMELSSLRSEDTAVYYCTREGYGNYGAWFAYWGQGTLVTVSS	DVQVTQSPSSLSASVGDRVTITCRSSQSLANSYGNTFLSWYLHKPGKAPQLLIYGISNRFSGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCLQGTHQPYTFGQGTKVEIK			None	None	None	2004	2005.0	CD22	Alliance for Clinical Trials in Oncology;Cancer Research UK;Case Comprehensive Cancer Center;Children's Oncology Group;Erasmus MC;M. D. Anderson Cancer Center;National Cancer Institute (USA);Pfizer;SWOG;University College London;University of Texas M. D. Anderson Cancer Center;Celltech Group	Precursor cell lymphoblastic leukaemia-lymphoma	Precursor B-cell lymphoblastic leukaemia-lymphoma;Chronic myeloid leukaemia	Acute biphenotypic leukaemia;Burkitt's lymphoma;Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma		
Intetumumab	Whole mAb	-umab	G1	Kappa	Phase-II	Discontinued	QVQLVESGGGVVQPGRSRRLSCAASGFTFSRYTMHWVRQAPGKGLEWVAVISFDGSNKYYVDSVKGRFTISRDNSENTLYLQVNILRAEDTAVYYCAREARGSYAFDIWGQGTMVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK			None	None	None	2009	2010.0	ITGAV_ITGB3	Centocor Inc;Janssen Biotech;Janssen-Cilag			Malignant melanoma;Prostate cancer	VelocImmune Mouse	
Ipilimumab	Whole mAb	-umab	G1	Kappa	Approved	Active	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK			5tru:HL:hl/5xj3:AB:DE:JK:GH/6jc2:HL	None	None	2005	2006.0	CTLA4	Aduro BioTech;AIO Studien gGmbH;Australian and New Zealand Urogenital and Prostate Cancer Group;Bavarian Nordic;Big Ten Cancer Research Consortium;BioGene Pharmaceutical;Bristol-Myers Squibb;Canadian Cancer Trials Group;Dana-Farber Cancer Institute;European Thoracic Oncology Platform;Grupo Espanol Multidisciplinar de Melanoma;Icahn School of Medicine at Mount Sinai;Intergroupe Francophone de Cancerologie Thoracique;Ludwig Institute for Cancer Research;Massachusetts General Hospital;Medarex;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);National University Hospital (Singapore);Northwestern University;Olivia Newton-John Cancer Research Institute;OncoTherapy Science;Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;University College London;University of California at San Francisco;University of Texas M. D. Anderson Cancer Center	Malignant melanoma;Renal cell carcinoma	Colorectal cancer;Non-small cell lung cancer;Gastric cancer;Glioblastoma;Head and neck cancer;Mesothelioma;Oesophageal cancer;Prostate cancer;Small cell lung cancer;Urogenital cancer;Adrenocortical carcinoma;Breast cancer;CNS cancer;Gastrointestinal cancer;Genitourinary disorders;Gynaecological cancer;Liver metastases;Meningeal carcinomatosis;Myelodysplastic syndromes;Neuroendocrine tumours;Ovarian cancer;Pancreatic cancer;Penile cancer;Solid tumours;Thyroid cancer;Uveal melanoma;Diffuse large B cell lymphoma;Liver cancer;Lung cancer;Glioma	HIV infections;Lymphoma	Medarex UltiMAb Mouse	
Iratumumab	Whole mAb	-umab	G1	Kappa	Phase-II	Discontinued	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSAYYWSWIRQPPGKGLEWIGDINHGGGTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCASLTAYWGQGSLVTVSS	DIQMTQSPTSLSASVGDRVTITCRASQGISSWLTWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPITFGQGTRLEIK			None	None	None	2005	2006.0	TNFRSF8	Medarex			Hodgkin's disease;Lymphoma;Non-Hodgkin's lymphoma	Medarex UltiMAb Mouse	
Isatuximab	Whole mAb	-ximab	G1	Kappa	Preregistration	Active	QVQLVQSGAEVAKPGTSVKLSCKASGYTFTDYWMQWVKQRPGQGLEWIGTIYPGDGDTGYAQKFQGKATLTADKSSKTVYMHLSSLASEDSAVYYCARGDYYGSNSLDYWGQGTSVTVSS	DIVMTQSHLSMSTSLGDPVSITCKASQDVSTVVAWYQQKPGQSPRRLIYSASYRYIGVPDRFTGSGAGTDFTFTISSVQAEDLAVYYCQQHYSPPYTFGGGTKLEIK			4cmh:BC	None	None	2014	2015.0	CD38	ImmunoGen;Huntsman Cancer Institute;Roche;Sanofi		Multiple myeloma;Acute myeloid leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma;T-cell lymphoma;Colorectal cancer;Diffuse large B cell lymphoma;Hodgkin's disease;Non-small cell lung cancer;Peripheral T-cell lymphoma;Prostate cancer;Solid tumours;Urogenital cancer			
Iscalimab	Whole mAb	-imab	G1	Kappa	Phase-II	Active	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYEESNRYHADSVKGRFTISRDNSKITLYLQMNSLRTEDTAVYYCARDGGIAAPGPDYWGQGTLVTVSS	DIVMTQSPLSLTVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQVLISLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPFTFGPGTKVDIR			None	None	None	2017	2018.0	CD40	Novartis;XOMA		Graves' disease;Lupus nephritis;Myasthenia gravis;Renal transplant rejection;Sjogren's syndrome;Systemic lupus erythematosus	Rheumatoid arthritis		
Isecarosmab	Bispecific Single Domains (VH-VH')	other	na;na	na;na	Phase-I	Active	DVQLVESGGGVVQPGGSLRLSCAASGRTVSSYAMGWFRQAPGKEREFVAGISRSAERTYYVDSLKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAADLDPNRIFSREEYAYWGQGTLVTVSS		EVQLVESGGGVVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSS		None;None	None;None	None;None	2019		ADAMTSL5;ALB	Merck		Solid tumours			
Istiratumab	Bispecific Mixed mAb and scFv	-umab	G1;na	Kappa;Lambda	Phase-II	Discontinued	EVQLLQSGGGLVQPGGSLRLSCAASGFMFSRYPMHWVRQAPGKGLEWVGSISGSGGATPYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDFYQILTGNAFDYWGQGTTVTVSS	DIQMTQSPSSLSASLGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAKSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDSATYYCQQYWTFPLTFGGGTKVEIK	QVQLVQSGGGLVQPGGSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVAGISWDSGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDLGAYQWVEGFDYWGQGTLVTVSS	SYELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSTSGNSASLTITGAQAEDEADYYCNSRDSPGNQWVFGGGTKVTVL	None;None	None;None	None;None	2017	2018.0	IGF1R;ERBB3	Adimab;Merrimack Pharmaceuticals			Ovarian cancer;Pancreatic cancer;Solid tumours		
Itepekimab	Whole mAb	-imab	G4	Kappa	Phase-II	Active	EVQLVESGGNLEQPGGSLRLSCTASGFTFSRSAMNWVRRAPGKGLEWVSGISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLSAEDTAAYYCAKDSYTTSWYGGMDVWGHGTTVTVSS	DIQMTQSPSSVSASVGDRVTITCRASQGIFSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQANSVPITFGQGTRLEIK			None	None	None	2019		IL33	Regeneron Pharmaceuticals;Sanofi		Asthma;COPD			
Itolizumab	Whole mAb	-zumab	G1	Kappa	Approved	Active	EVQLVESGGGLVKPGGSLKLSCAASGFKFSRYAMSWVRQAPGKRLEWVATISSGGSYIYYPDSVKGRFTISRDNVKNTLYLQMSSLRSEDTAMYYCARRDYDLDYFDSWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASRDIRSYLTWYQQKPGKAPKTLIYYATSLADGVPSRFSGSGSGQDYSLTISSLESDDTATYYCLQHGESPFTLGSGTKLEIK			None	None	None	2010	2011.0	CD6	Center of Molecular Immunology;Biocon;Biotech Pharmaceutical;Equillium	Plaque psoriasis	Rheumatoid arthritis;Graft-versus-host disease	Autoimmune disorders;Multiple sclerosis;Psoriasis		
Ivuxolimab	Whole mAb	-imab	G2	Kappa	Phase-II	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIDYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARESGWYLFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPPTFGGGTKVEIK			None	None	None	2019	2020.0	TNFRSF4	Pfizer;Dana-Farber Cancer Institute;M. D. Anderson Cancer Center;National Cancer Institute USA;University of Southern California		Breast cancer;Renal cell carcinoma;Solid tumours;Acute myeloid leukaemia;Squamous cell cancer;Follicular lymphoma			
Ixekizumab	Whole mAb	-zumab	G4	Kappa	Approved	Active	QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSS	DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIK			6nov:AB	6nou:AA	None	2011	2012.0	IL17A	Eli Lilly;Oregon Health & Science University;Torii Pharmaceutical	Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis	Ankylosing spondylitis;Spondylarthritis;Bullous pemphigoid;Pityriasis rubra pilaris;Pyoderma gangrenosum;Rheumatoid arthritis			
Izuralimab	Bispecific Mixed mAb and scFv	-imab	G1;na	Kappa;Kappa	TBC	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPHSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARTYYYDSSGYYHDAFDIWGQGTMVTVSS	DIQMTQSPSSVSASVGDRVTITCRASQGISRLLAWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGQGTKVEIK	EVQLVESGGGLVKPGGSLRLSCVASGFTFSNYWMNWVRQAPGKGLEWVAEIRLYSNNYATHYAESVKGRFTISRDDSKSTLYLQMNNLKTEDTGVYYCTRYYGNYGGYFDVWGRGTLVTVSS	EIVLTQSPATLSASPGERVTLTCRASQSVGNDVAWYQQKPGQAPRLLINYASHRYTGVPDRFTGSGYGTEFTLTISSVQSEDFGVYYCQQDFSSPRTFGGGTKVEIK	None;None	None;None	None;None	2020		ICOS;PDCD1	TBC	TBC	TBC	TBC		
Labetuzumab	Whole mAb ADC	-zumab	G1	Kappa	Phase-II	Active	EVQLVESGGGVVQPGRSLRLSCSASGFDFTTYWMSWVRQAPGKGLEWIGEIHPDSSTINYAPSLKDRFTISRDNAKNTLFLQMDSLRPEDTGVYFCASLYFGFPWFAYWGQGTPVTVSS	DIQLTQSPSSLSASVGDRVTITCKASQDVGTSVAWYQQKPGKAPKLLIYWTSTRHTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYSLYRSFGQGTKVEIK			None	None	None	2015	2016.0	CEACAM5	Immunomedics		Colorectal cancer			
Lacnotuzumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Active	QVQLQESGPGLVKPSQTLSLTCTVSDYSITSDYAWNWIRQFPGKGLEWMGYISYSGSTSYNPSLKSRITISRDTSKNQFSLQLNSVTAADTAVYYCASFDYAHAMDYWGQGTTVTVSS	DIVLTQSPAFLSVTPGEKVTFTCQASQSIGTSIHWYQQKTDQAPKLLIKYASESISGIPSRFSGSGSGTDFTLTISSVEAEDAADYYCQQINSWPTTFGGGTKLEIK			None	None	None	2016	2017.0	CSF1	Dana-Farber Cancer Institute;Novartis;Novartis Oncology;Seoul National University Hospital		Breast cancer;Gastric cancer;Giant cell tumour of tendon sheath;Pigmented villonodular synovitis;Malignant melanoma;Solid tumours	Bone metastases;Prostate cancer		
Lacutamab	Whole mAb	-amab	G1	Kappa	Phase-II	Active	QIQLVQSGSELKKPGASVKVSCKASGYTFTTAGMQWVRQAPGQGLEWIGWINSHSGVPKYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARGGDEGVMDYWGQGTTVTVSS	DIQMTQSPSFLSASVGDRVTITCKASQDVSTAVAWYQQKPGQPPKLLIYWTSTRHTGVPDRFSGSGSGTDYTLTISSLQAEDVAVYYCQQHYSTPWTFGGGTKVEIK			None	None	None	2018	2019.0	KIR3DL2	University of Genoa;Innate Pharma		Mycosis fungoides;Peripheral T-cell lymphoma;Sezary syndrome			
Ladiratuzumab	Whole mAb ADC	-zumab	G1	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGASVKVSCKASGLTIEDYYMHWVRQAPGQGLEWMGWIDPENGDTEYGPKFQGRVTMTRDTSINTAYMELSRLRSDDTAVYYCAVHNAHYGTWFAYWGQGTLVTVSS	DVVMTQSPLSLPVTLGQPASISCRSSQSLLHSSGNTYLEWYQQRPGQSPRPLIYKISTRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGGGTKVEIK			None	None	None	2017	2018.0	SLC39A6	Merck & Co;Quantum Leap Healthcare Collaborative;Seattle Genetics		Breast cancer			
Lambrolizumab	Whole mAb	-zumab	G4	Kappa	Approved	Active	QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS	EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIK			5dk3:GF:BA/5ggs:CD:AB/5b8c:BA:HG:KJ:ED/5jxe:GF:DC	None	None	2013	2014.0	PDCD1	Aduro BioTech;AIO Studien gGmbH;Amgen;Augusta University;Bayer;BerGenBio;Big Ten Cancer Research Consortium;BioLineRx;Canadian Cancer Trials Group;Celgene Corporation;Columbia University;Dana-Farber Cancer Institute;DNAtrix;Duke University;Eisai Co Ltd;Eli Lilly;Emory University;Fox Chase Cancer Center;Genexine;Gilead Sciences;H. Lee Moffitt Cancer Center and Research Institute;Hoosier Cancer Research Network;Icahn School of Medicine at Mount Sinai;ImmunoGen;Incyte Corporation;Institut fuer Frauengesundheit;Institute of Cancer Research;M. D. Anderson Cancer Center;Massachusetts General Hospital;Mayo Clinic;Memorial Sloan-Kettering Cancer Center;Merck & Co;Merck Sharp & Dohme;National Cancer Center Hospital East;National Cancer Institute (France);National Cancer Institute (USA);Netherlands Cancer Institute;Northwestern University;NYU Langone Medical Center;Oslo University Hospital;Plexxikon;Providence Health & Services;Royal Marsden NHS Foundation Trust;Sarcoma Alliance for Research through Collaboration;Sellas Life Sciences Group;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Spanish Breast Cancer Research Group;Syndax Pharmaceuticals;TG Therapeutics Inc;University Health Network;University of Alabama;University of Birmingham;University of California at Los Angeles;University of California at San Francisco;University of California San Diego;University of Colorado at Denver;University of Miami;University of Pittsburgh;University of Utah;University of Washington;Verastem Oncology;Wakayama Medical University;Washington University School of Medicine;Yale University;The Leukemia & Lymphoma Society	Cervical cancer;Colorectal cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Hodgkin's disease;Liver cancer;Malignant melanoma;Non-small cell lung cancer;Pancreatic cancer;Solid tumours;Urogenital cancer;Cancer;Merkel cell carcinoma;Renal cell carcinoma	Small cell lung cancer;Bladder cancer;Breast cancer;Endometrial cancer;Fallopian tube cancer;Gastrointestinal cancer;Mesothelioma;Multiple myeloma;Nasopharyngeal cancer;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Squamous cell cancer;Acute myeloid leukaemia;Adenoid cystic carcinoma;Bone cancer;Brain metastases;Cholangiocarcinoma;Follicular lymphoma;Germ cell and embryonal neoplasms;Glioblastoma;Glioma;Inflammatory breast cancer;Liver metastases;Lymphoma;Meningioma;Myelodysplastic syndromes;Neuroendocrine tumours;Non-Hodgkin's lymphoma;Osteosarcoma;Penile cancer;Rectal cancer;Recurrent respiratory papillomatosis;Sarcoma;Soft tissue sarcoma;Thymoma;Thyroid cancer;Uveal melanoma;Chronic lymphocytic leukaemia;Haematological malignancies;Leiomyosarcoma;Mantle-cell lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma;T-cell lymphoma;Gliosarcoma;Human papillomavirus infections			Pembrolizumab and Lambrolizumab are the same mAb
Lampalizumab	Fab	-zumab	G1	Kappa	Phase-III	Discontinued	EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSS	DIQVTQSPSSLSASVGDRVTITCITSTDIDDDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIK			4d9q:HL:ED/4d9r:HL:ED	None	None	2012	2013.0	CFD	Tanox;Genentech			Dry age-related macular degeneration		
Lanadelumab	Whole mAb	-umab	G1	Kappa	Approved	NFD	EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYIMMWVRQAPGKGLEWVSGIYSSGGITVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAYRRIGVPRRDEFDIWGQGTMVTVSS	DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYWTFGQGTKVEIK			4pub:HL/4ogy:HL:MN/4ogx:HL	None	None	2015	2016.0	KLKB1	Dyax;Shire;Takeda	Hereditary angioedema		Diabetic macular oedema		
Landogrozumab	Whole mAb	-zumab	G4	Kappa	Phase-II	Active	EVQLVESGGGLVQPGGSLRLSCAASGLTFSRYPMSWVRQAPGKGLVWVSAITSSGGSTYYSDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARLPDYWGQGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCRASSSVSSSYLHWYQQKPGQAPRLLIYSTSNLVAGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHHSGYHFTFGGGTKVEIK			None	None	None	2015	2016.0	MSTN	Eli Lilly		Cachexia;Muscular atrophy;Pancreatic cancer	Cancer		
Laprituximab	Whole mAb ADC	-ximab	G1	Kappa	Phase-I	Discontinued	QVQLVQSGAEVAKPGASVKLSCKASGYTFTSYWMQWVKQRPGQGLECIGTIYPGDGDTTYTQKFQGKATLTADKSSSTAYMQLSSLRSEDSAVYYCARYDAPGYAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDINNYLAWYQHKPGKGPKLLIHYTSTLHPGIPSRFSGSGSGRDYSFSISSLEPEDIATYYCLQYDNLLYTFGQGTKLEIK			None	None	None	2015	2016.0	EGFR	ImmunoGen			Solid tumours		
Larcaviximab	Whole mAb	-ximab	G1	Kappa	Phase-II	Active	EVQLQESGPELEMPGASVKISCKASGSSFTGFSMNWVKQSNGKSLEWIGNIDTYYGGTTYNQKFKGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCARSAYYGSTFAYWGQGTLVTVSA	DIQMTQSPASLSASVGETVTITCRASENIYSYLAWYQQKQGKSPQLLVYNAKTLIEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYFCQHHFGTPFTFGSGTELEIK			None	None	None	2016	2017.0	Zaire Ebolavirus GP	Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases		Ebola virus infections 		Zmapp Technology	
Lebrikizumab	Whole mAb	-zumab	G4	Kappa	Phase-III	Active	QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSS	DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIK			4i77:HL	None	None	2009	2010.0	IL13	Chugai Pharmaceutical;Comprehensive Clinical Research Network;Dermira;Genentech;Roche;Tanox		Atopic dermatitis	Asthma;Chronic obstructive pulmonary disease;Hodgkin's disease;Idiopathic pulmonary fibrosis		
Lecanemab	Whole mAb	-emab	G1	Kappa	Phase-II	Active	EVQLVESGGGLVQPGGSLRLSCSASGFTFSSFGMHWVRQAPGKGLEWVAYISSGSSTIYYGDTVKGRFTISRDNAKNSLFLQMSSLRAEDTAVYYCAREGGYYYGRSYYTMDYWGQGTTVTVSS	DVVMTQSPLSLPVTPGAPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNFRSGVPDRFSGSGSGTDFTLRISRVEAEDVGIYYCFQGSHVPPTFGPGTKLEIK			None	None	None	2019		APP	Biogen;Eisai		Dementia;Alzheimers			
Lenvervimab	Whole mAb	-imab	G1	Kappa	Phase-II/III	Active	EVQLVESGGGLVKPGGSLRLSCSASGFSLTKYKMTWVRQAPGKGLEWVSSISSTSRDIDYADSVKGRFTISRDNAKNSLFLQMSSLRVDDTAVYYCTRDGWLWGWDVRSNYYYNALDVWGQGTTVTVSS	DIVVTQSPSSLSASVGDRVTITCRASQGIYNSIAWYQQKPGKAPKLLLYSTSTLLSGVPSRFSGSGSGTDYTLTITNLQPEDFATYYCQQYFVTPETFGQGTKLEIK			None	None	None	2017	2018.0	HBV	Green Cross;GC Pharma;AbbVie		Hepatitis B			
Lenzilumab	Whole mAb	-umab	G1	Kappa	Phase-I/II	Active	QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCVRRQRFPYYFDYWGQGTLVTVSS	EIVLTQSPATLSVSPGERATLSCRASQSVGTNVAWYQQKPGQAPRVLIYSTSSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFNKSPLTFGGGTKVEIK			None	None	None	2014	2015.0	CSF2	Humanigen;KaloBios Pharmaceuticals		Drug hypersensitivity;Chronic myelomonocytic leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma;Solid tumours	Asthma;Rheumatoid arthritis	Humaneering Technology	
Leronlimab	Whole mAb	-imab	G4	Kappa	Preregistration	Active	EVQLVESGGGLVKPGGSLRLSCAASGYTFSNYWIGWVRQAPGKGLEWIGDIYPGGNYIRNNEKFKDKTTLSADTSKNTAYLQMNSLKTEDTAVYYCGSSFGSNYVFAWFTYWGQGTLVTVSS	DIVMTQSPLSLPVTPGEPASISCRSSQRLLSSYGHTYLHWYLQKPGQSPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPLTFGQGTKVEIK			None	None	None	2017	2018.0	CCR5	CytoDyn;Progenics Pharmaceuticals;The Scripps Research Institute		HIV infections;HIV-1 infections;Graft-versus-host disease;Breast cancer;Colorectal cancer;Non-alcoholic steatohepatitis;Prostate cancer			
Lesofavumab	Whole mAb	-umab	G1	Kappa	Phase-I	Discontinued	EVQLVQSGAEVKKPGESLKISCKVSGYSFTSQWIGWVRQMPGKGLEWIGMMYPGESETIYSPSFQGQVTISADNSISTAYLQWSSLKASDTAIYYCASGPGYSGYHYGWFDTWGQGTLVTVSS	DIVMTQSPLSLPVTPGEPASISCRSSQSLLRSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKLEIK			None	None	None	2016	2017.0	Influenza B Virus	Genentech			Influenza B virus infections		
Letaplimab	Whole mAb	-imab	G4	Kappa	TBC	Active	QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGKTGSAAWGQGTLVTVSS	DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTVSFPITFGGGTKVEIK			None	None	None	2020		CD47	TBC	TBC	TBC	TBC		
Letolizumab	Single Domain Variable Fragment;H	-zumab	G1		Phase-I/II	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFNWELMGWARQAPGKGLEWVSGIEGPGDVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVKVGKDAKSDYRGQGTLVTVSS				None	None	None	2016	2017.0	CD40LG	Bristol-Myers Squibb;H. Lee Moffitt Cancer Center and Research Institute		Graft-versus-host disease;Idiopathic thrombocytopenic purpura			
Levilimab	Whole mAb	-imab	G1	Kappa	Phase-II	Active	QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIYSDGTTHYGDSVKGRFTISRDNAKNTVYLQLNSLRAEDTAMYYCAKGAGPTWWYALDAWGQGTLVTVSS	DIQLTQSPSSVSVSVGERVTIDCKSSQSVLSASNTYLNWYQQKPGQAPQLLIYYASTRESGVPDRFSGSGSGTDFTLTISSLQAEDAAVYYCQQAYRAPVTFGQGTKLEIK			None	None	None	2018	2019.0	IL6R	Biocad		Rheumatoid arthritis	Autoimmune disorders		
Lexatumumab	Whole mAb	-umab	G1	Lambda	Phase-I	Discontinued	EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDLWGKGTTVTVSS	SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHVVFGGGTKLTVL			None	None	4od2:BA	2006	2007.0	TNFRSF10B	Cambridge Antibody Technology;Human Genome Sciences			Solid tumours		
Lifastuzumab	Whole mAb ADC	-zumab	G1	Kappa	Phase-II	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGFSFSDFAMSWVRQAPGKGLEWVATIGRVAFHTYYPDSMKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHRGFDVGHFDFWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRSSETLVHSSGNTYLEWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQGSFNPLTFGQGTKVEIK			None	None	None	2013	2014.0	SLC34A2	Genentech			Fallopian tube cancer;Non-small cell lung cancer;Ovarian cancer;Peritoneal cancer		
Ligelizumab	Whole mAb	-zumab	G1	Kappa	Phase-III	Active	QVQLVQSGAEVMKPGSSVKVSCKASGYTFSWYWLEWVRQAPGHGLEWMGEIDPGTFTTNYNEKFKARVTFTADTSTSTAYMELSSLRSEDTAVYYCARFSHFSGSNYDYFDYWGQGTLVTVSS	EIVMTQSPATLSVSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIYYASESISGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQSWSWPTTFGGGTKVEIK			6uqr:AC	None	None	2012	2013.0	IGHE	Novartis;Tanox		Urticaria;Allergic asthma;Atopic dermatitis;Bullous pemphigoid	Hypersensitivity		
Lilotomab	Whole mAb ADC	-omab	G1	Kappa	Phase-II	Active	EIQLQQSGPELVKPGASVKVSCKASGYSFTDYNMYWVKQSHGKSLEWIGYIDPYNGDTTYNQKFKGKATLTVDKSSSTAFIHLNSLTSEDSAVYYCARSPYGHYAMDYWGQGTSVTVSS	DIVMTQSHKLLSTSVGDRVSITCKASQDVSTAVDWYQQKPGQSPKLLINWASTRHTGVPDRFTGSGSGTDYTLTISSMQAEDLALYYCRQHYSTPFTFGSGTKLEIK			None	None	None	2014	2015.0	CD37	Nordic Nanovector		Follicular lymphoma;Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma			
Lintuzumab	Whole mAb Radiolabelled	-zumab	G1	Kappa	Phase-II	Discontinued	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYNMHWVRQAPGQGLEWIGYIYPYNGGTGYNQKFKSKATITADESTNTAYMELSSLRSEDTAVYYCARGRPAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASESVDNYGISFMNWFQQKPGKAPKLLIYAASNQGSGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQSKEVPWTFGQGTKVEIK			None	None	None	1996	1997.0	CD33	PDL BioPharma;Seattle Genetics			Acute myeloid leukaemia;Myelodysplastic syndromes		
Lirilumab	Whole mAb	-umab	G4	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSFYAISWVRQAPGQGLEWMGGFIPIFGAANYAQKFQGRVTITADESTSTAYMELSSLRSDDTAVYYCARIPSGSYYYDYDMDVWGQGTTVTVSS	EIVLTQSPVTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWMYTFGQGTKLEIK			None	None	None	2012	2013.0	KIRD2	Novo Nordisk;Bristol-Myers Squibb;Dana-Farber Cancer Institute;Innate Pharma;National Cancer Institute (USA);Ono Pharmaceutical;PrECOG;University of Texas M. D. Anderson Cancer Center		Chronic lymphocytic leukaemia;Head and neck cancer;Myelodysplastic syndromes;Solid tumours;Bladder cancer;Haematological malignancies;Multiple myeloma;Lymphoma	Acute myeloid leukaemia;Hepatitis C	Medarex UltiMAb Mouse	
Lodapolimab	Whole mAb	-imab	G1	Lambda	Phase-I	Active	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSPDYSPYYYYGMDVWGQGTTVTVSS	QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCQSYDSSLSGSVFGGGIKLTVL			None	None	None	2019	2020.0	PDL1	Dana-Farber Cancer Institute;Eli Lilly		Solid tumours			
Lodelcizumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Discontinued	QVQLVQSGAEVKKPGASVKVSCKASGYTFSTMYMSWVRQAPGQGLEWMGRIDPANEHTNYAQKFQGRVTMTRDTSISTAYMELSRLTSDDTAVYYCARSYYYYNMDYWGQGTLVTVSS	QIVLTQSPATLSVSPGERATLSCRASQSVSYMHWYQQKPGQAPRLLIYGVFRRATGIPDRFSGSGSGTDFTLTIGRLEPEDFAVYYCLQWSSDPPTFGQGTKLEIK			None	None	None	2012	2013.0	PCSK9	Novartis			Hypercholesterolaemia		
Lokivetmab	Canine Whole mAb	-vetmab	G2	Kappa	Approved	NFD	EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYGMSWVRQAPGKGLQWVATISYGGSYTYYPDNIKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRGYGYDTMDYWGQGTLVTVSS	EIVMTQSPASLSLSQEEKVTITCKASQSVSFAGTGLMHWYQQKPGQAPKLLIYRASNLEAGVPSRFSGSGSGTDFSFTISSLEPEDVAVYYCQQSREYPWTFGQGTKLEIK			None	None	None	2014	2015.0	IL31	Zoetis	Canine atopic dermatitis				
Loncastuximab	Whole mAb ADC	-ximab	G1	Kappa	Phase-II	Active	QVQLVQPGAEVVKPGASVKLSCKTSGYTFTSNWMHWVKQAPGQGLEWIGEIDPSDSYTNYNQNFQGKAKLTVDKSTSTAYMEVSSLRSDDTAVYYCARGSNPYYYAMDYWGQGTSVTVSS	EIVLTQSPAIMSASPGERVTMTCSASSGVNYMHWYQQKPGTSPRRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEPEDAATYYCHQRGSYTFGGGTKLEIK			None	6ani:HL:IM	None	2017	2018.0	CD19	ADC Therapeutics		Diffuse large B cell lymphoma;Follicular lymphoma;Mantle-cell lymphoma;Non-Hodgkin's lymphoma	Precursor B-cell lymphoblastic leukaemia-lymphoma		
Lorukafusp	Whole mAb Fusion	-fusp	G1	Kappa	Phase-II	Active	EVQLVQSGAEVEKPGASVKISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSTSTAYMHLKSLRSEDTAVYYCVSGMEYWGQGTSVTVSS	DVVMTQTPLSLPVTPGEPASISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK			None	None	4tuj:CD:AB/4tul:HL/4trp:HL/4tuo:CD:AB/4tuk:HL	2018	2019.0	Ganglioside GD2	Lexigen Pharmaceuticals;Apeiron Biologics;Merck KGaA;University of Wisconsin-Madison		Malignant melanoma;Neuroblastoma			
Lorvotuzumab	Whole mAb ADC	-zumab	G1	Kappa	Phase-II	Active	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSGSFTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARMRKGYAMDYWGQGTLVTVSS	DVVMTQSPLSLPVTLGQPASISCRSSQIIIHSDGNTYLEWFQQRPGQSPRRLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPHTFGQGTKVEIK			None	None	None	2010	2011.0	NCAM1	ImmunoGen		Haematological malignancies	Multiple myeloma;Solid tumours;Small cell lung cancer		
Losatuxizumab	Whole mAb ADC	-xizumab	G1	Kappa	Phase-I	Active	EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS	DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK			None	None	None	2016	2017.0	EGFR	AbbVie		Solid tumours			Losatuxizumab and Serclutamab have identical variable domains
Lucatumumab	Whole mAb	-umab	G1	Kappa	Phase-I	Discontinued	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYEESNRYHADSVKGRFTISRDNSKITLYLQMNSLRTEDTAVYYCARDGGIAAPGPDYWGQGTLVTVSS	DIVMTQSPLSLTVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQVLISLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPFTFGPGTKVDIR			None	None	None	2007	2008.0	CD40	Novartis;XOMA			Chronic lymphocytic leukaemia;Follicular lymphoma;Lymphoma;Multiple myeloma		
Lulizumab	Single Domain Variable Fragment;L	-zumab		Kappa	Phase-II	Active		DIQMTQSPSSLSASVGDRVTITCRASRPIWPFLEWYQQKPGKAPKLLIYFTSRLRHGVPSRFSGSGSGTCFTLTISSLQPEDFATYYCLQNVANPATFSQGTKVEIK			None	None	None	2014	2015.0	CD28	Bristol-Myers Squibb		Sjogren's syndrome;Systemic lupus erythematosus			
Lumiliximab	Whole mAb	-ximab	G1	Kappa	Phase-II	Discontinued	EVQLVESGGGLAKPGGSLRLSCAASGFRFTFNNYYMDWVRQAPGQGLEWVSRISSSGDPTWYADSVKGRFTISRENANNTLFLQMNSLRAEDTAVYYCASLTTGSDSWGQGVLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDIRYYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTVSSLQPEDFATYYCLQVYSTPRTFGQGTKVEIK			None	3fzu:HL:CD	None	2004	2004.0	FCER2	Biogen Idec			Allergic asthma;Allergic rhinitis;Chronic lymphocytic leukaemia		Lumiliximab and Gomiliximab are the same mAb
Lumretuzumab	Whole mAb	-zumab	G1	Kappa	Phase-I/II	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFRSSYISWVRQAPGQGLEWMGWIYAGTGSPSYNQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARHRDYYSNSLTYWGQGTLVTVSS	DIVMTQSPDSLAVSLGERATINCKSSQSVLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQSDYSYPYTFGQGTKLEIK			4leo:AB	None	None	2014	2015.0	ERBB3	Roche		Non-small cell lung cancer	Breast cancer;Solid tumours	GlycoMAb Technology	
Lupartumab	Whole mAb ADC	-umab	G1	Lambda	Phase-I	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGLWAFDYWGQGTLVTVSS	ESVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYVVHWYQQLPGTAPKLLIYDNNKRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDRLNGPVFGGGTKLTVL			None	None	None	2016	2017.0	LYPD3	Bayer HealthCare		Solid tumours			
Lutikizumab	Bispecific Dual Variable Domain IG	-zumab	G1	Kappa;Kappa	Phase-II	Discontinued	EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQGTPVTVSS	DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQIT	QVQLVESGGGVVQPGRSLRLSCTASGFTFSMFGVHWVRQAPGKGLEWVAAVSYDGSNKYYAESVKGRFTISRDNSKNILFLQMDSLRLEDTAVYYCARGRPKVVIPAPLAHWGQGTLVTFSS	DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYEASNLETGVPSRFSGSGSGSDFTLTISSLQPEDFATYYCQQTSSFLLSFGGGTKVEHK	None;None	None;None	None;None	2016	2017.0	IL1A;IL1B	Abbott Laboratories;AbbVie			Osteoarthritis	Dual Variable Domain Immunoglobulin Technology	
Maftivimab	Whole mAb	-imab	G1	Kappa	Preregistration	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGFTSSSYAMNWVRQAPGKGLEWVSTISGMGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRGYPHSFDIWGQGTMVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQSISSFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLTFGQGTRLEIK			None	None	None	2018	2019.0	Zaire Ebolavirus GP	Regeneron Pharmaceuticals			Ebola virus infections		
Magrolimab	Whole mAb	-imab	G4	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYNMHWVRQAPGQRLEWMGTIYPGNDDTSYNQKFKDRVTITADTSASTAYMELSSLRSEDTAVYYCARGGYRAMDYWGQGTLVTVSS	DIVMTQSPLSLPVTPGEPASISCRSSQSIVYSNGNTYLGWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGQGTKLEIK			None	5iwl:AA:BB	None	2018	2019.0	CD47	Forty Seven;Merck KGaA;Stanford University		Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Colorectal cancer;Solid tumours;Acute myeloid leukaemia;Myelodysplastic syndromes;Ovarian cancer	Lymphoma		
Manelimab	Whole mAb	-imab	G1	Lambda	Phase-I	Active	EVQLVESGGGVVRPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSDISWSGSNTNYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYHCARAPLLLAMTFGVGSWGQGTLVTVSS	QTVVTQEPSLSVSPGGTVTLTCGLSSGTVTAINYPGWYQQTPGQAPRTLIYNTNTRHSGVPDRFSGSISGNKAALTITGAQAEDEADYYCALYMGNGGHMFGGGTKLTVL			None	None	None	2019	2020.0	PDL1	Biocad		Solid tumours;Cancer			
Margetuximab	Whole mAb	-ximab	G1	Kappa	Phase-III	Active	QVQLQQSGPELVKPGASLKLSCTASGFNIKDTYIHWVKQRPEQGLEWIGRIYPTNGYTRYDPKFQDKATITADTSSNTAYLQVSRLTSEDTAVYYCSRWGGDGFYAMDYWGQGASVTVSS	DIVMTQSHKFMSTSVGDRVSITCKASQDVNTAVAWYQQKPGHSPKLLIYSASFRYTGVPDRFTGSRSGTDFTFTISSVQAEDLAVYYCQQHYTTPPTFGGGTKVEIK			None	None	None	2013	2014.0	ERBB2	Raven biotechnologies;GC Pharma;Green Cross;MacroGenics;Merck Sharp & Dohme		Breast cancer;Gastric cancer	Bladder cancer;Non-small cell lung cancer;Ovarian cancer		
Marstacimab	Whole mAb	-imab	G1	Lambda	Phase-III	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAILGATSLSAFDIWGQGTMVTVSS	QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSGVFGGGTKLTVL			None	None	None	2013	2014.0	ERBB2	Pfizer		Haemophilia			
Matuzumab	Whole mAb	-zumab	G1	nd	Phase-II	Discontinued	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYDGRYFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIK			3c08:HL/5vr9:HL:AB	5vsi:HL/3c09:HL:CB	None	2003	2003.0	EGFR	ImClone Systems;Merck KGaA;Takeda			Cervical cancer;Colorectal cancer;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer		
Mavezelimab	Whole mAb	-imab	G4	Kappa	Phase-II	Active	QMQLVQSGPEVKKPGTSVKVSCKASGYTFTDYNVDWVRQARGQRLEWIGDINPNDGGTIYAQKFQERVTITVDKSTSTAYMELSSLRSEDTAVYYCARNYRWFGAMDHWGQGTTVTVSS	DIVMTQTPLSLSVTPGQPASISCKASQSLDYEGDSDMNWYLQKPGQPPQLLIYGASNLESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSTEDPRTFGGGTKVEIK			None	None	None	2019		LAG3	Merck		Non-small cell lung cancer;Haematological malignancies;Solid tumours			
Mavrilimumab	Whole mAb	-umab	G4	Lambda	Phase-II	Active	QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFDPEENEIVYAQRFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCAIVGSFSPLTLGLWGQGTMVTVSS	QSVLTQPPSVSGAPGQRVTISCTGSGSNIGAPYDVSWYQQLPGTAPKLLIYHNNKRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCATVEAGLSGSVFGGGTKLTVL			None	None	None	2009	2010.0	CSF2RA	Zenyth Therapeutics Kiniksa Pharmaceuticals;MedImmune		Giant cell arteritis	Rheumatoid arthritis	CAT Phage Display	
Melrilimab	Whole mAb	-imab	G2	Kappa	TBC	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSIYDMIWVRQAPGKGLEWVSSIRGEGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPWSTEGSFFVLDYWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVDDDLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYITAPLTFGQGTKVEIK			None	None	None	2020		IL1RL1	TBC	TBC	TBC	TBC		
Mepolizumab	Whole mAb	-zumab	G1	Kappa	Approved	Active	QVTLRESGPALVKPTQTLTLTCTVSGFSLTSYSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSSLLRLDYWGRGTPVTVSS	DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIK			None	None	None	1999	2000.0	IL5	GlaxoSmithKline;McMaster University;National Institute of Allergy and Infectious Diseases	Asthma;Churg-Strauss syndrome	Chronic obstructive pulmonary disease;Hypereosinophilic syndrome;Nasal polyps;Atopic dermatitis;Eosinophilic oesophagitis			
Mezagitamab	Whole mAb	-amab	G1	Lambda	Phase-I/II	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSDISWNGGKTHYVDSVKGQFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSLFHDSSGFYFGHWGQGTLVTVSS	QSVLTQPPSASGTPGQRVTISCSGSSSNIGDNYVSWYQQLPGTAPKLLIYRDSQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQSYDSSLSGSVFGGGTKLTVL			None	None	None	2019	2020.0	CD38	Takeda		Multiple myeloma;Systemic lupus erythematosus	Rheumatoid arthritis		
Milatuzumab	Whole mAb	-zumab	G1	Kappa	Phase-I/II	Active	QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGVNWIKQAPGQGLQWMGWINPNTGEPTFDDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCSRSRGKNEAWFAYWGQGTLVTVSS	DIQLTQSPLSLPVTLGQPASISCRSSQSLVHRNGNTYLHWFQQRPGQSPRLLIYTVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSSHVPPTFGAGTRLEIK			None	None	None	2007	2008.0	CD74	Immunomedics		Systemic lupus erythematosus	Graft-versus-host disease;Haematological malignancies;Chronic lymphocytic leukaemia;Multiple myeloma;Non-Hodgkin's lymphoma		
Mipasetamab	Whole mAb	-amab	G1	Kappa	TBC	Active	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHPIYYTYDDTMDYWGQGTTVTVSS	EIVLTQSPGTLSLSPGERATLSCSASSSVSSGNFHWYQQKPGLAPRLLIYRTSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWSGYPWTFGGGTKLEIK			None	None	None	2020		AXL	TBC	TBC	TBC	TBC		
Miptenalimab	Whole mAb	-imab	G4	Kappa	Phase-I	Active	QVTLVESGGGVVQPGRSLRLSCAFSGFSLSTSDMGVGWIRQAPGKGLEWVAHIWWDDVKRYNPALKSRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARIEDYGVSYYFDYWGQGTTVTVSS	DIQMTQSPSFLSASVGDRVSITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSIPLTFGQGTKLEIK			None	None	None	2019		LAG3	Boehringer Ingelheim		Solid tumours;Lymphoma			
Mirikizumab	Whole mAb	-zumab	G4	Kappa	Phase-III	Active	QVQLVQSGAEVKKPGSSVKVSCKASGYKFTRYVMHWVRQAPGQGLEWMGYINPYNDGTNYNEKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNWDTGLWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCKASDHILKFLTWYQQKPGKAPKLLIYGATSLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQMYWSTPFTFGGGTKVEIK			None	None	None	2017	2018.0	IL23A	Eli Lilly		Plaque psoriasis;Ulcerative colitis;Crohn's disease			
Miromavimab	Whole mAb (Mouse)	-imab	G1	Kappa	Unknown	Active	QVQLQQPGSVLVRPGASVKLSCKTSGYAFTSSWMHWAKQRPGQGLEWIGQTHPNSGYTNYNEKFKGKATLTVDTSSSTAYVDLSSLTSEDSAVYYCARESGDGPHWYFDVWGAGTAVTVSS	DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSSPHTFGGGTKLETK			None	None	None	2019		Rabies Virus Strain ERA GP Ectodomain Epitope G-II	Candila Healthcare		Rabies post-exposure			
Mirvetuximab	Whole mAb ADC	-ximab	G1	Kappa	Phase-III	Active	QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFYNQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRAMDYWGQGTTVTVSS	DIVLTQSPLSLAVSLGQPAIISCKASQSVSFAGTSLMHWYHQKPGQQPRLLIYRASNLEAGVPDRFSGSGSKTDFTLTISPVEAEDAATYYCQQSREYPYTFGGGTKLEIK			None	None	None	2015	2016.0	FOLR1	ImmunoGen;National Comprehensive Cancer Network		Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Breast cancer;Endometrial cancer;Solid tumours			
Mirzotamab	Whole mAb	-amab	G1	Kappa	Phase-I	Active	EVQLQESGPGLVKPSETLSLTCAVTGYSITSGYSWHWIRQFPGNGLEWMGYIHSSGSTNYNPSLKSRISISRDTSKNQFFLKLSSVTAADTAVYYCAGYDDYFEYWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQNVGFNVAWYQQKPGKSPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFAEYFCQQYNWYPFTFGQGTKLEIK			None	None	None	2019		CD276	AbbVie		Haematological malignancies;Solid tumours			
Mitazalimab	Whole mAb	-imab	G1	Lambda	Phase-I	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWLSYISGGSSYIFYADSVRGRFTISRDNSENALYLQMNSLRAEDTAVYYCARILRGGSGMDLWGQGTLVTVSS	QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYNVYWYQQLPGTAPKLLIYGNINRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDKSISGLVFGGGTKLTVL			None	None	None	2017	2019.0	CD40	Alligator Bioscience;Janssen Biotech		Solid tumours			Mitazalimab and Vanalimab are the same mAb
Modakafusp	Whole mAb Fusion	-fusp	G4	Kappa	Phase-II	Active	EVQLVQSGAEVKKPGATVKISCKVSGYTFTDSVMNWVQQAPGKGLEWMGWIDPEYGRTDVAEKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCARTKYNSGYGFPYWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQNVDSDVDWYQQKPGKAPKLLIYKASNDYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCMQSNTHPRTFGGGTKVEIK			None	None	None	2019		ADPRC	Takeda		Multiple myeloma			
Modotuximab	Whole mAb	-ximab	G1	Kappa	Phase-II	Active	QVQLQQPGAELVEPGGSVKLSCKASGYTFTSHWMHWVKQRPGQGLEWIGEINPSSGRNNYNEKFKSKATLTVDKSSSTAYMQFSSLTSEDSAVYYCVRYYGYDEAMDYWGQGTSVTVSS	DIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPYTFGGGTKLEIK			None	None	None	2012	2014.0	EGFR	Symphogen;Merck		Colorectal cancer;Glioma;Non-small cell lung cancer	Head and neck cancer;Oesophageal cancer		
Mogamulizumab	Whole mAb	-zumab	G1	Kappa	Approved	Active	EVQLVESGGDLVQPGRSLRLSCAASGFIFSNYGMSWVRQAPGKGLEWVATISSASTYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRVEDTALYYCGRHSDGNFAFGYWGQGTLVTVSS	DVLMTQSPLSLPVTPGEPASISCRSSRNIVHINGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLLPWTFGQGTKVEIK			None	None	None	2010	2011.0	CCR4	Amgen;Bristol-Myers Squibb;Kagoshima University Dental School;Kyowa Hakko;Kyowa Hakko Kirin;Ono Pharmaceutical	Adult T-cell leukaemia-lymphoma;Cutaneous T-cell lymphoma;Peripheral T-cell lymphoma;Mycosis fungoides;Sezary syndrome	Spinal cord disorders;Solid tumours	Non-small cell lung cancer;Asthma;Hypersensitivity	POTELLIGENT Technology	
Monalizumab	Whole mAb	-zumab	G4	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGYDFDVGTLYWFFDVWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCRASENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGTPRTFGGGTKVEIK			None	None	None	2015	2016.0	KLRC1	Innate Pharma;MedImmune;NCIC Clinical Trials Group;Novo Nordisk		Head and neck cancer;Non-small cell lung cancer;Cervical cancer;Chronic lymphocytic leukaemia;Endometrial cancer;Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Solid tumours;Haematological malignancies	Inflammation;Rheumatoid arthritis		
Mosunetuzumab	Bispecific mAb	-zumab	G1	Kappa;Kappa	Phase-I/II	Active	EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQGLEWIGWIYPGDGNTKYNEKFKGRATLTADTSTSTAYLELSSLRSEDTAVYYCARDSYSNYYFDYWGQGTLVTVSS	DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCTQSFILRTFGQGTKVEIK	EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIK	None;None	None;None	None;4k7p:YX	2017	2018.0	CD3E;MS4A1	Genentech		Diffuse large B cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma			
Motavizumab	Whole mAb	-zumab	G1	Kappa	Phase-III	Discontinued	QVTLRESGPALVKPTQTLTLTCTFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKHYNPSLKDRLTISKDTSKNQVVLKVTNMDPADTATYYCARDMIFNFYFDVWGQGTTVTVSS	DIQMTQSPSTLSASVGDRVTITCSASSRVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKVEIK			3qwo:AB:HL/3ixt:HL:AB/4zyp:NO:JL:KM/6oe5:BC	5k8a:BA:FE:VM:HL/4jlr:AB:HL	None	2006	2007.0	RSV gpF	MedImmune			Respiratory syncytial virus infections	Affinity Matured from Palivizumab	
Moxetumomab	Fv Fusion	-omab		Kappa	Approved	NFD	EVQLVESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQTPEKCLEWVAYISSGGGTTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHSGYGTHWGVLFAYWGQGTLVTVSA	DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSILHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPWTFGCGTKLEI			None	None	None	2009	2010.0	CD22	National Cancer Institute (USA);AstraZeneca;M. D. Anderson Cancer Center;MedImmune;National Cancer Institute (USA)	Hairy cell leukaemia		Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma	CAT Phage Display	
Murlentamab	Whole mAb	-amab	G1	Kappa	Phase-II	Active	QVRLVQSGAEVKKPGASVKVSCKASGYTFTSYHIHWVRQAPGQRLEWMGWIYPGDDSTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCTRGDRFAYWGQGTLVTVSS	DIQMTQSPSTLSASVGDRVTITCRASSSVRYIAWYQQKPGKAPKLLTYPTSSLKSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCLQWSSYPWTFGGGTKVEIK			None	None	None	2018	2019.0	AMHR2	LFB Biotechnologies;GamaMabs Pharma		Colorectal cancer;Gynaecological cancer			
Muromonab	Whole mAb	other	G2a	Kappa	Approved	Discontinued	QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS	QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEIN			1sy6:HL	None	None	1988	1989.0	CD3E	Cancer Research UK;Ortho-McNeil;XOMA			Diabetes mellitus;Graft-versus-host disease;Renal transplant rejection;Rheumatoid arthritis		Muromonab and Zolimomab are the same mAb. LC IMGT 127 is N not K as in Jain paper.
Namilumab	Whole mAb	-umab	G1	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGASVKVSCKAFGYPFTDYLLHWVRQAPGQGLEWVGWLNPYSGDTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCTRTTLISVYFDYWGQGTMVTVSS	DIQMTQSPSSVSASVGDRVTIACRASQNIRNILNWYQQRPGKAPQLLIYAASNLQSGVPSRFSGSGSGTDFTLTINSLQPEDFATYYCQQSYSMPRTFGGGTKLEIK			None	None	None	2010	2011.0	CSF2	Micromet Inc;Izana Bioscience;Takeda Pharmaceuticals International GmbH		Ankylosing spondylitis	Plaque psoriasis;Rheumatoid arthritis	Human Phage Display	
Naptumomab	Fab Fusion	-omab	G1	Kappa	Phase-III	Discontinued	EVQLQQSGPDLVKPGASVKISCKASGYSFTGYYMHWVKQSPGKGLEWIGRINPNNGVTLYNQKFKDKATLTVDKSSTTAYMELRSLTSEDSAVYYCARSTMITNYVMDYWGQGTSVTVSS	SIVMTQTPTSLLVSAGDRVTITCKASQSVSNDVAWYQQKPGQSPKLLISYTSSRYAGVPDRFSGSGYGTDFTLTISSVQAEDAAVYFCQQDYNSPPTFGGGTKLEIK			None	None	None	2006	2007.0	TPBG	Active Biotech			Non-small cell lung cancer;Pancreatic cancer;Renal cancer		
Naratuximab	Whole mAb ADC	-ximab	G1	Kappa	Phase-II	Active	QVQVQESGPGLVAPSQTLSITCTVSGFSLTTSGVSWVRQPPGKGLEWLGVIWGDGSTNYHPSLKSRLSIKKDHSKSQVFLKLNSLTAADTATYYCAKGGYSLAHWGQGTLVTVSS	DIQMTQSPSSLSVSVGERVTITCRASENIRSNLAWYQQKPGKSPKLLVNVATNLADGVPSRFSGSGSGTDYSLKINSLQPEDFGTYYCQHYWGTTWTFGQGTKLEIK			None	None	None	2015	2016.0	CD37	ImmunoGen;Chronic lymphocytic leukaemia		Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma	Chronic lymphocytic leukaemia		
Narnatumab	Whole mAb	-umab	G1	Kappa	Phase-I	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYLMTWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLNLQMNSLRAEDTAVYYCTRDGYSSGRHYGMDVWGQGTTVIVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK			None	None	None	2011	2012.0	MST1R	ImClone Systems;Eli Lilly;ImClone Systems			Solid tumours		
Narsoplimab	Whole mAb	-imab	G4	Lambda	Preregistration	Active	QVTLKESGPVLVKPTETLTLTCTVSGFSLSRGKMGVSWIRQPPGKALEWLAHIFSSDEKSYRTSLKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIRRGGIDYWGQGTLVTVSS	QPVLTQPPSLSVSPGQTASITCSGEKLGDKYAYWYQQKPGQSPVLVMYQDKQRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTAVFGGGTKLTVL			None	None	None	2019	2020.0	MASP2	Omeros		Haemolytic uraemic syndrome;IgA nephropathy;Immediate hypersensitivity;Thrombotic microangiopathies;Glomerulonephritis;Lupus nephritis;Membranous glomerulonephritis	Stroke;Wet age-related macular degeneration		
Natalizumab	Whole mAb	-zumab	G4	Kappa	Approved	Active	QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIK			None	4irz:HL	None	1998	1999.0	ITGA4	Biogen;Biogen Idec;Elan Corporation;Perrigo	Crohn's disease;Multiple sclerosis	Epilepsy;Graft-versus-host disease;Stroke	Multiple myeloma;Rheumatoid arthritis		
Navivumab	Whole mAb	-umab	G1	Kappa	Preclinical	Discontinued	QVQLVQSGAEVKKPGASVKVSCKTSGYSFSTYGVSWVRQAPGQGPEWVGWISAYTGITDYAQKFQGRVTLTTDATTATAFLDLRSLRPDDTATYFCARDKVQGRVEVGSGGRHDYWGQGTLVIVSS	EVVLTQSPGTLALPPGERATLSCRASHRVGSTYIAWYQQKSGQAPRRLIYGASNRATDIPDRFSGSGSGTDFTLTIRRLEPEDSAVYYCQQFSVSPWTFGQGTRVEIK			4r8w:HL	6fg1:HL/6fg2:HL	None	2015	2016.0	Influenza A HA	Celltrion			Influenza A virus H1N1 subtype;Influenza A virus H5N1 subtype;Influenza virus infections		
Navicixizumab	Bispecific mAb	-xizumab	G2	Kappa;Kappa	Phase-I	Active	QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIHWVKQAPGQGLEWIGYISNYNRATNYNQKFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVGMDYWGQGTLVTVSS	DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIK	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGDINPSNGRTSYKEKFKRRVTLSVDKSSSTAYMELSSLRSEDTAVYFCTIHYDDKYYPLMDYWGQGTLVTVSS	DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIK	None;None	None;None	None;None	2015	2016.0	DLL4;VEGFA	OncoMed Pharmaceuticals		Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Solid tumours	Colorectal cancer		
Naxitamab	Whole mAb	-amab	G1	Kappa	Preregistration	Active	QVQLVESGPGVVQPGRSLRISCAVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLTISKDNSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDYWGQGTLVTVSS	EIVMTQTPATLSVSAGERVTITCKASQSVSNDVTWYQQKPGQAPRLLIYSASNRYSGVPARFSGSGYGTEFTFTISSVQSEDFAVYFCQQDYSSFGQGTKLEIK			None	None	None	2018	2019.0	Ganglioside GD2	Memorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics		Neuroblastoma;Osteosarcoma	Breast cancer;Sarcoma;Small cell lung cancer		
Necitumumab	Whole mAb	-umab	G1	Kappa	Approved	Active	QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSS	EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIK			6b3s:JK:CD:HL:FG/3b2u:WX:QR:TU:JK:CD:NO:FG:HL/3b2v:HL	None	None	2008	2009.0	EGFR	ImClone Systems;Eli Lilly	Non-small cell lung cancer	Solid tumours	Colorectal cancer		
Nemolizumab	Whole mAb	-zumab	G2	Kappa	Phase-III	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYIMNWVRQAPGQGLEWMGLINPYNGGTDYNPQFQDRVTITADKSTSTAYMELSSLRSEDTAVYYCARDGYDDGPYTLETWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCQASEDIYSFVAWYQQKPGKAPKLLIYNAQTEAQGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYDSPLTFGGGTKVEIK			None	None	None	2014	2015.0	IL31RA	Chugai Pharmaceutical;Galderma;Maruho		Atopic dermatitis;Prurigo nodularis;Pruritus			
Nesvacumab	Whole mAb	-umab	G1	Kappa	Phase-I	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDIHWVRQATGKGLEWVSAIGPAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARGLITFGGLIAPFDYWGQGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYDNSQTFGQGTKVEIK			None	None	None	2012	2013.0	ANGPT2	Regeneron Pharmaceuticals;Sanofi			Solid tumours		
Netakimab	Whole mAb	-imab	G1	Kappa	Approved	Active	QVQLVQSGGGLVQAGGSLRLSCAASGGTFATSPMGWLRQAPGKGTEFVAAISPSGGDRIYADSVKGRFTISRDNAGYFIYLQMNSLKPEDTAVYYCAVRRRFDGTSYYTGDYDSWGQGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYSYSPVTFGQGTKVEIK				None	None	2017	2018.0	IL17A	CJSC Biocad	Plaque psoriasis	Ankylosing spondylitis;Psoriatic Arthritis;Primary biliary cirrhosis			
Nidanilimab	Whole mAb	-imab	G1	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGSSVKVSCKASGYAFTSSWMNWVRQAPGQGLEWMGRIYPGDGNTHYAQKFQGRVTLTADKSTSTAYMELSSLRSEDTAVYYCGEGYLDPMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCQASQGINNYLNWYQQKPGKAPKLLIHYTSGLHAGVPSRFSGSGSGTDYTLTISSLEPEDVATYYCQQYSILPWTFGGGTKVEIK			None	None	None	2018	2019.0	IL1RAP	Lund University;Cantargia		Non-small cell lung cancer;Pancreatic cancer;Breast cancer;Colorectal cancer;Solid tumours			
Nimacimab	Whole mAb	-imab	G4	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGSSVKVSCKASGYEFSYYWMNWVRQAPGQGLEWMGQIYPGDGETKYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSHGNYLPYWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSSSYLHWYQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHRSPPTFGQGTKVEIK			None	None	None	2018	2019.0	CNR1	Bird Rock Bio		Diabetic nephropathies;Diabetic gastroparesis;Non-alcoholic fatty liver disease;Obesity;Non-alcoholic steatohepatitis	Non-alcoholic steatohepatitis		
Nimotuzumab	Whole mAb	-zumab	G1	Kappa	Approved	Active	QVQLQQSGAEVKKPGSSVKVSCKASGYTFTNYYIYWVRQAPGQGLEWIGGINPTSGGSNFNEKFKTRVTITADESSTTAYMELSSLRSEDTAFYFCTRQGLWFDSDGRGFDFWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCRSSQNIVHSNGNTYLDWYQQTPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFQYSHVPWTFGQGTKLQIT			None	3gkw:HL	None	2005	2006.0	EGFR	Biocon Biopharmaceuticals;Biotech Pharmaceutical;Center of Molecular Immunology;CIMYM;Daiichi Sankyo Inc;Eurofarma;Gilead Sciences;Innogene Kalbiotech;InnoMab;Kuhnil Pharmaceutical Company;Laboratorios Pisa;Oncoscience	Anaplastic astrocytoma;Brain cancer;Glioblastoma;Glioma;Head and neck cancer;Nasopharyngeal cancer;Oesophageal cancer	Cervical cancer;Gastric cancer;Non-small cell lung cancer;Pancreatic cancer;Breast cancer;Colorectal cancer			
Nipocalimab	Whole mAb	-imab	G1	Lambda	Phase-I	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSS	QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVL			None	None	5whk:HL/5whj:HL	2019		FCGRT	Momenta		Autoimmune diseases			
Nirsevimab	Whole mAb	-imab	G1	Kappa	Phase-III	Active	QVQLVQSGAEVKKPGSSVMVSCQASGGLLEDYIINWVRQAPGQGPEWMGGIIPVLGTVHYGPKFQGRVTITADESTDTAYMELSSLRSEDTAMYYCATETALVVSETYLPHYFDNWGQGTLVTVSS	DIQMTQSPSSLSAAVGDRVTITCQASQDIVNYLNWYQQKPGKAPKLLIYVASNLETGVPSRFSGSGSGTDFSLTISSLQPEDVATYYCQQYDNLPLTFGGGTKVEIK			5udc:HL:BC:EG	None	4jha:HL/4jhw:HL	2018	2019.0	RSV	AIMM Therapeutics;MedImmune		Respiratory syncytial virus infections			
Nivolumab	Whole mAb	-umab	G4	Kappa	Approved	Active	QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIK			5ggq:HL/5wt9:HL/5ggr:HL:AB	None	None	2012	2013.0	PDCD1	Aduro BioTech;AIO Studien gGmbH;Australian and New Zealand Urogenital and Prostate Cancer Group;Barbara Ann Karmanos Cancer Institute;Bavarian Nordic;Big Ten Cancer Research Consortium;Bristol-Myers Squibb;Canadian Cancer Trials Group;Celleron Therapeutics;Clatterbridge Cancer Centre NHS Foundation Trust;Clovis Oncology;Curie Institute;Daiichi Sankyo Company;Dana-Farber Cancer Institute;Duke University Medical Center;Eisai Inc;Eli Lilly;Emory University;European Thoracic Oncology Platform;Exelixis;Frontier Science foundation;Grupo Espanol Multidisciplinar de Melanoma;H. Lee Moffitt Cancer Center and Research Institute;Hellenic Genitourinary Cancer Group;Hoosier Cancer Research Network;HOVON Foundation;Incyte Corporation;Intergroupe Francophone de Cancerologie Thoracique;Janssen Biotech;Janssen Research & Development;Kansai Medical University;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;Massachusetts General Hospital;Medarex;Nantes University Hospital;National Cancer Center (Tokyo);National Cancer Centre (Singapore);National Cancer Institute (USA);Nektar Therapeutics;Neon Therapeutics;Netherlands Cancer Institute;Northwestern University;Ono Pharmaceutical;Pharmacyclics;PrECOG;Seattle Genetics;Sidney Kimmel Cancer Center;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syneos Health;The University of Montreal Hospital Research Center;UNICANCER;University College London;University of Liverpool;University of Pittsburgh;University of Texas M. D. Anderson Cancer Center;Vanderbilt-Ingram Cancer Center;Zucero Therapeutics	Colorectal cancer;Gastric cancer;Head and neck cancer;Hodgkin's disease;Malignant melanoma;Non-small cell lung cancer;Renal cell carcinoma;Urogenital cancer;Liver cancer;Mesothelioma;Small cell lung cancer	Bladder cancer;Fallopian tube cancer;Glioblastoma;Multiple myeloma;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Non-Hodgkin's lymphoma;Acute myeloid leukaemia;Adrenocortical carcinoma;Biliary cancer;Brain metastases;Breast cancer;Bronchopulmonary dysplasia;Cancer;Cervical cancer;Cholangiocarcinoma;Chronic lymphocytic leukaemia;CNS cancer;Diffuse large B cell lymphoma;Follicular lymphoma;Genitourinary disorders;Leucoplakia;Liver metastases;Meningeal carcinomatosis;Myelodysplastic syndromes;Nasopharyngeal cancer;Oropharyngeal cancer;Pancreatic cancer;Penile cancer;Prostate cancer;Soft tissue sarcoma;Solid tumours;Testicular cancer;Thyroid cancer;Uterine cancer;Uveal melanoma;Haematological malignancies;Lymphoma;Rectal cancer;Chronic myeloid leukaemia;Glioma;Hepatitis C;Sepsis		Medarex UltiMAb Mouse	
Nurulimab	Whole mAb	-imab	G1	Kappa	Phase-I	Active	EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK			None	5xj3:AB/5tru:HL/6jc2:HL	None	2019	2020.0	CTLA4	Biocad		Malignant melanoma			Likely to be an Ipilimumab Biosimilar
Obexelimab	Whole mAb	-imab	G1	Kappa	Phase-III	Active	EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS	DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK			None	None	None	2018	2019.0	CD19	Xencor		Autoimmune disorders;Rheumatoid arthritis;Systemic lupus erythematosus		XmAb Antibody Engineering Technology	
Obiltoxaximab	Whole mAb	-ximab	G1	Kappa	Approved	NFD	QVQLQQSGPELKKPGASVKVSCKDSGYAFSSSWMNWVRQAPGQGLEWIGRIYPGDGDTNYNGKFQGRVTITADKSSSTAYMELSSLRSEDTAVYFCARSGLLRYAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAVKLLIYYTSRLLPGVPSRFSGSGSGTDYSLTISSQEQEDIGTYFCQQGNTLPWTFGQGTKVEIR			None	None	None	2015	2016.0	Anthrax Protective Antigen	Elusys Therapeutics	Anthrax				
Obinutuzumab	Whole mAb	-zumab	G1	Kappa	Approved	Active	QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS	DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK			3pp3:HL:IK/3pp4:HL	None	None	2008	2011.0	MS4A1	GLYCART Biotechnology;Biogen Idec;Chugai Pharmaceutical;Dana-Farber Cancer Institute;Genentech;Lymphoma Academic Research Organisation;Nippon Shinyaku;OHSU Knight Cancer Institute;Pharmacyclics;Polish Myeloma Consortium;Roche;Thomas Jefferson University;University of Heidelberg;University of Leeds	Chronic lymphocytic leukaemia;Follicular lymphoma;Non-Hodgkin's lymphoma	Diffuse large B cell lymphoma;CNS cancer;Graft-versus-host disease;Lupus nephritis;Mantle-cell lymphoma;Waldenstrom's macroglobulinaemia	Primary biliary cirrhosis	GlycoMAb Technology	Obinutuzumab and Afutuzumab are the same mAb
Obrindatamab	Bispecific scFv with Domain Crossover	-amab		Kappa;Lambda	TBC	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSDSSAIYYADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTVSS	DIQLTQSPSFLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPFTFGQGTKLEIK	EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS	QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL	None;None	None;None	None;None	2020		CD276;CD3E	TBC	TBC	TBC	TBC		
Ocaratuzumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Discontinued	EVQLVQSGAEVKKPGESLKISCKGSGRTFTSYNMHWVRQMPGKGLEWMGAIYPLTGDTSYNQKSKLQVTISADKSISTAYLQWSSLKASDTAMYYCARSTYVGGDWQFDVWGKGTTVTVSS	EIVLTQSPGTLSLSPGERATLSCRASSSVPYIHWYQQKPGQAPRLLIYATSALASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQWLSNPPTFGQGTKLEIK			None	None	None	2012	2013.0	MS4A1	Applied Molecular Evolution;MENTRIK Biotech			Follicular lymphoma;Non-Hodgkin's lymphoma;Rheumatoid arthritis		
Ociperlimab	Whole mAb	-imab	G1	Kappa	TBC	Active	EVQLVESGGGLVQPGGSLRLSCASSGFTFSDYYMYWVRQAPGKGLEWVAYITKGGGSTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARQTNYDFTMDYWGQGTLVTVSS	EIVMTQSPATLSVSPGERATLSCKASQDVGTSVAWYQQKPGQAPRLLIYWASARHTGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYSSYPLTFGGGTKVEIK			None	None	None	2020		TIGIT	TBC	TBC	TBC	TBC		
Ocrelizumab	Whole mAb	-zumab	G1	Kappa	Approved	NFD	EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIK			None	None	4k7p:YX	2005	2006.0	MS4A1	Biogen;Biogen Idec;Chugai Pharmaceutical;Genentech;Roche	Multiple sclerosis		Eye disorders;Haematological malignancies;Lupus nephritis;Rheumatoid arthritis;Systemic lupus erythematosus		
Odesivimab	Whole mAb	-imab	G1	Kappa	Preregistration	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQATGKGLEWVSAIGTAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARTWFGELYFDYWGQGTLVTVSS	DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTEFTLTITSLQAEDVAVYYCQQYYSSPLTFGGGTKVEIK			None	None	None	2019	2020.0	Zaire Ebolavirus GP	Regeneron Pharmaceuticals		Ebola virus infections 			
Odronextamab	Bispecific mAb	-amab	G4	Kappa;Kappa	Phase-II	Active	EVQLVESGGGLVQPGRSLRLSCVASGFTFNDYAMHWVRQAPGKGLEWVSVISWNSDSIGYADSVKGRFTISRDNAKNSLYLQMHSLRAEDTALYYCAKDNHYGSGSYYYYQYGMDVWGQGTTVTVSS	EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQHYINWPLTFGGGTKVEIK	EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYTMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDNSGYGHYYYGMDVWGQGTTVTVAS	EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQHYINWPLTFGGGTKVEIK	None;None	None;None	None;None	2019	2020.0	MS4A1;CD3E	Regeneron Pharmaceuticals		Follicular lymphoma;B-cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma			
Ofatumumab	Whole mAb	-umab	G1	Kappa	Approved	Active	EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK			3giz:HL	None	None	2005	2006.0	MS4A1	Genmab;GlaxoSmithKline;Mundipharma International;National Cancer Centre (Singapore);Novartis;Roswell Park Cancer Institute;University Health Network	Chronic lymphocytic leukaemia	B-cell lymphoma;Diffuse large B cell lymphoma;Follicular lymphoma;Multiple sclerosis;Marginal zone B-cell lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma	Neuromyelitis optica;Pemphigus vulgaris;Rheumatoid arthritis;Waldenstrom's macroglobulinaemia	Medarex HuMAb Mouse	
Olaratumab	Whole mAb	-umab	G1	Kappa	Approved	Active	QLQLQESGPGLVKPSETLSLTCTVSGGSINSSSYYWGWLRQSPGKGLEWIGSFFYTGSTYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCARQSTYYYGSGNYYGWFDRWDQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAFGQGTKVEIK			None	None	None	2010	2011.0	PDGFRA	ImClone Systems;Eli Lilly;Institute for Clinical Oncological Research	Soft tissue sarcoma	Pancreatic cancer;Solid tumours	Gastrointestinal stromal tumours;Glioblastoma;Non-small cell lung cancer;Ovarian cancer;Prostate cancer	Medarex UltiMAb Mouse	
Oleclumab	Whole mAb	-umab	G1	Lambda	Phase-II	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAYSWVRQAPGKGLEWVSAISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLGYGRVDEWGRGTLVTVSS	QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNPVNWYQQLPGTAPKLLIYLDNLRLSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSHPGWTFGGGTKLTVL			None	None	None	2016	2017.0	NT5E	MedImmune;AstraZeneca;European Network of Gynaecological Oncological Trial Groups;Jules Bordet Institute		Non-small cell lung cancer;Ovarian cancer;Breast cancer;Pancreatic cancer;Bladder cancer;Solid tumours			
Olendalizumab	Whole mAb	-zumab	G2	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPGQGLEWMGAIHLNTGYTNYNQKFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGFYDGYSPMDYWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCRASESVDSYGNSFMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPYTFGGGTKVEIK			None	None	None	2015	2017.0	C5	Alexion Pharmaceuticals		Antiphospholipid syndrome;Graft-versus-host disease	Inflammation		
Olinvacimab	Whole mAb	-imab	G1	Lambda	Phase-II	Active	QMQLVQSGAEVKKPGASVKLSCKASGYTFSSYWMHWVRQAPGQRLEWMGEINPGNGHTNYNEKFKSRVTITVDKSASTAYMELSSLRSEDTAVYYCAKIWGPSLTSPFDYWGQGTLVTVSS	NFMLTQPPSVSVSPGKTARITCRGDNLGDVNVHWYQQRPGQAPVLVMYYDADRPSGIPERFSGSNSGNTATLTISGVEAGDEADYYCQVWDRTSEYVFGTGTKVTVL			None	None	None	2018	2019.0	KDR	PharmAbcine;3SBio		Glioblastoma;Breast cancer	Cancer;Choroidal neovascularisation;Solid tumours		Olinvacimab and Tanibirumab are the same mAb
Olokizumab	Whole mAb	-zumab	G4	Kappa	Phase-III	Active	EVQLVESGGGLVQPGGSLRLSCAASGFNFNDYFMNWVRQAPGKGLEWVAQMRNKNYQYGTYYAESLEGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARESYYGFTSYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCQASQDIGISLSWYQQKPGKAPKLLIYNANNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQHNSAPYTFGQGTKLEIK			4cni:HL:AB	None	None	2010	2011.0	IL6	R-Pharm;UCB		Rheumatoid arthritis			
Omalizumab	Whole mAb	-zumab	G1	Kappa	Approved	Active	EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYNPSVKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS	DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIK			4x7s:HL/2xa8:HL/4x7t:HL:AB/5hys:HL:AB:EF:CD/6tcm:HL/6tcn:HL/6tco:BA/6tcp:HL	5g64:IM:HL	None	2000	2001.0	IGHE	Dana-Farber Cancer Institute;Genentech;John Hopkins University;Novartis	Allergic asthma;Urticaria	Seasonal allergic rhinitis;Nasal polyps;Mastocytosis;Asthma;Nephritis	Hypersensitivity;Peanut hypersensitivity		HC IMGT 71 is V not L as in Jain paper
Omburtamab	Whole mAb Radiolabelled	-amab	G1	Kappa	Phase-II/III	Active	QVQLQQSGAELVKPGASVKLSCKASGYTFTNYDINWVRQRPEQGLEWIGWIFPGDGSTQYNEKFKGKATLTTDTSSSTAYMQLSRLTSEDSAVYFCARQTTATWFAYWGQGTLVTVSA	DIVMTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGSDFTLSINSVEPEDVGVYYCQNGHSFPLTFGAGTKLELK			5cma:BA	None	None	2018	2019.0	CD276	Memorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics		Neuroblastoma;Meningeal carcinomatosis;Soft tissue sarcoma	Peritoneal cancer;Solid tumours		
Omodenbamab	Whole mAb	-amab	G3	Kappa	TBC	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYGMSWVRQAPGKGLEWVSSITGSGRSTFYADSVKGRFTISRDNSTNTLSLQMNSLRAEDTAVYYCARSPADIVTGYYPWWFDLWGQGTLVTVSS	DIQMTQSPSSLSASIGDRVTITCRASQSINTYLNWYQQKPGKAPRLLIAGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGQGTRLEIK			None	None	None	2020		SpA	TBC	TBC	TBC	TBC		
Onartuzumab	Fab + di-Fc	-zumab	G1	Kappa	Phase-III	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIK			4k3j:HL	None	None	2010	2011.0	MET	Chugai Pharmaceutical;Genentech			Breast cancer;Colorectal cancer;Gastric cancer;Glioblastoma;Liver cancer;Non-small cell lung cancer;Solid tumours		
Onfekafusp	Whole mAb Fusion	-fusp		Kappa	Phase-III	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK			None	None	None	2010	2011.0	FN extra domain B	Philogen		Haematological malignancies;Hodgkin's disease	Brain cancer;Non-small cell lung cancer;Solid tumours		Radretumab+Bifikafusp+Onfekafusp have identical V domains
Ongericimab	Whole mAb	-imab	G4	Kappa	Phase-I	Active	QVQLQESGPGLVKPSQTLSLTCTVSGFSISSYGIHWIRQSPGKGLEWIGVIWRGGITDYNAPFMSRVTISKDNSKNQVSFKLSSVTAADTAVYYCANHRDWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCQASQDINKYIDWYQHKPGKAPKLLIHYASTLQPGVPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDDLWTFGQGTKVEIK			None	None	None	2019		PCSK9	Shanghai Junshi Biosciences		Hypercholesterolemia			
Ontamalimab	Whole mAb	-imab	G2	Kappa	Phase-III	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGINWVRQAPGQGLEWMGWISVYSGNTNYAQKVQGRVTMTADTSTSTAYMDLRSLRSDDTAVYYCAREGSSSSGDYYYGMDVWGQGTTVTVSS	DIVMTQTPLSLSVTPGQPASISCKSSQSLLHTDGTTYLYWYLQKPGQPPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCMQNIQLPWTFGQGTKVEIK			4hcr:MN:HL	None	None	2018	2019.0	MADCAM1	Pfizer;Takeda		Crohn's disease;Ulcerative colitis			
Ontuxizumab	Whole mAb	-xizumab	G1	Kappa	Phase-II	Active	QVQLQESGPGLVRPSQTLSLTCTASGYTFTDYVIHWVKQPPGRGLEWIGYINPYDDDTTYNQKFKGRVTMLVDTSSNTAYLRLSSVTAEDTAVYYCARRGNSYDGYFDYSMDYWGSGTPVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQNVGTAVAWLQQTPGKAPKLLIYSASNRYTGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQYTNYPMYTFGQGTKVQIK			None	None	None	2013	2014.0	CD248	Ludwig Institute for Cancer Research;Morphotek;National Cancer Institute (USA)		Colorectal cancer;Malignant melanoma;Soft tissue sarcoma;Lymphoma;Solid tumours			
Onvatilimab	Whole mAb	-imab	G1	Kappa	Phase-I	Discontinued	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSSYGWSYEFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQSIDTRLNWYQQKPGKAPKLLIYSASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSAYNPITFGQGTKVEIK			None	None	None	2017	2018.0	VSIR	Janssen Research & Development			Solid tumours		
Opicinumab	Whole mAb	-umab	G1	Kappa	Phase-II	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYEMKWVRQAPGKGLEWVSVIGPSGGFTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATEGDNDAFDIWGQGTTVTVSS	DIQMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPMYTFGQGTKLEIK			4oqt:HL	None	None	2015	2106.0	LINGO1	Biogen Idec;Dyax;Biogen		Multiple sclerosis;Optic neuritis		Dyax Human Phage Display	
Oportuzumab	scFv	-zumab		Kappa	Preregistration	Active	EVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDYWGQGTLLTVSS	DIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELK			None	None	None	2008	2009.0	EPCAM	University of Zurich;National Cancer Institute (USA);Sesen Bio;Viventia Biotechnologies		Bladder cancer;Head and neck cancer	Liver cancer;Ovarian cancer		
Opucolimab	Whole mAb	-imab	G1	Lambda	Phase-I	Active	EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYTMNWVRQAPGKGLEWVSSISSGSDYLYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARNELRWYPQAGAFDRWGQGTMVTVSS	QSVVTQPPSMSAAPGQRVTISCSGSSSYIESSYVGWYQQLPGTAPRLLIYDDDMRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCEIWRSGLGGVFGGGTKLTVLSQPKAAPSVTL			None	None	None	2019		PDL1	Shanghai Henlius Biotech		Solid tumours			
Orilanolimab	Whole mAb	-imab	G4	Kappa	Phase-II	Active	QVQLVQSGAELKKPGASVKLSCKASGYTFTSYGISWVKQATGQGLEWIGEIYPRSGNTYYNEKFKGRATLTADKSTSTAYMELRSLRSEDSAVYFCARSTTVRPPGIWGTGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCKASDHINNWLAWYQQKPGQAPRLLISGATSLETGVPSRFSGSGTGKDYTLTISSLQPEDFATYYCQQYWSTPYTFGGGTKVEIK			6nha:HL	None	None	2018	2019.0	FCGRT	Syntimmune		Autoimmune haemolytic anaemia;Autoimmune disorders;Pemphigus			
Orticumab	Whole mAb	-umab	G1	Lambda	Phase-II	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVSSISVGGHRTYYADSVKGRSTISRDNSKNTLYLQMNSLRAEDTAVYYCARIRVGPSGGAFDYWGQGTLVTVSS	QSVLTQPPSASGTPGQRVTISCSGSNTNIGKNYVSWYQQLPGTAPKLLIYANSNRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCASWDASLNGWVFGGGTKLTVL			None	None	None	2012	2013.0	OxLDL	Abcentra;BioInvent International;Genentech		Atherosclerosis;Psoriasis		Human Phage Display	
Osocimab	Whole mAb	-imab	G1	Kappa	Phase-II	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSQYGMDWVRQAPGKGLEWVSGIGPSGGSTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGGPYYYYGMDVWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQADSFPVTFGGGTKVEIK			None	6hhc:HL	None	2018	2019.0	F11	Bayer HealthCare		Venous thromboembolism	Arterial thrombosis;Venous thrombosis		
Otelixizumab	Whole mAb	-xizumab	G1	Lambda	Phase-II	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFPMAWVRQAPGKGLEWVSTISTSGGRTYYRDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFRQYSGGFDYWGQGTLVTVSS	DIQLTQPNSVSTSLGSTVKLSCTLSSGNIENNYVHWYQLYEGRSPTTMIYDDDKRPDGVPDRFSGSIDRSSNSAFLTIHNVAIEDEAIYFCHSYVSSFNVFGGGTKLTVL			None	None	None	2007	2008.0	CD3E	BTG;GlaxoSmithKline;Tolerx		Type 1 diabetes mellitus	Graves ophthalmopathy;Multiple sclerosis;Myasthenia gravis;Psoriasis;Psoriatic arthritis;Rheumatoid arthritis		
Otilimab	Whole mAb	-imab	G1	Lambda	Phase-III	Active	QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSGIENKYAGGATYYAASVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGFGTDFWGQGTLVTVSS	DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKLTVL			None	5c7x:MN:HL/5d7s:HL	5d72:MN:HL/5d71:HL	2018	2019.0	CSF2	GlaxoSmithKline;MorphoSys		Rheumatoid arthritis	Inflammation;Multiple sclerosis;Osteoarthritis	MorphoSys HuCAL Phage Display	
Otlertuzumab	di-scFv+Fc	-zumab	G1	Kappa	Phase-II	Discontinued	EVQLVQSGAEVKKPGESLKISCKGSGYSFTGYNMNWVRQMPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARSVGPFDSWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASENVYSYLAWYQQKPGQAPRLLIYFAKTLAEGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHHSDNPWTFGQGTKVEIK			None	None	None	2013	2014.0	CD37	Trubion Pharmaceuticals;Aptevo Therapeutics			Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma	ADAPTIR Monospecific Platform	
Oxelumab	Whole mAb	-umab	G1	Kappa	Phase-II	Discontinued	EVQLLESGGGLVQPGGSLRLSCAASGFTFNSYAMSWVRQAPGKGLEWVSIISGSGGFTYYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDRLVAPGTFDYWGQGALVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQGTKLEIK			None	None	None	2010	2011.0	TNFSF4	Genentech;Genmab;Roche			Allergic asthma;Allergic rhinitis		
Ozanezumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Discontinued	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSKATMTRDTSTSTAYMELSSLRSEDTAVYYCELMQGYWGQGTLVTVSS	DIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFLQRPGQSPQLLIYLMSTRASGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK			None	None	None	2012	2013.0	RTN4	GlaxoSmithKline			Amyotrophic lateral sclerosis;Multiple sclerosis		
Ozoralizumab	Bispecific Single Domains (VH-VH'-VH)	-zumab			Phase-III	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYWMYWVRQAPGKGLEWVSEINTNGLITKYPDSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYYCARSPSGFNRGQGTLVTVSS		EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS		None;None	None;None	5m2j:D;None	2011	2012.0	TNFA;ALB	Ablynx;Eddingpharm;Pfizer;Taisho Pharmaceutical		Rheumatoid arthritis	Ankylosing spondylitis;Crohn's disease;Psoriatic arthritis	Nanobody Technology	
Pabinafusp	Whole mAb Fusion	-fusp	G1	Kappa	Phase-III	Active	EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWLGWVRQMPGKGLEWMGDIYPGGDYPTYSEKFKVQVTISADKSISTAYLQWSSLKASDTAMYYCARSGNYDEVAYWGQGTLVTVSS	DIVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK			None	None	None	2018	2019.0	TFRC	JCR Pharmaceuticals		Mucopolysaccharidosis II			
Pacanalotamab	Bispecific scFv	-amab	na;na	Kappa;Lambda	TBC	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYPGYHAYNEKFQGRATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIK	EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS	QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL	None;None	None;None	None;None	2020		TNFRSF17;CD3E	TBC	TBC	TBC	TBC		
Pacmilimab	Whole mAb	-imab	G4	Kappa	Phase-II	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSSIWRNGIVTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKWSAAFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQDNGYPSTFGGGTKVEIK			None	None	None	2019	2020.0	PDL1	CytomX Therapeutics		Solid tumours;Lymphoma			
Palivizumab	Whole mAb	-zumab	G1	Kappa	Approved	NFD	QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS	DIQMTQSPSTLSASVGDRVTITCKCQLSVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKLEIK			None	2hwz:HL	None	1998	1999.0	RSV gpF	MedImmune	Respiratory syncytial virus infections			GS Gene Expression System	
Pamrevlumab	Whole mAb	-umab	G1	Kappa	Phase-III	Active	EGQLVQSGGGLVHPGGSLRLSCAGSGFTFSSYGMHWVRQAPGKGLEWVSGIGTGGGTYSTDSVKGRFTISRDNAKNSLYLQMNSLRAEDMAVYYCARGDYYGSGSFFDCWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPPTFGQGTKLEIK			None	None	None	2015	2016.0	CTGF	FibroGen		Duchenne muscular dystrophy;Idiopathic pulmonary fibrosis;Pancreatic cancer	Diabetic cardiomyopathy;Diabetic nephropathies;Diabetic neuropathies;Glioblastoma;Glomerulonephritis;Hepatic fibrosis		
Panitumumab	Whole mAb	-umab	G2	Kappa	Approved	Active	QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS	DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK			5sx5:HL:JK/5sx4:HL:JI	None	None	2004	2005.0	EGFR	Amgen;Grupo Espanol Multidisciplinario del Cancer Digestivo;Netherlands Cancer Institute;Novartis;Takeda;University of Texas M. D. Anderson Cancer Center;Wissenschaftlicher Service Pharma	Colorectal cancer	Anal cancer;Bladder cancer;Breast cancer;Gastric cancer;Neuroendocrine tumours;Oesophageal cancer;Rectal cancer	Head and neck cancer;Malignant melanoma;Prostate cancer;Renal cell carcinoma;Solid tumours	Abgenix XenoMouse	
PankoMab	Whole mAb	other	G1	Kappa	Phase-II	Active	EVQLVESGGGLVQPGGSMRLSCVASGFPFSNYWMNWVRQAPGKGLEWVGEIRLKSNNYTTHYAESVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTRHYYFDYWGQGTLVTVSS	DIVMTQSPLSNPVTPGEPASISCRSSKSLLHSNGITYFFWYLQKPGQSPQLLIYQMSNLASGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGQGTKVEIK			None	None	None	2016	2017.0	MUC1	NEMOD Biotherapeutics;Glycotope		Ovarian cancer;Solid tumours		GlycoExpress Technology	
Panobacumab	Whole mAb	-umab	M	Kappa	Phase-II	Active	EEQVVESGGGFVQPGGSLRLSCAASGFTFSPYWMHWVRQAPGKGLVWVSRINSDGSTYYADSVKGRFTISRDNARNTLYLQMNSLRAEDTAVYYCARDRYYGPEMWGQGTMVTVSS	DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGGGTKVEIK			None	None	None	2008	2009.0	Serotype IATS O11	Berna Biotech;Aridis Pharmaceuticals		Nosocomial pneumonia			
Parsatuzumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGYTFIDYYMNWVRQAPGKGLEWVGDINLDNSGTHYNQKFKGRFTISRDKSKNTAYLQMNSLRAEDTAVYYCAREGVYHDYDDYAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRTSQSLVHINAITYLHWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGQSTHVPLTFGQGTKVEIK			None	None	None	2012	2013.0	EGFL7	Chugai Pharmaceutical;Genentech			Colorectal cancer;Non-small cell lung cancer;Solid tumours		
Pasotuxizumab	Bispecific scFv	-xizumab		Kappa;Lambda	Phase-I	Discontinued	QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKGLEWVAIISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYRYSDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQYDSYPYTFGGGTKLEIK	EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS	QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL	None;None	None;None	None;None	2014	2015.0	FOLH1;CD3E	Amgen;Bayer HealthCare Pharmaceuticals;Micromet Inc			Prostate cancer		
Pateclizumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYVIHWVRQAPGKGLEWVGYNNPYNAGTNYNEKFKGRFTISSDKSKNTAYLQMNSLRAEDTAVYYCSRPTMLPWFAYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQAVSSAVAWYQQKPGKAPKLLIYSASHRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQESYSTPWTFGQGTKVEIK			4mxv:HL:YX:FE/4mxw:HL:WV	None	None	2011	2012.0	LTA	Genentech			Rheumatoid arthritis		
Patritumab	Whole mAb	-umab	G1	Kappa	Phase-III	Active	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFDLWGRGTLVTVSS	DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEIK			None	None	None	2011	2012.0	ERBB3	Amgen;U3 Pharma;Daiichi Sankyo Company		Non-small cell lung cancer;Head and neck cancer;Breast cancer	Solid tumours		
Pavunalimab	Bispecific Mixed mAb and scFv	-imab	G1	Kappa	TBC	Active	EVQLVESGGGLVQPGGSLRLSCASSGFTFDDAWMSWVRQAPGKGLEWVAEISTKANNHATYYAESVKGRFTISRDDSKSSVYLQMNSLRAEDTAVYYCTRLATWDWYFDVWGQGTTVTVSS	DIVLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKPPKLLIYAASELESGIPARFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPFTFGSGTKLEIK	EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVSFISYDGNYKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGHLGPFDLWGQGTMVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK	None;None	None;None	None;None	2020		LAG3;CTLA4	TBC	TBC	TBC	TBC		
Pavurutamab	Bispecific scFv	-amab	na;na	Kappa;Lambda	TBC	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQCLEWMGYINPYPGYHAYNEKFQGRATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGCGTKVEIK	EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS	QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL	None;None	None;None	None;None	2020		TNFRSF17;CD3E	TBC	TBC	TBC	TBC		
Pembrolizumab	Whole mAb	-zumab	G4	Kappa	Approved	Active	QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS	EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIK			5dk3:GF:BA/5ggs:CD:AB/5b8c:BA:HG:KJ:ED/5jxe:GF:DC	None	None	2013	2014.0	PDCD1	Aduro BioTech;AIO Studien gGmbH;Amgen;Augusta University;Bayer;BerGenBio;Big Ten Cancer Research Consortium;BioLineRx;Canadian Cancer Trials Group;Celgene Corporation;Columbia University;Dana-Farber Cancer Institute;DNAtrix;Duke University;Eisai Co Ltd;Eli Lilly;Emory University;Fox Chase Cancer Center;Genexine;Gilead Sciences;H. Lee Moffitt Cancer Center and Research Institute;Hoosier Cancer Research Network;Icahn School of Medicine at Mount Sinai;ImmunoGen;Incyte Corporation;Institut fuer Frauengesundheit;Institute of Cancer Research;M. D. Anderson Cancer Center;Massachusetts General Hospital;Mayo Clinic;Memorial Sloan-Kettering Cancer Center;Merck & Co;Merck Sharp & Dohme;National Cancer Center Hospital East;National Cancer Institute (France);National Cancer Institute (USA);Netherlands Cancer Institute;Northwestern University;NYU Langone Medical Center;Oslo University Hospital;Plexxikon;Providence Health & Services;Royal Marsden NHS Foundation Trust;Sarcoma Alliance for Research through Collaboration;Sellas Life Sciences Group;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Spanish Breast Cancer Research Group;Syndax Pharmaceuticals;TG Therapeutics Inc;University Health Network;University of Alabama;University of Birmingham;University of California at Los Angeles;University of California at San Francisco;University of California San Diego;University of Colorado at Denver;University of Miami;University of Pittsburgh;University of Utah;University of Washington;Verastem Oncology;Wakayama Medical University;Washington University School of Medicine;Yale University;The Leukemia & Lymphoma Society	Cervical cancer;Colorectal cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Hodgkin's disease;Liver cancer;Malignant melanoma;Non-small cell lung cancer;Pancreatic cancer;Solid tumours;Urogenital cancer;Cancer;Merkel cell carcinoma;Renal cell carcinoma	Small cell lung cancer;Bladder cancer;Breast cancer;Endometrial cancer;Fallopian tube cancer;Gastrointestinal cancer;Mesothelioma;Multiple myeloma;Nasopharyngeal cancer;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Squamous cell cancer;Acute myeloid leukaemia;Adenoid cystic carcinoma;Bone cancer;Brain metastases;Cholangiocarcinoma;Follicular lymphoma;Germ cell and embryonal neoplasms;Glioblastoma;Glioma;Inflammatory breast cancer;Liver metastases;Lymphoma;Meningioma;Myelodysplastic syndromes;Neuroendocrine tumours;Non-Hodgkin's lymphoma;Osteosarcoma;Penile cancer;Rectal cancer;Recurrent respiratory papillomatosis;Sarcoma;Soft tissue sarcoma;Thymoma;Thyroid cancer;Uveal melanoma;Chronic lymphocytic leukaemia;Haematological malignancies;Leiomyosarcoma;Mantle-cell lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma;T-cell lymphoma;Gliosarcoma;Human papillomavirus infections			Pembrolizumab and Lambrolizumab are the same mAb
Penpulimab	Whole mAb	-imab	G1	Kappa	Phase-III	Active	EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLVTVSS	DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK			None	None	None	2020		PDCD1	Akeso Biopharma;Chia Tai Tianqing Pharmaceutical		Non-small cell lung cancer;Cholangiocarcinoma;Colorectal cancer;Gastric cancer;Head and neck cancer;Liver cancer;Nasopharyngeal cancer;Neuroendocrine tumours;Urogenital cancer;Hodgkin's disease;Solid tumours			
Pepinemab	Whole mAb	-emab	G4	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGSSVKVSCKASGYSFSDYYMHWVRQAPGQGLEWMGQINPTTGGASYNQKFKGKATITVDKSTSTAYMELSSLRSEDTAVYYCARYYYGRHFDVWGQGTTVTVSS	DIVMTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPYTFGQGTKLEIK			None	None	None	2018	2019.0	SEMA4D	Bristol-Myers Squibb;Children's Oncology Group;Emory University;Merck KGaA;National Cancer Institute (USA);Teva Pharmaceutical Industries;UCLAs Jonsson Comprehensive Cancer Center;Vaccinex		Huntington's disease;Non-small cell lung cancer;Osteosarcoma;Solid tumours;Colorectal cancer;Head and neck cancer;Malignant melanoma;Pancreatic cancer	Multiple sclerosis		
Perakizumab	Whole mAb	-zumab	G1	Kappa	Phase-I	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYTMLWVRQAPGKGLEWVAIIKSGGSYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGDYGSSYGAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDINSYLSWFQQKPGKAPKSLIVRANRLVDGVPSRFSGSGSGQDYSLTISSLQPEDFATYYCLQYDAFPPYTFGQGTKLEIK			None	None	None	2012	2013.0	IL17A	Roche			Psoriatic arthritis		
Pertuzumab	Whole mAb	-zumab	G1	Kappa	Approved	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK			1l7i:HL/4llu:AB:CD/1s78:FE:DC	None	4lly:AB:CD/4llw:CD:AB/5vsh:CD:AB:EF:HL	2003	2004.0	ERBB2	Chugai Pharmaceutical;Dana-Farber Cancer Institute;FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO;Genentech;International Breast Cancer Study Group;Japan Breast Cancer Research Group;Medica Scientia Innovation Research;Roche;West German Study Group	Breast cancer	Ovarian cancer;Brain metastases;Colorectal cancer	Gastric cancer;Non-small cell lung cancer;Prostate cancer		
Petosemtamab	Bispecific mAb	-amab	G1	Kappa;Kappa	Phase-I	Active	QVQLVQSGSELKKPGASVKISCKASGYDFTNYAMNWVRQAPGHGLEWMGWINANTGDPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDSAVYYCTRERFLEWLHFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK	EVQLVQSGSKLKKPGASVKVSCKASGYTFTSYTMNWVRQAPGQGLEWMGWINTDTGDPTYAQGFTGRFVFSLDTSVSTAFLQINSLKAEDTAVYYCARGDCDSTSCYRYSYGYEDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK	None;None	None;None	None;None	2019	2020.0	EGFR;LGR5	Merus		Colorectal cancer;Solid tumours			
Pidilizumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Active	QVQLVQSGSELKKPGASVKISCKASGYTFTNYGMNWVRQAPGQGLQWMGWINTDSGESTYAEEFKGRFVFSLDTSVNTAYLQITSLTAEDTGMYFCVRVGYDALDYWGQGTLVTVSS	EIVLTQSPSSLSASVGDRVTITCSARSSVSYMHWFQQKPGKAPKLWIYRTSNLASGVPSRFSGSGSGTSYCLTINSLQPEDFATYYCQQRSSFPLTFGGGTKLEIK			None	None	None	2012	2013.0	PDCD1	American Cancer Society;Beth Israel Deaconess Medical Center;CureTech;Georgia Regents University;Hadassah Medical Organization;Northwestern University;The Ohio State University Comprehensive Cancer Center;University of Texas M. D. Anderson Cancer Center		Acute myeloid leukaemia;Colorectal cancer;Diffuse large B cell lymphoma;Follicular lymphoma;Malignant melanoma;Multiple myeloma;Pancreatic cancer;Prostate cancer;Renal cell carcinoma;Glioma;Hepatitis C;Liver cancer			
Pimivalimab	Whole mAb	-imab	G4	Kappa	TBC	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFPSYYMHWVRQAPGQGLEWMGIINPEGGSTAYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGTYYDYTYWGQGTLVTVSS	DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSFPPTFGGGTKVEIK			None	None	None	2020		PDCD1	TBC	TBC	TBC	TBC		
Pimurutamab	Whole mAb	-amab	G1	Kappa	Phase-I	Active	EVQLVESGGGLVQPGGSLRLSCAASGFSLTNYGVHWVRQAPGKGLESWLGVIWSGGNTDYGNEFTSRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARALDYYDYEFAYWGQGTMVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIKYASESISGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQNNNWPTSFGGGTKVEIK			None	None	None	2019		EGFR	Shanghai Henlius Biotech		Oncology			
Pinatuzumab	Whole mAb ADC	-zumab	G1	Kappa	Phase-II	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGYEFSRSWMNWVRQAPGKGLEWVGRIYPGDGDTNYSGKFKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDGSSWDWYFDVWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRSSQSIVHSVGNTFLEWYQQKPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQGSQFPYTFGQGTKVEIK			None	6and:HL	None	2012	2013.0	CD22	Genentech			Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma		
Placulumab	Single Domain Variable Fragment + Fc	-umab	G1	Kappa	Phase-II	Discontinued		DIQMTQSPSSLSASVGDRVTITCRASQAIDSYLHWYQQKPGKAPKLLIYSASNLETGVPSRFSGSGSGTDFTLTISSLLPEDFATYYCQQVVWRPFTFGQGTKVEIK			None	None	None	2012	2013.0	TNFA	Domantis;Peptech;Arana Therapeutics;Teva Pharmaceutical Industries			Inflammation;Psoriasis;Rheumatoid arthritis;Sciatica		
Plamotamab	Bispecific Mixed mAb and scFv	-amab	G1	Kappa;Kappa	Phase-I	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGAIYPGNGDTSYNQKFQGRVTITADKSISTAYMELSSLRSEDTAVYYCARSTYYGGDWYFNVWGAGTLVTVSS	QIVLTQSPSSLSASVGDRVTITCRASSSVSYIHWFQQKPGKSPKPLIYATSNLASGVPVRFSGSGSGTDYTLTISSLQPEDFATYYCQQWTSNPPTFGGGTKVEIK	EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS	QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVLEPK	None;None	None;None	None;None	2018	2019.0	MS4A1;CD3E	Xencor		B-cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma			
Plozalizumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Active	EVQLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNWVRQAPGKGLEWVGRIRTKNNNYATYYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNGVWGQGTLVTVSS	DVVMTQSPLSLPVTLGQPASISCKSSQSLLDSDGKTFLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPYTFGQGTRLEIK			None	None	None	2015	2016.0	CCR2	Millennium;Millennium Pharmaceuticals;Takeda;Takeda Oncology		Atherosclerosis;Diabetic nephropathies;Malignant melanoma	Multiple sclerosis;Rheumatoid arthritis;Scleroderma;Solid tumours	Humanization by CDR Grafting	
Pogalizumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Discontinued	EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQGLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRSEDTAVYYCVLAPRWYFSVWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHTLPPTFGQGTKVEIK			6okn:AB:CB/6ogx:CD	None	None	2015	2017.0	TNFRSF4	Genentech			Solid tumours;Urogenital cancer		Vonlerolizumab and Pogalizumab are the same mAb
Polatuzumab	Whole mAb ADC	-zumab	G1	Kappa	Approved	Active	EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS	DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIK			None	None	None	2012	2013.0	CD79B	Chugai Pharmaceutical;Genentech;Roche	Diffuse large B cell lymphoma	Non-Hodgkin's lymphoma;Follicular lymphoma	Chronic lymphocytic leukaemia		
Ponezumab	Whole mAb	-zumab	G2	Kappa	Phase-II	Discontinued	QVQLVQSGAEVKKPGASVKVSCKASGYYTEAYYIHWVRQAPGQGLEWMGRIDPATGNTKYAPRLQDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCASLYSLPVYWGQGTTVTVSS	DVVMTQSPLSLPVTLGQPASISCKSSQSLLYSDAKTYLNWFQQRPGQSPRRLIYQISRLDPGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHYPVLFGQGTRLEIK			3u0t:BA:DC	None	None	2010	2011.0	APP	Rinat Neuroscience;Pfizer			Alzheimer's disease;Cerebral amyloid angiopathy		
Porgaviximab	Whole mAb	-ximab	G1	Kappa	Phase-II	Active	EVQLQESGGGLMQPGGSMKLSCVASGFTFSNYWMNWVRQSPEKGLEWVAEIRLKSNNYATHYAESVKGRFTISRDDSKRSVYLQMNTLRAEDTGIYYCTRGNGNYRAMDYWGQGTSVTVSS	DIQMTQSPASLSVSVGETVSITCRASENIYSSLAWYQQKQGKSPQLLVYSATILADGVPSRFSGSGSGTQYSLKINSLQSEDFGTYYCQHFWGTPYTFGGGTKLEIK			None	None	None	2016	2017.0	Zaire Ebolavirus GP	Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases		Ebola virus infections 		Zmapp Technology	
Praluzatamab	Whole mAb	-amab	G1	Kappa	Phase-II	Active	QITLKESGPTLVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWSEDKHYSPSLKSRLTITKDTSKNQVVLTITNVDPVDTATYYCVQIDYGNDYAFTYWGQGTLVTVSS	DIVMTQSPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGQGTKLEIK			None	None	None	2019	2020.0	CD166	CytomX Therapeutics;Immunogen		Solid tumours			
Prasinezumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVASISSGGGSTYYPDNVKGRFTISRDDAKNSLYLQMNSLRAEDTAVYYCARGGAGIDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKSIQTLLYSSNQKNYLAWFQQKPGKAPKLLIYWASIRKSGVPSRFSGSGSGTDFTLTISSLQPEDLATYYCQQYYSYPLTFGGGTKLEIK			None	None	None	2017	2018.0	SNCA	Neotope Biosciences;Chugai Pharmaceutical;Prothena;Roche		Parkinson's disease			
Prezalumab	Whole mAb	-umab	G2	Kappa	Phase-II	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPRTFGQGTKVEIK			None	None	None	2015	2016.0	ICOSLG	Amgen;MedImmune			Cutaneous lupus erythematosus;Psoriasis;Sjogren's syndrome;Systemic lupus erythematosus		May have had a former name of Prezalizumab
Pritoxaximab	Whole mAb	-ximab	G1	Kappa	Phase-II	Discontinued	QVQLQESGAELVRSGASVRMSCKASGYTFTSYNMHWVKQTPGQGLEWIGYIYPGNGGTNYIQKFKGKAILTADTSSSTAYMQISSLTSEDSAVYFCTRSPSHYSSDPYFDYWGQGTTLTVSS	DIVMSQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQNPGQSPKFLIYWASTRHTGVPDRFTGSGSGTDFTLTITNVQSEDLADYFCQQYSSYPLTFGAGTSLELK			None	None	None	2012	2013.0	Shiga Toxin Type 1	Sunol Molecular Corporation;Uniformed Services University of the Health Sciences;BELLUS Health;Taro Pharmaceuticals Inc			Haemolytic uraemic syndrome;Shiga-toxigenic Escherichia coli infections		
Prolgolimab	Whole mAb	-imab	G1	Lambda	Phase-II/III	Active	QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYWMYWVRQVPGKGLEWVSAIDTGGGRTYYADSVKGRFAISRVNAKNTMYLQMNSLRAEDTAVYYCARDEGGGTGWGVLKDWPYGLDAWGQGTLVTVSS	QPVLTQPLSVSVALGQTARITCGGNNIGSKNVHWYQQKPGQAPVLVIYRDSNRPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCQVWDSSTAVFGTGTKLTVL			None	None	None	2018	2019.0	PDCD1	Biocad		Malignant melanoma;Cervical cancer;Solid tumours			
Quavonlimab	Whole mAb	-imab	G1	Kappa	Phase-I	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDNWMNWVRQAPGKGLEWLAQIRNKPYNYETYYSASVKGRFTISRDDSKNSVYLQMNSLKTEDTGVYYCTAQFAYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRTSENIYGGLNWYQRKPGKSPKLLIYGATNLASGVSSRFSGSGSGTDYTLTISSLQPEDVATYYCQNVLRSPFTFGSGTKLEIK			None	None	None	2019		CTLA4	Merck		Solid tumours			
Quetmolimab	Whole mAb	-imab	G2	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVKQAPGQGLEWIGWIYPGDGSPKFNERFKGRTTLTADKSTNTAYMLLSSLRSEDTAVYFCATGPTDGDYFDYWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCRASGNIHNFLAWYQQKPGKAPKLLIYNEKTLADGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQFWSTPYTFGGGTKVEIK			None	None	None	2018	2019.0	CX3CL1	KAN Research Institute;EA Pharma;Eisai Co Ltd		Crohn's disease;Rheumatoid arthritis	Primary biliary cirrhosis		
Quilizumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGIAWVRQAPGKGLEWVAFISDLAYTIYYADTVTGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDNWDAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRSSQSLVHNNANTYLHWYQQKPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCSQNTLVPWTFGQGTKVEIK			3hr5:HL:JQ:BA:IP	None	None	2011	2012.0	IGHE	Genentech			Allergic asthma;Allergic rhinitis;Urticaria		
Racotumomab	Whole mAb	-omab	G1	Kappa	Approved	Active	QVQLQQSGAELVKPGASVKLSCKASGYTFTSYDINWVRQRPEQGLEWIGWIFPGDGSTKYNEKFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCAREDYYDNSYYFDYWGQGTTLTVSS	DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFGGGTKLEIK			None	None	None	2008	2009.0	Idiotope of anti-NeuGc-ganliosides	Center of Molecular Immunology;Elea;Innogene Kalbiotech;Recombio	Non-small cell lung cancer	Neuroblastoma	Breast cancer;Colorectal cancer;Malignant melanoma;Small cell lung cancer;Solid tumours		
Radretumab	di-scFv + CH4	-umab	E	Kappa	Phase-II	Discontinued	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK			None	None	None	2010	2011.0	FN extra domain B	Philogen			Brain cancer;Non-small cell lung cancer;Solid tumours;Haematological malignancies;Hodgkin's disease		Radretumab+Bifikafusp+Onfekafusp have identical V domains
Rafivirumab	Whole mAb	-umab	G1	Lambda	Phase-II	Discontinued	QVQLVQSGAEVKKPGSSVKVSCKASGGTFNRYTVNWVRQAPGQGLEWMGGIIPIFGTANYAQRFQGRLTITADESTSTAYMELSSLRSDDTAVYFCARENLDNSGTYYYFSGWFDPWGQGTLVTVSS	QSALTQPRSVSGSPGQSVTISCTGTSSDIGGYNFVSWYQQHPGKAPKLMIYDATKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGDYTPGVVFGGGTKLTVL			None	None	None	2008	2009.0	RV Antigenic Site III	Crucell;Sanofi Pasteur			Rabies	Human Phage Display	
Ragifilimab	Whole mAb	-imab	G1	Kappa	Phase-I/II	Active	QVQLVQSGAEVKKPGASVKVSCKGSGYTFTDYAMYWVRQAPGQGLEWIGVIRTYSGDVTYNQKFKDRATMTVDKSISTAYMELSRLRSDDTAVYYCAKSGTVRGFAYWGQGTLVTVSS	DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYHCQNDYSYPYTFGQGTKLEIK			None	None	None	2019		TNFRSF18	Incyte		Solid tumours			
Ralpancizumab	Whole mAb	-zumab	G2	Kappa	Phase-I	Discontinued	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGEIHPSGGRTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARERPLYASDLWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQDVHTAVAWYQQKPGKAPKLLIYHASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQRYSLWRTFGQGTKLEIK			None	None	3sqo:HL	2013	2014.0	PCSK9	Pfizer			Hypercholesterolaemia		
Ramucirumab	Whole mAb	-umab	G1	Kappa	Approved	Active	EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSS	DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIK			3s34:HL/3s37:HL/3s36:HL	None	None	2008	2009.0	KDR	Dyax;AstraZeneca;Dana-Farber Cancer Institute;Eli Lilly;Merck Sharp & Dohme;University of Texas M. D. Anderson Cancer Center;Washington University School of Medicine	Colorectal cancer;Gastric cancer;Non-small cell lung cancer;Liver cancer	Oesophageal cancer;Urogenital cancer;Biliary cancer;Carcinoid tumour;Solid tumours;Pancreatic cancer	Breast cancer;Malignant melanoma;Ovarian cancer;Prostate cancer;Renal cell carcinoma	Dyax Human Phage Display	
Ranevetmab	Canine Whole mAb	-vetmab	G1	Kappa	Unknown	Active	EVQLVESGGGLVQPGGSLRLSCVASGFSLTNNNVNWVRQAPGKGLEWVGGVWAGGATDYNSALKSRFTISRDNAKNTVFLQMHSLRSEDTAVYYCARDGGYSSSTLYAMDAWGQGTSVTVSS	DIVMTQSPASLSLSQGETVTITCRASEDIYNALAWYQQKPGQAPKLLIYNTDTLHTGVPSRFSGSGSGTDFSLTISSLEPEDVAVYYCQHYFHYPRTFGQGTKVELK			None	None	None	2016	2017.0	NGFB	Nexvet		Osterarthritis		PETization Technology	
Ranibizumab	Fab	-zumab	G1	Kappa	Approved	Active	EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS	DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK			1cz8:HL:YX	None	1bj1:HL:KJ/6bft:HL:AB	2004	2004.0	VEGFA	Genentech;Manhattan Eye Ear & Throat Hospital;Novartis Ophthalmics;University of Bonn	Choroidal neovascularisation;Degenerative myopia;Diabetic macular oedema;Retinal oedema;Wet age-related macular degeneration;Diabetic retinopathy	Retinopathy of prematurity;Polypoidal choroidal vasculopathy	Retinal telangiectasis		
Ravagalimab	Whole mAb	-imab	G1	Kappa	Phase-II	Active	EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYGMNWVRQAPGKGLEWIAYISSGRGNIYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSWGYFDVWGQGTTVTVSS	DIVMTQSPDSLAVSLGERATINCKSSQSLLNRGNQKNYLTWFQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYTYPLTFGQGTKLEIK			6pe7:HL/6pe8:HL:AB	None	None	2017	2018.0	CD40	AbbVie		Ulcerative colitis	Crohn's disease		
Ravulizumab	Whole mAb	-zumab	G2	Kappa	Approved	Active	QVQLVQSGAEVKKPGASVKVSCKASGHIFSNYWIQWVRQAPGQGLEWMGEILPGSGHTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK			None	5i5k:HL:XY	None	2017	2018.0	C5	Alexion Pharmaceuticals	Paroxysmal nocturnal haemoglobinuria	Haemolytic uraemic syndrome;Myasthenia gravis;IgA nephropathy			
Recaticimab	Whole mAb	-imab	G1	Kappa	TBC	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYWMHWVRQAPGQGLEWMGYINPSSGFTKYHQNFKDRVTMTRDTSISTAYMELSRLRSDDTAVYYCARQYDYDEDWYFDVWGQGTTVTVSS	DIVMSQSPSSLSASVGDRVTITCKSSQSLLNSRTRKNFLAWYQQKPGKSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCKQSFNLFTFGQGTKLEIK			None	None	None	2020		PCSK9	TBC	TBC	TBC	TBC		
Refanezumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Discontinued	QVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGEPTYADDFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARNPINYYGINYEGYVMDYWGQGTLVTVSS	DIVMTQSPDSLAVSLGERATINCKSSHSVLYSSNQKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYLSSLTFGQGTKLEIK			None	None	None	2015	2016.0	MAG	GlaxoSmithKline			CNS trauma;Stroke		
Relatlimab	Whole mAb	-imab	G4	Kappa	Phase-II/III	Active	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRQPPGKGLEWIGEINHRGSTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYNWFDPWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTNLEIK			None	None	None	2018	2019.0	LAG3	Bristol-Myers Squibb;Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins		Malignant melanoma;Colorectal cancer;Gastric cancer;Renal cell carcinoma;Solid tumours;Oesophageal cancer;Glioblastoma	Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Hodgkin's disease;Mantle-cell lymphoma;Non-Hodgkin's lymphoma		
Relfovetmab	Feline Whole mAb	-vetmab	G1	Kappa	Unknown	Active	DVQLVESGGDLVKPGGSLRLTCVASGFTYSNYWMHWVRQAPGKGLQWVARIDPYGGGTKHNEKFKRRFTISRDNAKNTLYLQMNSLKTEDTATYYCVRSGYDYYFDVWGQGTLVTVSS	EIQMTQSPSSLSASPGDRVTITCRASENIYSFLAWYQQKPGKVPKLLIYNANTLAEGVPSRFSGSGSGTDFTLTISSLEPEDAATYYCQHHFGTPFTFGSGTKLEIK			None	None	None	2018	2019.0	NGFB						
Remtolumab	Bispecific Dual Variable Domain IG	-umab	G1	Kappa;Kappa	Phase-II	Discontinued	EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK	EVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSS	EIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKVDIK	4nyl:EF:AB:HL:CD/6cr1:HL;None 	3wd5:HL;None	None;None	2016	2017.0	IL17A;TNFA	Abbott Laboratories;Abbvie			Psoriatic arthritis;Rheumatoid arthritis	Dual Variable Domain Immunoglobulin Technology	
Reslizumab	Whole mAb	-zumab	G4	Kappa	Approved	Active	EVQLVESGGGLVQPGGSLRLSCAVSGLSLTSNSVNWIRQAPGKGLEWVGLIWSNGDTDYNSAIKSRFTISRDTSKSTVYLQMNSLRAEDTAVYYCAREYYGYFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCLASEGISSYLAWYQQKPGKAPKLLIYGANSLQTGVPSRFSGSGSATDYTLTISSLQPEDFATYYCQQSYKFPNTFGQGTKVEVK			None	None	None	2001	2002.0	IL5	Celltech R&D;Schering-Plough;Allergy and Asthma Clinical Research;Celltech R&D;Teva Pharmaceutical Industries	Asthma	Sinusitis;Churg-Strauss syndrome	Oesophagitis		
Retifanlimab	Whole mAb	-imab	G4	Kappa	Phase-II/III	Active	QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWMNWVRQAPGQGLEWIGVIHPSDSETWLDQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCAREHYGTSPFAYWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASESVDNYGMSFMNWFQQKPGQPPKLLIHAASNQGSGVPSRFSGSGSGTDFTLTISSLEPEDFAVYFCQQSKEVPYTFGGGTKVEIK			None	None	None	2019	2020.0	PDCD1	MacroGenics;Incyte Corporation;ZAI Lab		Gastic cancers;Oesophageal cancer;Anal cancer;Endometrial cancer;Merkel cell carcinoma;Solid tumours;Colorectal cancer;Acute myeloid leukaemia	Haematological malignancies		
Revdofilimab	Whole mAb	-imab	G1	Kappa	Phase-I	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYGMSWVRQAPGKGLELVATINSNGGRTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGITTAYAMDYWGQGTTVTVSS	DIVMTQSPDSLAVSLGERATINCKASQSVDYDGDSYMHWYQQKPGQPPKLLIYAASILESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPRTFGGGTKVEIK			None	None	None	2019		TNFRSF4	AbbVie		Solid tumours			
Rilotumumab	Whole mAb	-umab	G2	Kappa	Phase-II	Discontinued	QVQLQESGPGLVKPSETLSLTCTVSGGSISIYYWSWIRQPPGKGLEWIGYVYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCARGGYDFWSGYFDYWGQGTLVTVSS	EIVMTQSPATLSVSPGERATLSCRASQSVDSNLAWYRQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYINWPPITFGQGTRLEIK			None	None	None	2009	2010.0	HGF	Amgen;Astellas Pharma			Colorectal cancer;Gastric cancer;Glioma;Prostate cancer;Renal cancer;Small cell lung cancer;Solid tumours	Abgenix XenoMouse	
Rinucumab	Whole mAb	-umab	G4	Kappa	Phase-II	Discontinued	QLQLQESGPGLVKPSETLSLTCTVSGGSITSSSYYWGWIRQPPGKGLEWIGSIYYRGSTNYNPSLKSRVTISVDSSKNQFYLKVSSVTAVDTAVYYCARQNGAARPSWFDPWGQGTLVTVSS	EIVLTQSPDTISLSPGERATLSCRASQSISSIYLAWYQQKPGQAPRLLIYGASSRVTGIPDRFSVSGSGTDFTLTISRLEPEDFAVYYCQHYGISPFTFGPGTKVDIR			None	None	None	2015	2016.0	PDGFRB	Regeneron Pharmaceuticals			Wet age-related macular degeneration		
Ripertamab	Whole mAb	-amab	G1	Kappa	Phase-II	Active	QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA	QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK			2osl:HL:AB	4kaq:HL	None	2019		MS4A1	Sinocelltech		B-cell Lymphoma			Chimeric, Likely to be a Rituximab biosimilar
Risankizumab	Whole mAb	-zumab	G1	Kappa	Approved	Active	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDQTIHWMRQAPGQGLEWIGYIYPRDDSPKYNENFKGKVTITADKSTSTAYMELSSLRSEDTAVYYCAIPDRSGYAWFIYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASRDVAIAVAWYQQKPGKVPKLLIYWASTRHTGVPSRFSGSGSRTDFTLTISSLQPEDVADYFCHQYSSYPFTFGSGTKLEIK			None	None	None	2015	2016.0	IL23A	AbbVie;Boehringer Ingelheim	Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis	Crohn's disease;Ulcerative colitis;Atopic dermatitis	Psoriasis;Ankylosing spondylitis;Asthma		
Rituximab	Whole mAb	-ximab	G1	Kappa	Approved	Active	QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA	QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK			2osl:HL:AB	4kaq:HL	None	1997	1998.0	MS4A1	Biogen;Biogen Idec;Cedars-Sinai Medical Center;Chugai Pharmaceutical;Genentech;Hackensack University Medical Center;Hoosier Cancer Research Network;Janssen Research & Development;M. D. Anderson Cancer Center;Mayo Clinic;Nagoya University;Oregon Health & Science University;Roche;SCRI Development Innovations;Takeda Oncology;University of Gottingen;University of Texas M. D. Anderson Cancer Center;University of Tours;Zenyaku Kogyo	Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Follicular lymphoma;Idiopathic thrombocytopenic purpura;Lymphoproliferative disorders;Microscopic polyangiitis;Nephrotic syndrome;Non-Hodgkin's lymphoma;Pemphigus vulgaris;Rheumatoid arthritis;Wegener's granulomatosis	Mantle-cell lymphoma;Transplant rejection;Neuromyelitis optica;B-cell lymphoma;Chronic inflammatory demyelinating polyradiculoneuropathy;Glomerulonephritis;Precursor cell lymphoblastic leukaemia-lymphoma;Renal transplant rejection	Multiple sclerosis;Ocular inflammation;Primary biliary cirrhosis;Scleritis;Sjogren's syndrome;Ulcerative colitis;Dermatomyositis;Graft-versus-host disease;Lupus nephritis;Systemic lupus erythematosus		
Rivabazumab	Fab	-zumab	G1	Kappa	Phase-II	Discontinued	EVQLVESGGGVVQPGRSLRLSCAASGFTFSNYPMHWVRQAPGKGLEWVAVISYDGSEKWYADSVKGRFTISRDNSKNTLYLEMNSLRPEDTAVYYCARNRGDIYYDFTYAMDIWGQGTTVTVSS	DIQLTQSPSTLSASVGDSVTITCRASEGVDRWLAWYQQKPGRAPKLLIYDASTLQSGVPSRFSGSGSGTEFSLTISSLQPDDVATYYCQHFWGTPYTFGQGTKLEIK			None	None	None	2015	2016.0	PcrV type III secretion system	KaloBios Pharmaceuticals Inc			Infectiology;Inflammation;Inherited diseases	Humaneering Technology	
Robatumumab	Whole mAb	-umab	G1	Kappa	Phase-II	Discontinued	EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWISVIDTRGATYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGNFYYGMDVWGQGTTVTVSS	EIVLTQSPGTLSVSPGERATLSCRASQSIGSSLHWYQQKPGQAPRLLIKYASQSLSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQSSRLPHTFGQGTKVEIK			None	None	None	2008	2009.0	IGF1R	Merck & Co;Schering-Plough			Colorectal cancer;Osteosarcoma;Sarcoma;Solid tumours		
Roledumab	Whole mAb	-umab	G1	Kappa	Phase-II/III	Active	QVQLVESGGGVVQPGRSLRLSCTASGFTFKNYAMHWVRQAPAKGLEWVATISYDGRNIQYADSVKGRFTFSRDNSQDTLYLQLNSLRPEDTAVYYCARPVRSRWLQLGLEDAFHIWGQGTMVTVSS	AIRMTQSPSSFSASTGDRVTITCRASQDIRNYVAWYQQKSGKAPKFLIYAASTLQSGVPSRFSGSGSGTDFTLTINSLQSEDFATYYCQQYYNSPPTFGQGTRVEIT			None	None	None	2010	2011.0	RHD	LFB Biotechnologies		Haemolytic disease of newborn		EMABling Platform	
Rolinsatamab	Whole mAb ADC	-amab	G1	Kappa	Phase-I	Active	EVQLVQSGAEVKKPGSSVKVSCKASGYTFTTYWMHWVRQAPGQGLEWIGEIDPSDSYSNYNQKFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNGGLGPAWFSYWGQGTLVTVSS	DIQMTQSPSSVSASVGDRVTITCKASQYVGTAVAWYQQKPGKSPKLLIYSASNRYTGVPSRFSDSGSGTDFTLTISSLQPEDFATYFCQQYSSYPWTFGGGTKVEIK			None	None	None	2018	2019.0	PRLR	AbbVie		Solid tumours			
Romilkimab	Bispecific Dual Variable Domain IG	-imab	G1	Kappa;Kappa	Phase-II	Active	EVQLKESGPGLVAPGGSLSITCTVSGFSLTDSSINWVRQPPGKGLEWLGMIWGDGRIDYADALKSRLSISKDSSKSQVFLEMTSLRTDDTATYYCARDGYFPYAMDFWGQGTSVTVSS	DIVLTQSPASLAVSLGQRATISCRASESVDSYGQSYMHWYQQKAGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVQAEDAATYYCQQNAEDSRTFGGGTKLEIK	QVQLQQSGPELVKPGASVKISCKASGYSFTSYWIHWIKQRPGQGLEWIGMIDPSDGETRLNQRFQGRATLTVDESTSTAYMQLRSPTSEDSAVYYCTRLKEYGNYDSFYFDVWGAGTLVTVSS	DIQMTQSPASLSVSVGDTITLTCHASQNIDVWLSWFQQKPGNIPKLLIYKASNLHTGVPSRFSGSGSGTGFTLTISSLQPEDIATYYCQQAHSYPFTFGGGTKLEIK	None;None	None;None	None;None	2017	2018.0	IL13;IL4	Sanofi		Systemic scleroderma	Idiopathic pulmonary fibrosis		
Romosozumab	Whole mAb	-zumab	G2	Kappa	Approved	NFD	EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMHWVRQAPGQGLEWMGEINPNSGGAGYNQKFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARLGYDDIYDDWYFDVWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDTLPYTFGGGTKVEIK			None	None	None	2011	2012.0	SOST	ChiroscienceGroup plc;Amgen;UCB	Male osteoporosis;Postmenopausal osteoporosis		Fracture		
Rontalizumab	Whole mAb	-zumab	G2	Kappa	Phase-II	Discontinued	EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYIIHWVRQAPGKGLEWVASINPDYDITNYNQRFKGRFTISLDKSKRTAYLQMNSLRAEDTAVYYCASWISDFFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQSVSTSSYSYMHWYQQKPGKAPKVLISYASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSWGIPRTFGQGTKVEIK			4z5r:WV:BA:UT:SR:KJ:ML:QP:ZY	None	None	2009	2010.0	IFNA1	Chugai Pharmaceutical;Genentech			Systemic lupus erythematosus		
Rosmantuzumab	Whole mAb	-zumab	G1	Kappa	Phase-I	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSIHWVRQAPGQGLEWIGYIYPSNGDSGYNQKFKNRVTMTRDTSTSTAYMELSRLRSEDTAVYYCATYFANNFDYWGQGTTLTVSS	DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISPVQAEDFATYYCQQSNEDPLTFGAGTKLELK			None	None	None	2016	2017.0	RSPO3	OncoMed Pharmaceuticals		Colorectal cancer;Solid tumours			
Rosopatamab	Whole mAb	-amab	G1	Kappa	Phase-II	Active	EVQLVQSGPEVKKPGATVKISCKTSGYTFTEYTIHWVKQAPGKGLEWIGNINPNNGGTTYNQKFEDKATLTVDKSTDTAYMELSSLRSEDTAVYYCAAGWNFDYWGQGTLLTVSS	DIQMTQSPSSLSTSVGDRVTLTCKASQDVGTAVDWYQQKPGPSPKLLIYWASTRHTGIPSRFSGSGSGTDFTLTISSLQPEDFADYYCQQYNSYPLTFGPGTKVDIK			None	None	None	2019		FOLH1	Weill Cornell Medical		Prostate cancer;Cancers			
Rovalpituzumab	Whole mAb ADC	-zumab	G1	Kappa	Phase-III	Discontinued	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGEPTYADDFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARIGDSSPSDYWGQGTLVTVSS	EIVMTQSPATLSVSPGERATLSCKASQSVSNDVVWYQQKPGQAPRLLIYYASNRYTGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQDYTSPWTFGQGTKLEIK			None	None	None	2015	2016.0	DLL3	Bristol-Myers Squibb;Stemcentrx			Small cell lung cancer;Solid tumours		
Rozanolixizumab	Whole mAb	-xizumab	G4	Kappa	Phase-III	Active	EVPLVESGGGLVQPGGSLRLSCAVSGFTFSNYGMVWVRQAPGKGLEWVAYIDSDGDNTYYRDSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCTTGIVRPFLYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKSSQSLVGASGKTYLYWLFQKPGKAPKRLIYLVSTLDSGIPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQGTHFPHTFGQGTKLEIK			6fgb:HL	None	None	2016	2017.0	FCGRT	UCB		Chronic inflammatory demyelinating polyradiculoneuropathy;Idiopathic thrombocytopenic purpura;Myasthenia gravis	Immunological disorders		
Rozipafusp	Whole mAb Fusion	-fusp	G2	Kappa	Phase-I	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPRTFGQGTKVEIK			None	None	None	2018		ICOS	Amgen		Rheumatoid arthritis	Systemic lupus erythematosus		
Ruplizumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Discontinued	QVQLVQSGAEVVKPGASVKLSCKASGYIFTSYYMYWVKQAPGQGLEWIGEINPSNGDTNFNEKFKSKATLTVDKSASTAYMELSSLRSEDTAVYYCTRSDGRNDMDSWGQGTLVTVSS	DIVLTQSPATLSVSPGERATISCRASQRVSSSTYSYMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLTISSVEPEDFATYYCQHSWEIPPTFGGGTKLEIK			1i9r:HL:KM:XY	None	None	2000	2001.0	CD40LG	Biogen			Autoimmune disorders;Haemophilia A;Idiopathic thrombocytopenic purpura;Multiple sclerosis;Renal transplant rejection;Systemic lupus erythematosus		
Sabatolimab	Whole mAb	-imab	G4	Kappa	Phase-I/II	Active	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGDIYPGNGDTSYNQKFKGRVTITADKSTSTVYMELSSLRSEDTAVYYCARVGGAFPMDYWGQGTTVTVSS	AIQLTQSPSSLSASVGDRVTITCRASESVEYYGTSLMQWYQQKPGKAPKLLIYAASNVESGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSRKDPSTFGGGTKVEIK			None	None	None	2019		HAVCR2	Novartis		Solid tumours			
Sacituzumab	Whole mAb ADC	-zumab	G1	Kappa	Preregistration	Active	QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWINTYTGEPTYTDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCARGGFGSSYWYFDVWGQGSLVTVSS	DIQLTQSPSSLSASVGDRVSITCKASQDVSIAVAWYQQKPGKAPKLLIYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGAGTKVEIK			None	None	None	2016	2017.0	TACSTD2	IBC Pharmaceuticals;Immunomedics;University of Wisconsin Comprehensive Cancer Center;Yale University		Breast cancer;Prostate cancer;Solid tumours;Urogenital cancer;Endometrial cancer	Pancreatic cancer;Small cell lung cancer		
Samalizumab	Whole mAb	-zumab	G2	Kappa	Phase-I	Discontinued	QVQLQQSGSELKKPGASVKISCKASGYSFTDYIILWVRQNPGKGLEWIGHIDPYYGSSNYNLKFKGRVTITADQSTTTAYMELSSLRSEDTAVYYCGRSKRDYFDYWGQGTTLTVSS	DIQMTQSPSSLSASIGDRVTITCKASQDINSYLSWFQQKPGKAPKLLIYRANRLVDGVPSRFSGSGSGTDYTLTISSLQPEDFAVYYCLQYDEFPYTFGGGTKLEIK			None	None	None	2010	2011.0	CD200	Alexion Pharmaceuticals;The Leukemia & Lymphoma Society			Acute myeloid leukaemia;Chronic lymphocytic leukaemia;Multiple myeloma;Solid tumours		
Samrotamab	Whole mAb ADC	-amab	G1	Kappa	Phase-I	Active	EVQLVQSGAEVKKPGASVKVSCKASGYKFSSYWIEWVKQAPGQGLEWIGEILPGSDTTNYNEKFKDRATFTSDTSINTAYMELSRLRSDDTAVYYCARDRGNYRAWFGYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGGAVKFLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQGEALPWTFGGGTKVEIK			None	None	None	2017	2018.0	LRRC15	AbbVie			Solid tumours		
Sapelizumab	Whole mAb	-zumab	G2	Kappa	Preregistration	Active	QVQLQESGPGLVKPSETLSLTCAVSGHSISHDHAWSWVRQPPGEGLEWIGFISYSGITNYNPSLQGRVTISRDNSKNTLYLQMNSLRAEDTAVYYCARSLARTTAMDYWGEGTLVTVSS	DIQMTQSPSSLSASVGDSVTITCQASTDISSHLNWYQQKPGKAPELLIYYGSHLLSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCGQGNRLPYTFGQGTKVEIE			None	None	None	2015	2017.0	IL6R	Chugai Pharmaceutical;Roche		Neuromyelitis optica	Rheumatoid arthritis		Satralizumab and Sapelizumab are the same mAb
Sarilumab	Whole mAb	-umab	G1	Kappa	Approved	Active	EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSS	DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIK			None	None	None	2011	2012.0	IL6R	Asahi Kasei Pharma Corp;Regeneron Pharmaceuticals;Sanofi	Rheumatoid arthritis	Giant cell arteritis;Polymyalgia rheumatica;Juvenile rheumatoid arthritis;Uveitis	Ankylosing spondylitis	VelocImmune Mouse	
Sasanlimab	Whole mAb	-imab	G4	Kappa	Phase-I	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWINWVRQAPGQGLEWMGNIYPGSSLTNYNEKFKNRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARLSTGTFAYWGQGTLVTVSS	DIVMTQSPDSLAVSLGERATINCKSSQSLWDSGNQKNFLTWYQQKPGQPPKLLIYWTSYRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYFYPHTFGGGTKVEIK			None	None	None	2019	2020.0	PDCD1	Pfizer		Solid tumours			
Satralizumab	Whole mAb	-zumab	G2	Kappa	Preregistration	Active	QVQLQESGPGLVKPSETLSLTCAVSGHSISHDHAWSWVRQPPGEGLEWIGFISYSGITNYNPSLQGRVTISRDNSKNTLYLQMNSLRAEDTAVYYCARSLARTTAMDYWGEGTLVTVSS	DIQMTQSPSSLSASVGDSVTITCQASTDISSHLNWYQQKPGKAPELLIYYGSHLLSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCGQGNRLPYTFGQGTKVEIE			None	None	None	2015	2017.0	IL6R	Chugai Pharmaceutical;Roche		Neuromyelitis optica	Rheumatoid arthritis		Satralizumab and Sapelizumab are the same mAb
Secukinumab	Whole mAb	-umab	G1	Kappa	Approved	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPCTFGQGTRLEIK			None	None	None	2009	2010.0	IL17A	Beth Israel Deaconess Medical Center;GWT-TUD GmbH;Icahn School of Medicine at Mount Sinai;Novartis;Alcon	Ankylosing spondylitis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis	Hidradenitis suppurativa;Juvenile rheumatoid arthritis;Non-radiographic axial spondyloarthritis;Rheumatoid arthritis;Alopecia areata;Atopic dermatitis;Giant cell arteritis;Necrobiosis lipoidica;Tendon injuries	Asthma;Crohn's disease;Dry eyes;Multiple sclerosis;Polymyalgia rheumatica;Type 1 diabetes mellitus;Uveitis	Abgenix XenoMouse	
Selicrelumab	Whole mAb	-umab	G2	Kappa	Phase-I	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPDSGGTNYAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARDQPLGYCTNGVCSYFDYWGQGTLVTVSS	DIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQKPGKAPNLLIYTASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANIFPLTFGGGTKVEIK			None	None	None	2016	2017.0	CD40	Abramson Cancer Center of the University of Pennsylvania;Roche		Pancreatic cancer;Solid tumours			
Semorinemab	Whole mAb	-emab	G4	Kappa	Phase-II	Active	EVQLVESGGGLVQPGGSLRLSCAASGLIFRSYGMSWVRQAPGKGLEWVATINSGGTYTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCANSYSGAMDYWGQGTLVTVSS	DDVLTQTPLSLPVTPGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLVPWTFGQGTKVEIK			None	None	None	2018		MAPT	AC Immune;Genentech		Alzheimer's disease			
Serclutamab	Whole mAb ADC	-amab	G1	Kappa	Phase-I	Active	EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS	DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK			None	None	None	2016	2017.0	EGFR	AbbVie		Solid tumours			Losatuxizumab and Serclutamab have identical variable domains
Seribantumab	Whole mAb	-umab	G2	Lambda	Phase-II	Discontinued	EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMAWVRQAPGKGLEWVSSISSSGGWTLYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATIFDYWGQGTLVTVSS	QSALTQPASVSGSPGQSITISCTGTSSDVGSYNVVSWYQQHPGKAPKLIIYEVSQRPSGVSNRFSGSKSGNTASLTISGLQTEDEADYYCCSYAGSSIFVIFGGGTKVTVL			None	None	None	2012	2013.0	ERBB3	Merrimack Pharmaceuticals;Sanofi			Breast cancer;Gynaecological cancer;Non-small cell lung cancer;Ovarian cancer;Solid tumours	Dyax Human Phage Display	
Serplulimab	Whole mAb	-imab	G4	Kappa	Phase-III	Active	QVQLVESGGGLVKPGGSLRLSCAASGFTFSNYGMSWIRQAPGKGLEWVSTISGGGSNIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCVSYYYGIDFWGQGTSVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQDVTTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTIPWTFGGGTKLEIK			None	None	None	2019	2020.0	PDCD1	Henlix Biotech;Shanghai Henlius Biotech		Non-small cell lung cancer;Oesophageal cancer;Small cell lung cancer;Hepatitis B			
Setoxaximab	Whole mAb	-ximab	G1	Kappa	Phase-II	Discontinued	EVQLQQPGPELEKPGASVKLSCKASGYSFTDYNMNWVKQNNGESLEWIGKIDPYYGGPSYNQKFKDKATLTVDKSSSTAYMQLKSLTSEDSAVYYCTRGGNRDWYFDVWGAGTTLTVSA	DIVLSQSPSSLVVSVGEKVTMSCKSSQSLLYSRNQKNYLAWYQQKPGQSPKVLIYWASTRESGVPDRLTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELK			None	None	None	2012	2013.0	Shiga Toxin Type 2	Sunol Molecular Corporation;Uniformed Services University of the Health Sciences;BELLUS Health;Taro Pharmaceuticals Inc			Haemolytic uraemic syndrome;Shiga-toxigenic Escherichia coli infections		
Setrusumab	Whole mAb	-umab	G2	Lambda	Phase-II	Active	QVQLVESGGGLVQPGGSLRLSCAASGFTFRSHWLSWVRQAPGKGLEWVSNINYDGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDTYLHFDYWGQGTLVTVSS	DIALTQPASVSGSPGQSITISCTGTSSDVGDINDVSWYQQHPGKAPKLMIYDVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCQSYAGSYLSEVFGGGTKLTVL			None	None	None	2017	2018.0	SOST	MorphoSys;Novartis;Mereo BioPharma		Osteogenesis imperfecta	Hypophosphatasia;Postmenopausal osteoporosis	MorphoSys HuCAL Phage Display	
Sifalimumab	Whole mAb	-umab	G1	Kappa	Phase-II	Discontinued	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYSISWVRQAPGQGLEWMGWISVYNGNTNYAQKFQGRVTMTTDTSTSTAYLELRSLRSDDTAVYYCARDPIAAGYWGQGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK			4ypg:HL:BA	None	None	2009	2010.0	IFNA1	Medarex;MedImmune			Myositis;Psoriasis;Systemic lupus erythematosus		
Siltuximab	Whole mAb	-ximab	G1	Kappa	Approved	Centocor Inc;Janssen Biotech;Memorial Sloan-Kettering Cancer Center	EVQLVESGGKLLKPGGSLKLSCAASGFTFSSFAMSWFRQSPEKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCARGLWGYYALDYWGQGTSVTVSS	QIVLIQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSGYPYTFGGGTKLEIK			None	None	None	2008	2009.0	IL6	Centocor Inc;Janssen Biotech;Memorial Sloan-Kettering Cancer Center	Giant lymph node hyperplasia	Multiple myeloma	Paraproteinaemia;Myelodysplastic syndromes;Non-Hodgkin's lymphoma;Prostate cancer;Renal cell carcinoma		
Simlukafusp	Whole mAb Fusion	-fusp	G1	Kappa	Phase-II	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIIGSGASTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGWFGGFNYWGQGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVTSSYLAWYQQKPGQAPRLLINVGSRRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQGIMLPPTFGQGTKVEIK			None	None	None	2019		FAP	Roche		Solid tumours;Malignant melanoma;Renal cell carcinoma			
Simtuzumab	Whole mAb	-zumab	G4	Kappa	Phase-II	Discontinued	QVQLVQSGAEVKKPGASVKVSCKASGYAFTYYLIEWVRQAPGQGLEWIGVINPGSGGTNYNEKFKGRATITADKSTSTAYMELSSLRSEDTAVYFCARNWMNFDYWGQGTTVTVSS	DIVMTQTPLSLSVTPGQPASISCRSSKSLLHSNGNTYLYWFLQKPGQSPQFLIYRMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPYTFGGGTKVEIK			None	None	None	2012	2013.0	LOXL2	Arresto Biosciences;Gilead Sciences			Colorectal cancer;Hepatic fibrosis;Idiopathic pulmonary fibrosis;Liver cirrhosis;Myelofibrosis;Non-alcoholic steatohepatitis;Pancreatic cancer;Primary sclerosing cholangitis		
Sintilimab	Whole mAb	-imab	G4	Kappa	Approved	Active	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGLIIPMFDTAGYAQKFQGRVAITVDESTSTAYMELSSLRSEDTAVYYCARAEHSSTGTFDYWGQGTLVTVSS	DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANHLPFTFGGGTKVEIK			None	None	None	2018	2019.0	PDCD1	Adimab;Innovent Biologics;Jiangsu Provincial Peoples Hospital;Sun Yat-Sen University	Hodgkin's disease	Gastric cancer;Non-small cell lung cancer;Oesophageal cancer;Liver cancer;Extranodal NK-T-cell lymphoma;Small cell lung cancer;Solid tumours			
Sirtratumab	Whole mAb ADC	-umab	G2	Kappa	Phase-I	Active	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNQYYADSVKGRFTISRDNSKNTLFLQMHSLRAEDTAVYYCARGLTSGRYGMDVWGQGTTVTVSS	DIVMTQSPLSLPVTPGEPASISCRSSQSLLLSHGFNYLDWYLQKPGQSPQLLIYLGSSRASGVPDRFSGSGSGTDFTLKISRVEAEDVGLYYCMQPLQIPWTFGQGTKVEIK			None	None	None	2017		SLITRK6	Astellas/Agensys;Seattle Genetics		Bladder Cancer			
Sirukumab	Whole mAb	-umab	G1	Kappa	Phase-III	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSPFAMSWVRQAPGKGLEWVAKISPGGSWTYYSDTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLWGYYALDIWGQGTTVTVSS	EIVLTQSPATLSLSPGERATLSCSASISVSYMYWYQQKPGQAPRLLIYDMSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCMQWSGYPYTFGGGTKVEIK			None	None	None	2011	2012.0	IL6	Centocor Inc;GlaxoSmithKline;Janssen Biotech		Giant cell arteritis;Asthma;Lupus nephritis;Major depressive disorder	Rheumatoid arthritis;Atherosclerosis		
Sofituzumab	Whole mAb ADC	-zumab	G1	Kappa	Phase-I	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGYSITNDYAWNWVRQAPGKGLEWVGYISYSGYTTYNPSLKSRFTISRDTSKNTLYLQMNSLRAEDTAVYYCARWTSGLDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASDLIHNWLAWYQQKPGKAPKLLIYGATSLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYWTTPFTFGQGTKVEIK			None	None	None	2013	2014.0	MUC16	Genentech			Fallopian tube cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer		
Solanezumab	Whole mAb	-zumab	G1	Kappa	Phase-III	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYSMSWVRQAPGKGLELVAQINSVGNSTYYPDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASGDYWGQGTLVTVSS	DVVMTQSPLSLPVTLGQPASISCRSSQSLIYSDGNAYLHWFLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK			None	4xxd:ED:BA	None	2008	2009.0	APP	Eli Lilly		Alzheimer's disease			
Solitomab	Bispecific scFv	-omab		Kappa;Kappa	Phase-I	Discontinued	EVQLLEQSGAELVRPGTSVKISCKASGYAFTNYWLGWVKQRPGHGLEWIGDIFPGSGNIHYNEKFKGKATLTADKSSSTAYMQLSSLTFEDSAVYFCARLRNWDEPMDYWGQGTTVTVSS	ELVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPLTFGAGTKLEIK	DVQLVQSGAEVKKPGASVKVSCKASGYTFTRYTMHWVRQAPGQGLEWIGYINPSRGYTNYADSVKGRFTITTDKSTSTAYMELSSLRSEDTATYYCARYYDDHYCLDYWGQGTTVTVSS	DIVLTQSPATLSLSPGERATLSCRASQSVSYMNWYQQKPGKAPKRWIYDTSKVASGVPARFSGSGSGTDYSLTINSLEAEDAATYYCQQWSSNPLTFGGGTKVEIK	None;None	None;None	None;None	2011	2012.0	EPCAM;CD3E	Micromet Inc;Amgen			Solid tumours		
Sotigalimab	Whole mAb	-imab	G1	Kappa	TBC	Active	QVQLVESGGGVVQPGRSLRLSCAASGFSFSSTYVCWVRQAPGKGLEWIACIYTGDGTNYSASWAKGRFTISKDSSKNTVYLQMNSLRAEDTAVYFCARPDITYGFAINFWGPGTLVTVSS	DIQMTQSPSSLSASVGDRVTIKCQASQSISSRLAWYQQKPGKPPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQCTGYGISWPIGGGTKVEIK			None	None	None	2020		CD40	TBC	TBC	TBC	TBC		
Spartalizumab	Whole mAb	-zumab	G4	Kappa	Phase-III	Active	EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYWMHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKNRVTITADKSTSTAYMELSSLRSEDTAVYYCTRWTTGTGAYWGQGTTVTVSS	EIVLTQSPATLSLSPGERATLSCKSSQSLLDSGNQKNFLTWYQQKPGQAPRLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQNDYSYPYTFGQGTKVEIK			None	None	None	2017	2018.0	PDCD1	Asan Medical Center;Dana-Farber Cancer Institute;Novartis;Novartis Oncology;Palobiofarma;Seoul National University Hospital		Malignant melanoma;Breast cancer;Colorectal cancer;Diffuse large B cell lymphoma;Gastric cancer;Nasopharyngeal cancer;Non-small cell lung cancer;Solid tumours;Acute myeloid leukaemia;Cancer;Liver cancer;Lymphoma;Multiple myeloma;Myelodysplastic syndromes;Ovarian cancer;Pancreatic cancer;Renal cancer	Neuroendocrine tumours		
Spesolimab	Whole mAb	-imab	G1	Kappa	Phase-III	Active	QVQLVQSGAEVKKPGASVKVSCKASGYSFTSSWIHWVKQAPGQGLEWMGEINPGNVRTNYNENFRNKVTMTVDTSISTAYMELSRLRSDDTAVYYCTVVFYGEPYFPYWGQGTLVTVSS	QIVLTQSPGTLSLSPGERATMTCTASSSVSSSYFHWYQQKPGQAPRLWIYRTSRLASGVPDRFSGSGSGTDFTLTISRLEPEDAATYYCHQFHRSPLTFGAGTKLEIK			6u6u:HL	None	None	2018	2019.0	IL36RN			Ulcerative colitis;Atopic dermatitis;Crohn's disease;Palmoplantar pustulosis;Pustular psoriasis			
Sugemalimab	Whole mAb	-imab	G4	Lambda	Phase-III	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGISGSGGFTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPPRGYNYGPFDYWGQGTLVTVSS	SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL			None	None	None	2019		PDL1	Cstone Pharmaceuticals		Cancers;Non-small Cell Lung Cancer;T-cell Lymphoma;Solid tumours;Hodgkin Lymphoma			
Suptavumab	Whole mAb	-umab	G1	Kappa	Phase-III	Discontinued	EVQLVESGGDLVQPGRSLRLSCVASGFTFDDYAMHWVRQAPGKGLEWVSGVSWSGSTVGYADSVKGRFTVSRDNAQKSLYLQMNSLRAEDTALYYCVKDAYKFNYYYYGLDVWGQGTTVTVSS	EIVMTQSPATLSVSPGERATLSCRASQTILSNLAWYLQKPGQAPRLLIYGASTRATGLPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIK			None	None	None	2016	2017.0	RSV gpF	Regeneron Pharmaceuticals			Respiratory syncytial virus infections	VelocImmune Mouse;VelociGene	
Sutimlimab	Whole mAb	-imab	G4	Kappa	Phase-III	Active	EVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVATISSGGSHTYYLDSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCARLFTGYAMDYWGQGTLVTVSS	QIVLTQSPATLSLSPGERATMSCTASSSVSSSYLHWYQQKPGKAPKLWIYSTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCHQYYRLPPITFGQGTKLEIK			None	None	None	2017	2018.0	C1S	Bioverativ;True North Therapeutics		Autoimmune haemolytic anaemia;Idiopathic thrombocytopenic purpura	Bullous pemphigoid;Renal transplant rejection		
Suvizumab	Whole mAb	-zumab	G1	Kappa	Phase-I	Discontinued	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNSWIGWFRQAPGQGLEWIGDIYPGGGYTNYNEIFKGKATMTADTSTNTAYMELSSLRSEDTAVYYCSRGIPGYAMDYWGQGTLVTVSS	DIQMTQRPDSLSASVGDRVTMSCKSSQSLLNSGDQKNYLTWYQQKPGQPPKLLIYWASTGESGVPDRFSGSGSGTDFTFTISSLQPEDIATYYCQNDYSYPWTFGQGTKVEIK			3ntc:HL	None	None	2009	2010.0	HIV-1 gp120	Kaketsuken;Kumamoto University;University of Missouri-Columbia			HIV-1 infections		
Suvratoxumab	Whole mAb	-umab	G1	Kappa	Phase-II	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSHDMHWVRQATGKGLEWVSGIGTAGDTYYPDSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDRYSPTGHYYGMDVWGQGTTVTVSS	DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCKQYADYWTFGQGTKVEIK			4u6v:HL:KM	None	None	2016	2017.0	Toxin A	Biosynexus;GlaxoSmithKline;Regeneron Pharmaceuticals;MedImmune		Nosocomial pneumonia			
Tabalumab	Whole mAb	-umab	G4	Kappa	Phase-III	Discontinued	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGYYDILTGYYYYFDYWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDSTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK			None	None	None	2011	2012.0	TNFSF13B	Eli Lilly			Multiple myeloma;Multiple sclerosis;Renal failure;Rheumatoid arthritis;Systemic lupus erythematosus		
Tabituximab	Whole mAb ADC	-ximab	G1	Kappa	Phase-I	Discontinued	EVQLQQSGAELVKPGASVKLSCTASGFNINDTYMHWVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCARGARGSRFAYWGQGTLVTVSA	DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYVATNLADGVPSRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWGTPYTFGGGTKLEIK			None	None	None	2018	2019.0	FZD10	OncoTherapy Science;Centre Leon Berard			Synovial sarcoma		
Tadocizumab	Fab	-zumab	G1	Kappa	Phase-II	Discontinued	QVQLVQSGAEVKKPGSSVKVSCKASGYAFTNYLIEWVRQAPGQGLEWIGVIYPGSGGTNYNEKFKGRVTLTVDESTNTAYMELSSLRSEDTAVYFCARRDGNYGWFAYWGQGTLVTVSS	DIQMTQTPSTLSASVGDRVTISCRASQDINNYLNWYQQKPGKAPKLLIYYTSTLHSGVPSRFSGSGSGTDYTLTISSLQPDDFATYFCQQGNTLPWTFGQGTKVEVK			None	None	None	2005	2006.0	ITGA2B_ITGB3	PDL BioPharma;Yamanouchi			Coronary artery restenosis;Stroke;Thrombosis		
Tafasitamab	Whole mAb	-amab	G1	Kappa	Phase-III	Active	EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS	DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK			None	None	None	2018	2019.0	CD19	MorphoSys;The Ohio State University Comprehensive Cancer Center;Xencor		Diffuse large B cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma		MorphoSys HuCAL Phage Display;XmAb Engineering Technology	
Tafolecimab	Whole mAb	-imab	G2	Kappa	Phase-III	Active	QLQLQESGPGLVKPSETLSLTCTVSGGSISSASYYWSWIRQPPGKGLEWIGSINYRGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARENSGVVPAAGPNWFGPWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRRNWFTFGGGTKVEIK			None	None	None	2019	2020.0	PCSK9	Innovent Biologics		Hypercholesterolaemia			
Talacotuzumab	Whole mAb	-zumab	G1	Kappa	Phase-III	Active	EVQLVQSGAEVKKPGESLKISCKGSGYSFTDYYMKWARQMPGKGLEWMGDIIPSNGATFYNQKFKGQVTISADKSISTTYLQWSSLKASDTAMYYCARSHLLRASWFAYWGQGTMVTVSS	DIVMTQSPDSLAVSLGERATINCESSQSLLNSGNQKNYLTWYQQKPGQPPKPLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGQGTKLEIK			4jzj:HL:AB	None	None	2017	2018.0	IL3RA	CSL;Janssen Biotech		Acute myeloid leukaemia;Myelodysplastic syndromes;Systemic lupus erythematosus			
Talquetamab	Bispecific mAb	-amab	G4	Kappa;Lambda	Phase-I	Active	QVQLVQSGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQGLEWMGLINPYNSDTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVALRVALDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQNVATHVGWYQQKPGKAPKRLIYSASYRYSGVPSRFSGSGSGTEFTLTISNLQPEDFATYYCQQYNRYPYTFGQGTKLEIK	EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSWFAYWGQGTLVTVSS	QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNLWVFGGGTKLTVL	None;None	None;None	None;None	2019	2020.0	GPRC5D;CD3E	Genmab;Janssen Research & Development		Multiple myeloma			
Tamrintamab	Whole mAb ADC	-amab	G1	Kappa	Phase-I	Active	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYWIEWVRQAPGQGLEWMGEILPGSGNTYYNERFKDRVTITADESTSTAYMELSSLRSEDTAVYYCARRAAAYYSNPEWFAYWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCTASSSVNSFYLHWYQQKPGLAPRLLIYSTSNLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHRSPYTFGQGTKLEIK			6vgr:HL:CD	None	None	2018		DPEP3	Stemcentrx		Ovarian cancer;Solid tumours			
Tamtuvetmab	Canine Whole mAb	-vetmab	G2	Kappa	Unknown	Active	EVKLLESGGGLVQPGGSMRLSCAGSGFTFTDFYMNWIRQPAGKAPEWLGFIRDKAKGYTTEYNPSVKGRFTISRDNTQNMLYLQMNTLRAEDTATYYCAREGHTAAPFDYWGQGTLVTVSS	DIKMTQSPSFLSASVGDRVTLNCKASQNIDKYLNWYQQKLGESPKLLIYNTNNLQTGIPSRFSGSGSGTDFTLTISSLQPEDVATYFCLQHISRPRTFGGGTHLTVL			None	None	1bfo:HG:FE:BA:DC	2015	2016.0	CD52	Aratana Pharmaceuticals		Canine T-cell lymphoma			
Tanezumab	Whole mAb	-zumab	G2	Kappa	Phase-III	Active	QVQLQESGPGLVKPSETLSLTCTVSGFSLIGYDLNWIRQPPGKGLEWIGIIWGDGTTDYNSAVKSRVTISKDTSKNQFSLKLSSVTAADTAVYYCARGGYWYATSYYFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQSISNNLNWYQQKPGKAPKLLIYYTSRFHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQEHTLPYTFGQGTKLEIK			4edw:HL	None	None	2008	2009.0	NGFB	Rinat Neuroscience;Pfizer		Back pain;Cancer pain;Musculoskeletal pain;Pain	Diabetic neuropathies;Postherpetic neuralgia		
Tanibirumab	Whole mAb	-umab	G1	Lambda	Phase-II	Active	QMQLVQSGAEVKKPGASVKLSCKASGYTFSSYWMHWVRQAPGQRLEWMGEINPGNGHTNYNEKFKSRVTITVDKSASTAYMELSSLRSEDTAVYYCAKIWGPSLTSPFDYWGQGTLVTVSS	NFMLTQPPSVSVSPGKTARITCRGDNLGDVNVHWYQQRPGQAPVLVMYYDADRPSGIPERFSGSNSGNTATLTISGVEAGDEADYYCQVWDRTSEYVFGTGTKVTVL			None	None	None	2018	2019.0	KDR	PharmAbcine;3SBio		Glioblastoma;Breast cancer	Cancer;Choroidal neovascularisation;Solid tumours		Olinvacimab and Tanibirumab are the same mAb
Tarextumab	Whole mAb	-umab	G2	Kappa	Phase-II	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSSGMSWVRQAPGKGLEWVSVIASSGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSIFYTTWGQGTLVTVSS	DIVLTQSPATLSLSPGERATLSCRASQSVRSNYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYSNFPITFGQGTKVEIK			None	None	None	2013	2014.0	NOTCH2&3	OncoMed Pharmaceuticals		Pancreatic cancer;Small cell lung cancer	Solid tumours	MorphoSys HuCAL Phage Display;XmAb Engineering Technology	
Tarlatamab	Bispecific scFv	-amab	na;na	Kappa;Lambda	TBC	Active	QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKCLEWIGYVYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAVTGFYFDYWGQGTLVTVSS	EIVLTQSPGTLSLSPGERVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGCGTKLEIK	EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS	QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL	None;None	None;None	None;None	2020		DLL3;CD3E	TBC	TBC	TBC	TBC		
Tavolimab	Whole mAb	-imab	G1	Kappa	Phase-II	Discontinued	QVQLQESGPGLVKPSQTLSLTCAVYGGSFSSGYWNWIRKHPGKGLEYIGYISYNGITYHNPSLKSRITINRDTSKNQYSLQLNSVTPEDTAVYYCARYKYDYDGGHAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGSALPWTFGQGTKVEIK			None	None	None	2016	2018.0	TNFSF4	European Network of Gynaecological Oncological Trial Groups;MedImmune			Ovarian cancer;Solid tumours		Tavolimab and Tavolixizumab are the same mAb
Tavolixizumab	Whole mAb	-xizumab	G1	Kappa	Phase-II	Discontinued	QVQLQESGPGLVKPSQTLSLTCAVYGGSFSSGYWNWIRKHPGKGLEYIGYISYNGITYHNPSLKSRITINRDTSKNQYSLQLNSVTPEDTAVYYCARYKYDYDGGHAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGSALPWTFGQGTKVEIK			None	None	None	2016	2018.0	TNFSF4	European Network of Gynaecological Oncological Trial Groups;MedImmune			Ovarian cancer;Solid tumours		Tavolimab and Tavolixizumab are the same mAb
Tebentafusp	scFv Fusion	-fusp		Kappa	Phase-II	Active	EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSS	AIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIK			None	None	None	2017	2018.0	CD3E	Immunocore;MedImmune		Malignant melanoma;Uveal melanoma			T-Beta section specific for PMEL peptide 280-288 presented by MH1
Tebotelimab	Bispecific scFv with Crossover	-imab	G4	Kappa;Kappa	Phase-I	Active	QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWMNWVRQAPGQGLEWIGVIHPSDSETWLDQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCAREHYGTSPFAYWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASESVDNYGMSFMNWFQQKPGQPPKLLIHAASNQGSGVPSRFSGSGSGTDFTLTISSLEPEDFAVYFCQQSKEVPYTFGGGTKVEIK	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWMGDINPDNGVTIYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREADYFYFDYWGQGTTLTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDVSSVVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFGGGTKLEIK	None;None	None;None	None;None	2019		PDCD1;LAG3	MacroGenics		Solid tumours;Hematologic-blood cancer			
Teclistamab	Bispecific mAb	-amab	G4	Lambda;Lambda	Phase-I	Active	QLQLQESGPGLVKPSETLSLTCTVSGGSISSGSYFWGWIRQPPGKGLEWIGSIYYSGITYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHDGAVAGLFDYWGQGTLVTVSS	SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQPPGQAPVVVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEAVYYCQVWDSSSDHVVFGGGTKLTVL	EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSWFAYWGQGTLVTVSS	QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNLWVFGGGTKLTVL	None;None	None;None	None;None	2018		TNFRSF17;CD3E	Genmab;Janssen Research & Development		Multiple myeloma			
Telazorlimab	Whole mAb	-imab	G1	Kappa	Phase-II	Active	QVTLKESGPALVKPTQTLTLTCSFSGFSLSTSGMGVGWIRQPPGKALEWIAHIWWDDDKYYNTALKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIDWDGFAYWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASSSVSYMHWYQQKPGQAPRPWIYATSNRATGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCQQWSSNPWTFGQGTKVEIK			None	None	None	2019		TNFRSF4	Glenmark Pharmaceuticals		Atopic dermatitis			
Telisotuzumab	Whole mAb ADC	-zumab	G1	Kappa	Phase-I	Discontinued	QVQLVQSGAEVKKPGASVKVSCKASGYIFTAYTMHWVRQAPGQGLEWMGWIKPNNGLANYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSEITTEFDYWGQGTLVTVSS	DIVMTQSPDSLAVSLGERATINCKSSESVDSYANSFLHWYQQKPGQPPKLLIYRASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPLTFGGGTKVEIK			None	None	None	2016	2017.0	MET	Pierre Fabre;AbbVie			Solid tumours		
Temelimab	Whole mAb	-imab	G4	Kappa	Phase-II	Active	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEMHWVRQAPGQGLEWIGAVAPETGGTAYNQKFKGRATITADKSTSTAYMELSSLRSEDTAVYYCTSTVVPFAYWGQGTLVTVSS	QIQLTQSPSSLSASVGDRVTITCSASSSVSYMYWYQQKPGKAPKAWIYRTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYQSLPLTFGGGTKVEIK			None	None	None	2018	2019.0	MRSV envelope protein	GeNeuro		Multiple sclerosis;Type 1 diabetes mellitus;Chronic inflammatory demyelinating polyradiculoneuropathy			
Tenatumomab	Whole mAb Radiolabelled	-omab	G2b	Kappa	Phase-I	Discontinued	EIQLQQSGPELVKPGASVKVSCKASGYAFTSYNMYWVKQSHGKSLEWIGYIDPYNGVTSYNQKFKGKATLTVDKSSSTAYMHLNSLTSEDSAVYYCARGGGSIYYAMDYWGQGTSVTVSS	DIVMTQAAPSVPVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPLTFGAGTKLELK			None	None	None	2007	2008.0	TNC	sigma-tau SpA			Cancer		
Teplizumab	Whole mAb	-zumab	G1	Kappa	Phase-III	Active	QVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISRDNSKNTAFLQMDSLRPEDTGVYFCARYYDDHYCLDYWGQGTPVTVSS	DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQIT			None	None	None	2007	2008.0	CD3E	Immune Tolerance Network;MacroGenics;National Institute of Diabetes and Digestive and Kidney Diseases;National Institutes of Health (USA);Provention Bio;Tolerance Therapeutics		Type 1 diabetes mellitus	Multiple sclerosis;Psoriasis;Psoriatic arthritis		
Tepoditamab	Bispecific mAb	-amab	G1	Kappa;Kappa	Phase-I	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAKGTTGDWFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK	QVQLVQSGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAAIWYNARKQDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGTGYNWFDPWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK	None;None	None;None	None;None	2017	2018.0	CLEC12A;CD3E	Genmab;Janssen Research & Development		Multiple myeloma			
Teprotumumab	Whole mAb	-umab	G1	Kappa	Preregistration	Active	QVELVESGGGVVQPGRSQRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWFDGSSTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARELGRRYFDLWGRGTLVSVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASKRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSKWPPWTFGQGTKVESK			None	None	None	2009	2010.0	IGF1R	Genmab;Roche;Horizon Therapeutics plc		Graves ophthalmopathy	Diabetic macular oedema;Advanced breast cancer;Hodgkin's disease;Non-Hodgkin's lymphoma;Non-small cell lung cancer;Sarcoma;Solid tumours	Medarex UltiMAb Mouse	
Tesidolumab	Whole mAb	-umab	G1	Lambda	Phase-II	Active	EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIGPFFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDTPYFDYWGQGTLVTVSS	SYELTQPLSVSVALGQTARITCSGDSIPNYYVYWYQQKPGQAPVLVIYDDSNRPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCQSFDSSLNAEVFGGGTKLTVL			None	None	None	2014	2015.0	C5	MorphoSys;Novartis		Paroxysmal nocturnal haemoglobinuria	Choroiditis;Dry age-related macular degeneration;Panuveitis;Thrombotic microangiopathy;Wet age-related macular degeneration	MorphoSys HuCAL Phage Display;XmAb Engineering Technology	
Tesnatilimab	Whole mAb	-imab	G4	Kappa	Phase-II	Active	QVHLQESGPGLVKPSETLSLTCTVSDDSISSYYWSWIRQPPGKGLEWIGHISYSGSANYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCANWDDAFNIWGQGTMVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK			None	None	None	2019		KLRK1	Janssen Research & Development		Crohn's disease			
Tezepelumab	Whole mAb	-umab	G2	Lambda	Phase-III	Active	QMQLVESGGGVVQPGRSLRLSCAASGFTFRTYGMHWVRQAPGKGLEWVAVIWYDGSNKHYADSVKGRFTITRDNSKNTLNLQMNSLRAEDTAVYYCARAPQWELVHEAFDIWGQGTMVTVSS	SYVLTQPPSVSVAPGQTARITCGGNNLGSKSVHWYQQKPGQAPVLVVYDDSDRPSWIPERFSGSNSGNTATLTISRGEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL			5j13:CB	None	None	2015	2016.0	TSLP	Amgen;AstraZeneca;Bispebjerg Hospital;Lund University;MedImmune;University of Copenhagen;University of Newcastle in Australia		Asthma;Atopic dermatitis			
Tibulizumab	Bispecific Mixed mAb and scFv	-zumab	G4	Kappa;Kappa	Phase-I	Discontinued	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGYYDILTGYYYYFDYWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDSTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK	QVQLVQSGAEVKKPGSSVKVSCKASGYKFTDYHIHWVRQAPGQCLEWMGVINPTYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSS	DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGETYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGCGTKLEIK	None;None	None;None	None;6nou:AA/6nov:AB	2017	2018.0	TNFSF13B;IL17A	Eli Lilly			Rheumatoid arthritis;Sjogren's syndrome		
Ticilimumab	Whole mAb	-umab	G2	Kappa	Phase-III	Active	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK			5ggu:HL:AB/5ggv:HL	None	None	2005	2008.0	CTLA4	AIO Studien gGmbH;Amgen;ARCAGY/GINECO Group;AstraZeneca;Azienda Ospedaliera Universitaria Senese;Canadian Cancer Trials Group;Charite - Universitatsmedizin Berlin;Dana-Farber Cancer Institute;Fondazione IRCCS Istituto Nazionale dei Tumori;Grupo Espanol de Tumores Neuroendocrinos;Hoosier Cancer Research Network;Immunocore;Institute Gustave-Roussy;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);Northwestern University;Pfizer;Seoul National University Hospital;UNICANCER;University College London;University of Maryland Greenbaum Cancer Center;Yonsei University College of Medicine		Head and neck cancer;Liver cancer;Mesothelioma;Non-small cell lung cancer;Renal cell carcinoma;Small cell lung cancer;Solid tumours;Urogenital cancer;Biliary cancer;Bladder cancer;Breast cancer;Cholangiocarcinoma;Colorectal cancer;Endometrial cancer;Fallopian tube cancer;Gallbladder cancer;Gastric cancer;Gastrointestinal cancer;Germ cell and embryonal neoplasms;Glioblastoma;Lung cancer;Neuroendocrine tumours;Oropharyngeal cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Prostate cancer;Sarcoma;Soft tissue sarcoma;Thyroid cancer;Haematological malignancies;Malignant melanoma;Oesophageal cancer;Cervical cancer;Diffuse large B cell lymphoma;Gynaecological cancer;Myelodysplastic syndromes;Vulvovaginal cancer		Abgenix XenoMouse	Tremelimumab and Ticilimumab are the same mAb
Tidutamab	Bispecific Mixed mAb and scFv	-amab	G1	Kappa;Lambda	Phase-I	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMAWFRQAPGKGLEWVSFISNLGYSIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARAPYDYDSFDPMDYWGQGTLVTVSS	DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRNRKNYLAWYQQKPDQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYYLWTFGGGTKVEIK	EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS	QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVL	None;None	None;None	None;None	2018		SSTR2;CD3E	ICON;Xencor		Gastrointestinal stromal tumours;Neuroendocrine tumours			
Tigatuzumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGDSMITTDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSYRTFGQGTKVEIK			None	None	None	2007	2008.0	TNFRSF10B	Daiichi Sankyo Company;University of Alabama at Birmingham			Breast cancer;Colorectal cancer;Liver cancer;Lymphoma;Non-small cell lung cancer;Ovarian cancer;Pancreatic cancer		
Tilavonemab	Whole mAb	-emab	G4	Kappa	Phase-II	Active	EVKVVESGGGLVQPGGSMKLSCVVSGFTFSNYWVNWVRQAPGKGLEWVAQIRLKSDNYATHYEESVKGRFTISRDDSKSSVYLQMNNLRAEDSGIYYCTNWEDYWGQGTTVTVSS	DIVLTQSPDSLAVSLGERATISCRASQSVSTSRYSYIHWYQQKPGQPPKLLIKYASNLESGVPSRFGSGSGTDFTLNIHPLEPEDFATYYCHHSWEIPLTFGQGTKLEIK			None	None	None	2018		MAPT	AbbVie;C2N Diagnostics		Alzheimer's disease;Progressive supranuclear palsy			
Tildrakizumab	Whole mAb	-zumab	G1	Kappa	Approved	Active	QVQLVQSGAEVKKPGASVKVSCKASGYIFITYWMTWVRQAPGQGLEWMGQIFPASGSADYNEKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGGGFAYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRTSENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGIPFTFGQGTKVEIK			None	None	None	2012	2013.0	IL23A	Almirall S.A.;Merck & Co;Schering-Plough;Sun Pharmaceutical Industries	Plaque psoriasis	Ankylosing spondylitis;Intervertebral disc degeneration;Non-radiographic axial spondyloarthritis;Psoriatic arthritis	Autoimmune disorders		
Tilogotamab	Whole mAb	-amab	G1	Kappa	Phase-I/II	Active	QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTHMHWVRQAPGQRLEWIGRIDPANGNTEYDQKFQGRVTITVDTSASTAYMELSSLRSEDTAVYYCARWGTNVYFAYWGQGTLVTVSS	DIQLTQSPSSLSASVGDRVTITCSASSSVSYMYWYQQKPGKAPKPWIYRTSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYHSYPPTFGGGTVEIK			None	None	None	2019		TNFRSF10B	Genmab		Solid tumours			
Tilvestamab	Whole mAb	-amab	G1	Kappa	Phase-I	Active	EVQLVESGGGLVQPGGSLRLSCAASGYSFTDFYINWWVRQAPGKGLEWVARIFPGGDNTYYNEKFKGRFTLSADTSKSTAYLQMNSLRAEDTAVYYCARRGLYYAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGIPYLHWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCSQGTHVPPTFGQGTKVEIK			None	None	None	2019	2020.0	AXL	BerGenBio		Cancer			
Timigutuzumab	Whole mAb	-zumab	G1	Kappa	Phase-I	NFD	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK			1fvc:DC:BA/4hkz:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD	1fve:BA:DC/4x4x:AB:CD/6bgt:BA	5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL	1997	1998.0	ERBB2	Roche	Breast cancer				Timigutuzumab is a biosimilar of Trastuzumab and Coprelotamab with an identical Variable region. Cinrebafusp have identical V domain.
Timolumab	Whole mAb	-umab	G4	Kappa	Phase-II	Active	QVQLVESGGGVVQPGRSLRLSCAASGFTFFSYAMHWVRQTPGKGLEWVAVIWFDGSNENYVDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDAWSYFDYWGQGTLVTVSS	VIQLTQSPSSLSASVGDRVTITCRASQGISRALAWYQQKPGKGPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK			None	None	None	2015	2016.0	AOC3	Acorda Therapeutics;Biotie Therapies Corp.;Seikagaku Corporation		Primary sclerosing cholangitis	Inflammation;Plaque psoriasis;Rheumatoid arthritis		
Tinurilimab	Whole mAb	-imab	G2	Kappa	Phase-I	Active	QVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGIGVGWIRQPPGKALEWLAHIWWNDNKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARISLPYFDYWGQGTTLTVSS	DIQLTQSPSFLSASVGDRVTITCKASQNVGTAVAWYQQKPGKAPKLLIYSASNRYTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQYSSYPLTFGGGTKVEIK			None	None	None	2019	2020.0	CEACAM6	Bayer;German Cancer Research Center		Solid tumours			
Tiragolumab	Whole mAb	-umab	G1	Kappa	Phase-II	Active	EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGKTYYRFKWYSDYAVSVKGRITINPDTSKNQFSLQLNSVTPEDTAVFYCTRESTTYDLLAGPFDYWGQGTLVTVSS	DIVMTQSPDSLAVSLGERATINCKSSQTVLYSSNNKKYLAWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPFTFGPGTKVEIK			None	None	None	2017	2018.0	TIGIT	Genentech		Non-small cell lung cancer;Solid tumours			
Tislelizumab	Whole mAb	-zumab	G4	Kappa	Preregistration	Active	QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGVHWIRQPPGKGLEWIGVIYADGSTNYNPSLKSRVTISKDTSKNQVSLKLSSVTAADTAVYYCARAYGNYWYIDVWGQGTTVTVSS	DIVMTQSPDSLAVSLGERATINCKSSESVSNDVAWYQQKPGQPPKLLINYAFHRFTGVPDRFSGSGYGTDFTLTISSLQAEDVAVYYCHQAYSSPYTFGQGTKLEIK			None	None	None	2017	2018.0	PDCD1	BeiGene;Celgene Corporation		Hodgkin's disease;Gastric cancer;Liver cancer;Nasopharyngeal cancer;Non-small cell lung cancer;Oesophageal cancer;Lung cancer;Lymphoma;Urogenital cancer;Solid tumours;Ovarian cancer;Renal cancer			
Tisotumab	Whole mAb	-umab	G1	Kappa	Phase-II	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSSISGSGDYTYYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSPWGYYLDSWGQGTLVTVSS	DIQMTQSPPSLSASAGDRVTITCRASQGISSRLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQGTKLEIK			None	None	None	2015	2016.0	F3	Genmab;Seattle Genetics		Bladder cancer;Cervical cancer;Endometrial cancer;Fallopian tube cancer;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Solid tumours			
Tocilizumab	Whole mAb	-zumab	G1	Kappa	Approved	Active	QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQPPGRGLEWIGYISYSGITTYNPSLKSRVTMLRDTSKNQFSLRLSSVTAADTAVYYCARSLARTTAMDYWGQGSLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIK			None	None	None	2004	2004.0	IL6R	Assistance Publique Hopitaux de Paris;Charite - Universitatsmedizin Berlin;Chugai Pharmaceutical;Hospital for Special Surgery;JW Pharmaceutical;Roche;University Hospital Inselspital;University Hospital;Osaka University Tubingen;University of Bern;University of Pittsburgh	Drug hypersensitivity;Giant cell arteritis;Giant lymph node hyperplasia;Juvenile rheumatoid arthritis;Rheumatoid arthritis;Vasculitis	Adult-onset Still's disease;Osteoarthritis;Systemic scleroderma;Amyotrophic lateral sclerosis;Dermatomyositis;Familial Mediterranean fever;Polymyalgia rheumatica;Polymyositis;Pulmonary arterial hypertension;Schnitzler syndrome;Urogenital cancer	Chronic lymphocytic leukaemia;Ankylosing spondylitis;Crohn's disease;Multiple myeloma;Pancreatic cancer;Systemic lupus erythematosus		
Tomaralimab	Whole mAb	-imab	G4	Kappa	Phase-II	Active	EVQLVQSGSELKKPGASVKLSCKASGFTFTTYGINWVRQAPGQGLEWIGWIYPRDGSTNFNENFKDRATITVDTSASTAYMELSSLRSEDTAVYFCARLTGGTFLDYWGQGTTVTVSS	DIVLTQSPATLSLSPGERATLSCRASESVEYYGTSLMQWYQQKPGQPPKLLIFGASNVESGVPDRFSGSGSGTDFTLKISRVEAEDVGMYFCQQSRKLPWTFGGGTKVEIK			None	None	None	2018		TLR2	Opsona Therapeutics		Delayed graft function;Myelodysplastic syndromes;Cancer	Autoimmune disorders;Inflammation		
Tomuzotuximab	Whole mAb	-ximab	G1	Kappa	Phase-II	Active	QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVST	DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK			None	6au5:DC:BA/6axp:BA:DC/6ayn:BA:DC/6azk:DC:BA/6azl:BA:DC/5i76:DC:BA/1yy8:DC:BA/5th2:DC:BA/5f88:DC:BA/5hyq:DC:BA/5ir1:DC:BA/5ivz:DC:BA/5iv2:DC:BA/5t1k:DC:BA/5t1l:DC:BA/5id0:DC:BA/5id1:DC:BA/5euk:DC:BA/5ff6:DC:BA/5iop:DC:BA/5icy:DC:BA/5itf:DC:BA/5etu:DC:BA/5t1m:DC:BA/5esq:DC:BA/5icz:DC:BA/5i2i:DC:BA/5icx:DC:BA/5hpm:DC:BA/4gw5:DC:BA/4gw1:DC:BA/1yy9:DC/4krp:DC/4kro:DC	5gz0:BA:DC/6arp:BA:DC/6aru:CB	2016	2017.0	EGFR	Glycotope		Head and neck cancer;Colorectal cancer;Gastric cancer;Non-small cell lung cancer;Renal cancer;Solid tumours		GlycoExpress Technology	
Toripalimab	Whole mAb	-imab	G4	Kappa	Approved	Active	QGQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPIHGLEWIGVIESETGGTAYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREGITTVATTYYWYFDVWGQGTTVTVSS	DVVMTQSPLSLPVTLGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPLTFGQGTKLEIK			6jbt:HL	None	None	2018	2019.0	PDCD1	Fudan University;Peking University;Shanghai Junshi Biosciences;Sun Yat-Sen University	Malignant melanoma	Nasopharyngeal cancer;Oesophageal cancer;Biliary cancer;Gastric cancer;Non-small cell lung cancer;Solid tumours;Urogenital cancer;Head and neck cancer;Alveolar soft part sarcoma;Breast cancer;Cancer;Liver cancer;Lymphoma;Neuroendocrine tumours;Renal cancer			
Tosatoxumab	Whole mAb	-umab	G1	Lambda	Phase-III	Active	EVQMVQSGAEVKKPGEPLKISCKGSGYKFGTHWIGWVRQRPGKGLEWMGIIHPADSETKYSPSFQGQVSFSADKSSNTAYLHWSTLRASDTAMYYCARRSGSSSWYALDFWGQGTMVTVSS	QSVLTQSPSASGTPGQRVTISCSGGSSNIGSNTVNWYQQFPGAAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGLYVFGTGTKVTVL			None	None	None	2013	2014.0	Toxin A	Aridis Pharmaceuticals;Kenta Biotech		Nosocomial pneumonia	Sepsis		
Tovetumab	Whole mAb	-umab	G2	Kappa	Phase-II	Discontinued	QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMNWIRQAPGKGLEWVSYISSSGSIIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGRIAARGMDVWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVSITCRPSQSFSRYINWYQQKPGKAPKLLIHAASSLVGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYSNPPITFGQGTRLEMK			None	None	None	2013	2014.0	PDGFRA	Cambridge Antibody Technology;MedImmune			Glioblastoma;Non-small cell lung cancer;Solid tumours		
Tralokinumab	Whole mAb	-umab	G4	Lambda	Phase-III	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLSWVRQAPGQGLEWMGWISANNGDTNYGQEFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDSSSSWARWFFDLWGRGTLVTVSS	SYVLTQPPSVSVAPGKTARITCGGNIIGSKLVHWYQQKPGQAPVLVIYDDGDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDTGSDPVVFGGGTKLTVL			5l6y:HL	None	None	2009	2010.0	IL13	Cambridge Antibody Technology;Icahn School of Medicine at Mount Sinai;LEO Pharma;MedImmune		Atopic dermatitis;Alopecia areata	Asthma;Chronic obstructive pulmonary disease;Idiopathic pulmonary fibrosis;Ulcerative colitis		
Trastuzumab	Whole mAb	-zumab	G1	Kappa	Approved	NFD	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK			1fvc:DC:BA/4hkz:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED	1fve:BA:DC/4x4x:AB:CD/6bgt:BA	5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL	1997	1998.0	ERBB2	Roche	Breast cancer				Timigutuzumab is a biosimilar of Trastuzumab and Coprelotamab with an identical Variable region. Cinrebafusp have identical V domain.
Tregalizumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Discontinued	EEQLVESGGGLVKPGGSLRLSCAASGFSFSDCRMYWLRQAPGKGLEWIGVISVKSENYGANYAESVRGRFTISRDDSKNTVYLQMNSLKTEDTAVYYCSASYYRYDVGAWFAYWGQGTLVTVSS	DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSYIYWYQQKPGQPPKLLIYLASILESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSRELPWTFGQGTKVEIK			None	None	None	2010	2011.0	CD4	Biotest AG			Multiple sclerosis;Plaque psoriasis;Rheumatoid arthritis		
Tremelimumab	Whole mAb	-umab	G2	Kappa	Phase-III	Active	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK			5ggu:HL:AB/5ggv:HL	None	None	2005	2008.0	CTLA4	AIO Studien gGmbH;Amgen;ARCAGY/GINECO Group;AstraZeneca;Azienda Ospedaliera Universitaria Senese;Canadian Cancer Trials Group;Charite - Universitatsmedizin Berlin;Dana-Farber Cancer Institute;Fondazione IRCCS Istituto Nazionale dei Tumori;Grupo Espanol de Tumores Neuroendocrinos;Hoosier Cancer Research Network;Immunocore;Institute Gustave-Roussy;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);Northwestern University;Pfizer;Seoul National University Hospital;UNICANCER;University College London;University of Maryland Greenbaum Cancer Center;Yonsei University College of Medicine		Head and neck cancer;Liver cancer;Mesothelioma;Non-small cell lung cancer;Renal cell carcinoma;Small cell lung cancer;Solid tumours;Urogenital cancer;Biliary cancer;Bladder cancer;Breast cancer;Cholangiocarcinoma;Colorectal cancer;Endometrial cancer;Fallopian tube cancer;Gallbladder cancer;Gastric cancer;Gastrointestinal cancer;Germ cell and embryonal neoplasms;Glioblastoma;Lung cancer;Neuroendocrine tumours;Oropharyngeal cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Prostate cancer;Sarcoma;Soft tissue sarcoma;Thyroid cancer;Haematological malignancies;Malignant melanoma;Oesophageal cancer;Cervical cancer;Diffuse large B cell lymphoma;Gynaecological cancer;Myelodysplastic syndromes;Vulvovaginal cancer		Abgenix XenoMouse	Tremelimumab and Ticilimumab are the same mAb
Trevogrumab	Whole mAb	-umab	G4	Kappa	Phase-II	Active	EVQVLESGGDLVQPGGSLRLSCAASGFTFSAYAMTWVRQAPGKGLEWVSAISGSGGSAYYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAKDGAWKMSGLDVWGQGTTVIVSS	DIQMTQSPASLSASVGDRVTITCRASQDISDYLAWYQQKPGKIPRLLIYTTSTLQSGVPSRFRGSGSGTDFTLTISSLQPEDVATYYCQKYDSAPLTFGGGTKVEIK			None	None	None	2015	2016.0	MSTN	Regeneron Pharmaceuticals;Sanofi		Muscular atrophy;Musculoskeletal disorders		VelocImmune Mouse	
Tusamitamab	Whole mAb	-amab	G1	Kappa	TBC	Active	EVQLQESGPGLVKPGGSLSLSCAASGFVFSSYDMSWVRQTPERGLEWVAYISSGGGITYAPSTVKGRFTVSRDNAKNTLYLQMNSLTSEDTAVYYCAAHYFGSSGPFAYWGQGTLVTVSS	DIQMTQSPASLSASVGDRVTITCRASENIFSYLAWYQQKPGKSPKLLVYNTRTLAEGVPSRFSGSGSGTDFSLTISSLQPEDFATYYCQHHYGTPFTFGSGTKLEIK			None	None	None	2020		CEACAM5	TBC	TBC	TBC	TBC		
Ublituximab	Whole mAb	-ximab	G1	Kappa	Phase-III	Active	QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGGIYPGNGDTSYNQKFKGKATLTVGKSSSTAYMQLSSLTSEDSAVYFCARYDYNYAMDYWGQGTSVTVSS	QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPARFSGSGSGTSYSFTISRVEAEDAATYYCQQWTFNPPTFGGGTRLEIK			None	None	None	2010	2011.0	MS4A1	LFB Biotechnologies;rEVO Biologics;Johns Hopkins University;TG Therapeutics Inc		Chronic lymphocytic leukaemia;Multiple sclerosis;Diffuse large B cell lymphoma;Follicular lymphoma;Mantle-cell lymphoma;Non-Hodgkin's lymphoma;Neuromyelitis optica		EMABling Platform	
Ulocuplumab	Whole mAb	-umab	G4	Kappa	Phase-I/II	Active	EVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPGKGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARDYGGQPPYYYYYGMDVWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIK			None	None	None	2013	2014.0	CXCR4	Bristol-Myers Squibb;Medarex;University of Bari		Acute myeloid leukaemia;Solid tumours;Waldenstrom's macroglobulinaemia;Multiple myeloma;Neuroectodermal tumours	B-cell lymphoma;B-cell prolymphocytic leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma 		
Upifitamab	Whole mAb	-amab	G1	Kappa	Phase-I	Active	QVQLVQSGAEVVKPGASVKMSCKASGYTFTGYNIHWVKQAPGQGLEWIGAIYPGNGDTSYKQKFRGRATLTADTSTSTVYMELSSLRSEDSAVYYCARGETARATFAYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCSASQDIGNFLNWYQQKPGKTVKVLIYYTSSLYSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYSKLPLTFGQGTKLELK			None	None	None	2019		SLC34A2	Mersana Therapeutics		Solid tumours			
Urabrelimab	Whole mAb	-imab	G4	Kappa	Phase-I	Active	QVQLQESGPGLVKPSGTLSLTCAVSGVSIRSINWWNWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLNSVTAADTAVYYCARDGGIAVTDYYYYGLDVWGQGTTVTVSS	EIVLTQSPATLSLSPGERATLSCRASESVSSNLAWYQQKPGQAPRLLIYGAFNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSDWFTFGGGTKVEIK			None	None	None	2019		CD47	Surface Oncology		Cancers;Multiple myeloma			
Urelumab	Whole mAb	-umab	G4	Kappa	Phase-II	Active	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQSPEKGLEWIGEINHGGYVTYNPSLESRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYGPGNYDWYFDLWGRGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPALTFGGGTKVEIK			6mhr:AB:DE	None	None	2010	2011.0	TNFRSF9	Bristol-Myers Squibb;National Cancer Institute (USA);Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;University of Chicago;Medarex		Non-Hodgkin's lymphoma;Solid tumours;Glioblastoma;Multiple myeloma	Colorectal cancer;Head and neck cancer;Malignant melanoma;Non-small cell lung cancer	Medarex UltiMAb Mouse	"Jain paper: ""VL sequence modified at one position to match patent document (US7659384) and JK germline"""
Ustekinumab	Whole mAb	-umab	G1	Kappa	Approved	Active	EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRYSPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPYTFGQGTKLEIK			3hmw:HL/3hmx:HL	None	None	2008	2009.0	IL12B	Centocor Inc;Janssen Biotech;Medarex	Crohn's disease;Plaque psoriasis;Psoriatic arthritis	Ulcerative colitis;Spondylarthritis;Systemic lupus erythematosus;Atopic dermatitis	Multiple sclerosis;Palmoplantar pustulosis;Primary biliary cirrhosis;Rheumatoid arthritis;Sarcoidosis	Medarex UltiMAb Mouse	
Utomilumab	Whole mAb	-umab	G2	Lambda	Phase-II	Active	EVQLVQSGAEVKKPGESLRISCKGSGYSFSTYWISWVRQMPGKGLEWMGKIYPGDSYTNYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGYGIFDYWGQGTLVTVSS	SYELTQPPSVSVSPGQTASITCSGDNIGDQYAHWYQQKPGQSPVLVIYQDKNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYTGFGSLAVFGGGTKLTVL			6a3w:GH:DE:AB:JK/6mi2:DE:AB	None	None	2016	2017.0	TNFRSF9	Dana-Farber Cancer Institute;Immatics US;Kite Pharma;Kyowa Hakko Kirin;M. D. Anderson Cancer Center;Pfizer		Breast cancer;Oropharyngeal cancer;Solid tumours;B-cell lymphoma;Diffuse large B cell lymphoma;Colorectal cancer;Follicular lymphoma;Ovarian cancer	Non-Hodgkin's lymphoma	MorphoSys HuCAL Phage Display	
Vadastuximab	Whole mAb ADC	-ximab	G1	Kappa	Phase-III	Discontinued	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYDINWVRQAPGQGLEWIGWIYPGDGSTKYNEKFKAKATLTADTSTSTAYMELRSLRSDDTAVYYCASGYEDAMDYWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTINCKASQDINSYLSWFQQKPGKAPKTLIYRANRLVDGVPSRFSGSGSGQDYTLTISSLQPEDFATYYCLQYDEFPLTFGGGTKVEIK			None	None	None	2015	2016.0	CD33	Seattle Genetics			Acute myeloid leukaemia;Myelodysplastic syndromes		
Valanafusp	Whole mAb Fusion	-fusp	G1	Kappa	Phase-II	Active	QVQLQQSGPELVKPGALVKISCKASGYTFTNYDIHWVKQRPGQGLEWIGWIYPGDGSTKYNEKFKGKATLTADKSSSTAYMHLSSLTSEKSAVYFCAREWAYWGQGTLVTVSA	DIQMTQSPSSLSASLGERVSLTCRASQDIGGNLYWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYSSSPWTFGGGTKMEIK			None	5kqv:PQ:CD/4zxb:CD	3loh:CD/2dtg:CD/3w14:CD:PQ	2017	2018.0	INSR	ArmaGen Technologies		Mucopolysaccharidosis I			
Vanalimab	Whole mAb	-imab	G1	Lambda	Phase-I	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWLSYISGGSSYIFYADSVRGRFTISRDNSENALYLQMNSLRAEDTAVYYCARILRGGSGMDLWGQGTLVTVSS	QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYNVYWYQQLPGTAPKLLIYGNINRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDKSISGLVFGGGTKLTVL			None	None	None	2017	2019.0	CD40	Alligator Bioscience;Janssen Biotech		Solid tumours			Mitazalimab and Vanalimab are the same mAb
Vandortuzumab	Whole mAb ADC	-zumab	G1	Kappa	Phase-I	Discontinued	EVQLVESGGGLVQPGGSLRLSCAVSGYSITSDYAWNWVRQAPGKGLEWVGYISNSGSTSYNPSLKSRFTISRDTSKNTLYLQMNSLRAEDTAVYYCARERNYDYDDYYYAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKSSQSLLYRSNQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYNYPRTFGQGTKVEIK			None	None	None	2014	2015.0	STEAP1	Roche;Genentech			Cancers;Prostate Cancer		
Vantictumab	Whole mAb	-umab	G2	Lambda	Phase-I	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSHYTLSWVRQAPGKGLEWVSVISGDGSYTYYADSVKGRFTISSDNSKNTLYLQMNSLRAEDTAVYYCARNFIKYVFANWGQGTLVTVSS	DIELTQPPSVSVAPGQTARISCSGDNIGSFYVHWYQQKPGQAPVLVIYDKSNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYANTLSLVFGGGTKLTVL			None	None	None	2013	2014.0	FZD Family	Bayer HealthCare Pharmaceuticals;OncoMed Pharmaceuticals		Breast cancer;Non-small cell lung cancer;Pancreatic cancer		MorphoSys HuCAL Phage Display	
Vanucizumab	Bispecific mAb	-zumab	G1	Lambda;Kappa	Phase-II	Discontinued	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSPNPYYYDSSGYYYPGAFDIWGQGTMVTVSS	QPGLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHYVFGTGTKVTVL	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK	4imk:AD:BC/4iml:HL:AB;1bj1:HL:KJ	None;None	None;6bft:AB:HL/1cz8:HL:YX	2014	2015.0	ANGPT2;VEGFA	Roche			Solid tumours;Colorectal cancer		
Varisacumab	Whole mAb	-umab	G1	Kappa	Phase-II/III	Active	QVQLVQSGAEVKKPGASVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGRSMVRGVIIPFNGMDVWGQGTTVTVSS	DIRMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK			None	None	None	2016	2017.0	VEGFA	Peregrine Pharmaceuticals;University of Texas Southwestern Medical Center;Affitech Research AS		Breast cancer;Colorectal cancer;Eye disorders;Glioblastoma;Non-small cell lung cancer			
Varlilumab	Whole mAb	-umab	G1	Kappa	Phase-II	Active	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYDMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSGNWGFFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQGISRWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNTYPRTFGQGTKVEIK			None	None	None	2014	2015.0	CD27	Celldex Therapeutics Inc;Oncothyreon;University of California at San Francisco;University of Virginia		Malignant melanoma;Solid tumours;Non-Hodgkin's lymphoma;Renal cell carcinoma;Glioma	Haematological malignancies;Prostate cancer;Breast cancer;Ovarian cancer		
Vatelizumab	Whole mAb	-zumab	G4	Kappa	Phase-II/III	Discontinued	QVQLQESGPGLVKPSETLSLTCTVSGFSLTNYGIHWIRQPPGKGLEWLGVIWARGFTNYNSALMSRLTISKDNSKNQVSLKLSSVTAADTAVYYCARANDGVYYAMDYWGQGTLVTVSS	DFVMTQSPAFLSVTPGEKVTITCSAQSSVNYIHWYQQKPDQAPKKLIYDTSKLASGVPSRFSGSGSGTDYTFTISSLEAEDAATYYCQQWTTNPLTFGQGTKVEIK			None	None	None	2011	2012.0	ITGA2	Chromos Molecular Systems;Glenmark Pharmaceuticals S.A.;Sanofi			Cancer;Chronic obstructive pulmonary disease;Multiple sclerosis;Retinal disorders;Rheumatoid arthritis;Ulcerative colitis		
Vedolizumab	Whole mAb	-zumab	G1	Kappa	Approved	Active	QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSS	DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIK			None	None	None	2008	2009.0	ITGA4_ITGB7	Medical College of Wisconsin;Millennium Pharmaceuticals;Takeda;Takeda Oncology	Crohn's disease;Ulcerative colitis	Graft-versus-host disease;Coeliac disease;Malignant melanoma			
Veltuzumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Active	QVQLQQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVKQAPGQGLEWIGAIYPGMGDTSYNQKFKGKATLTADESTNTAYMELSSLRSEDTAFYYCARSTYYGGDWYFDVWGQGTTVTVSS	DIQLTQSPSSLSASVGDRVTMTCRASSSVSYIHWFQQKPGKAPKPWIYATSNLASGVPVRFSGSGSGTDYTFTISSLQPEDIATYYCQQWTSNPPTFGGGTKLEIK			None	None	None	2007	2008.0	MS4A1	Immunomedics;Weill Cornell Medical College		Idiopathic thrombocytopenic purpura;Non-Hodgkin's lymphoma;Follicular lymphoma	Chronic lymphocytic leukaemia;Rheumatoid arthritis		
Vesencumab	Whole mAb	-umab	G1	Kappa	Phase-I	Discontinued	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSQISPAGGYTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGELPYYRMSKVMDVWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQYFSSYLAWYQQKPGKAPKLLIYGASSRASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLGSPPTFGQGTKVEIK			2qqn:HL	None	None	2010	2011.0	NRP1	Genentech;Roche			Solid tumours		
Vibecotamab	Bispecific Mixed mAb and scFv	-amab	G1	Kappa;Kappa	Phase-I	Active	QVQLQQSGAEVKKPGASVKVSCKASGYTFTDYYMKWVKQSHGKSLEWMGDIIPSNGATFYNQKFKGKATLTVDRSTSTAYMELSSLRSEDTAVYYCARSHLLRASWFAYWGQGTLVTVSS	DFVMTQSPDSLAVSLGERATINCKSSQSLLNTGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGGGTKLEIK	EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS	QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVLEPK	None;None	None;None	None;None	2018		IL3RA;CD3E	Xencor		Haematological malignancies			
Vibostolimab	Whole mAb	-imab	G1	Kappa	Phase-I	Active	EVQLVQSGAEVKKPGSSVKVSCKASGYTFSSYVMHWVRQAPGQGLEWIGYIDPYNDGAKYAQKFQGRVTLTSDKSTSTAYMELSSLRSEDTAVYYCARGGPYGWYFDVWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCRASEHIYSYLSWYQQKPGKVPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQHHFGSPLTFGQGTRLEIK			None	None	None	2019	2020.0	TIGIT	Merck		Solid tumours			
Vilobelimab	Whole mAb	-imab	G4	Kappa	Phase-II	Active	QVQLQQSGPQLVRPGTSVKISCKASGYSFTTFWMDWVKQRPGQGLEWIGRIDPSDSESRLDQRFKDRATLTVDKSSSTVYMQLSSPTSEDSAVYYCARGNDGYYGFAYWGQGTLVTVSS	DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMKWYQQKPGQPPKLLIYAASNLQSGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPYTFGGGTKLEIK			None	None	None	2019		C5	InflaRX		Hidradenitis suppurativa;Inflammation			Chimeric
Visilizumab	Whole mAb	-zumab	G2	nd	Phase-III	Discontinued	QVQLVQSGAEVKKPGASVKVSCKASGYTFISYTMHWVRQAPGQGLEWMGYINPRSGYTHYNQKLKDKATLTADKSASTAYMELSSLRSEDTAVYYCARSAYYDYDGFAYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQKPGKAPKRLIYDTSKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSNPPTFGGGTKVEIK			None	None	None	2000	2001.0	CD3E	PDL BioPharma			Crohn's disease;Graft-versus-host disease;Psoriasis;Renal transplant rejection;Ulcerative colitis		
Vixarelimab	Whole mAb	-imab	G4-G1	Lambda	Phase-II	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYEINWVRQATGQGLEWMGWMNPNSGYTGYAQKFQGRVTMTRDTSISTAYMEMSSLRSEDTAVYYCARDIVAANTDYYFYYGMDVWGQGTTVTVSS	QSVLTQPPSASGTPGQRVTISCSGSNSNIGSNTVNWYHQLPGTAPKLLIYNINKRPSGVPDRFSGSKSGSSASLAISGLQSEDEADYYCSTWDDSLDGVVFGGGTKLTVL			None	None	None	2020		OSMR	Kiniksa Pharmaceuticals		Prurigo nodularis;Pruritus;Atopic dermatitis			
Vobarilizumab	Bispecific Single Domains (VH-VH')	-zumab			Phase-II	Active	EVQLVESGGGLVQPGGSLRLSCAASGSVFKINVMAWYRQAPGKGRELVAGIISGGSTSYADSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYYCAFITTESDYDLGRRYWGQGTLVTVSS		EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS		None;None	None;None	None;None	2015	2016.0	IL6R;ALB	Ablynx		Rheumatoid arthritis;Systemic lupus erythematosus		Nanobody Technology	
Vofatamab	Whole mAb	-amab	G1	Kappa	Phase-I/II	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFTSTGISWVRQAPGKGLEWVGRIYPTSGSTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARTYGIYDLYVDYTEYVMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDVDTSLAWYKQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTGHPQTFGQGTKVEIK			None	None	4wv1:BA:ED/3grw:HL	2018		FGFR3	BioClin Therapeutics;Rainier Therapeutics		Bladder cancer;Urogenital cancer;Achondroplasia	Multiple myeloma;Solid tumours		
Volagidemab	Whole mAb	-emab	G2	Kappa	Phase-II	Active	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVMWYDGSNKDYVDSVKGRFTISRDNSKNTLYLQMNRLRAEDTAVYYCAREKDHYDILTGYNYYYGLDVWGQGTTVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSVQPEDFVTYYCLQHNSNPLTFGGGTKVEIK			None	4lf3:ED:BA/5xf1:HL:CD/5xez:CD:HL/4ers:HL	None	2018		GCCR	Amgen;REMD Biotherapeutics		Type 1 diabetes mellitus;Type 2 diabetes mellitus;Metabolic disorders			
Vonlerolizumab	Whole mAb	-zumab	G1	Kappa	Phase-II	Discontinued	EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQGLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRSEDTAVYYCVLAPRWYFSVWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHTLPPTFGQGTKVEIK			6okn:AB:CB/6ogx:CD	None	None	2015	2017.0	TNFRSF4	Genentech			Solid tumours;Urogenital cancer		Vonlerolizumab and Pogalizumab are the same mAb
Vopratelimab	Whole mAb	-imab	G1	Kappa	Phase-II	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYWMDWVRQAPGKGLVWVSNIDEDGSITEYSPFVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCTRWGRFGFDSWGQGTLVTVSS	DIVMTQSPDSLAVSLGERATINCKSSQSLLSGSFNYLTWYQQKPGQPPKLLIFYASTRHTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHHHYNAPPTFGPGTKVDIK			None	None	None	2017	2018.0	ICOS	Jounce Therapeutics		Solid tumours			
Vorsetuzumab	Whole mAb ADC	-zumab	G1	Kappa	Phase-I	Discontinued	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLKWMGWINTYTGEPTYADAFKGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDYGDYGMDYWGQGTTVTVSS	DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSREVPWTFGQGTKVEIK			None	None	None	2012	2013.0	CD70	Seattle Genetics			Autoimmune disorders;Cancer;Inflammation;Plaque psoriasis		
Vudalimab	Bispecific Mixed mAb and scFv	-imab	G1	Kappa;Kappa	TBC	Active	EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVSFISYDGNNKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARTGWLGPFDYWGQGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK	EVQLVESGGGLVKPGGSLRLSCVASGFTFSNYWMNWVRQAPGKGLEWVAEIRLYSNNYATHYAESVKGRFTISRDDSKSTLYLQMNNLKTEDTGVYYCTRYYGNYGGYFDVWGRGTLVTVSS	EIVLTQSPATLSASPGERVTLTCRASQSVGNDVAWYQQKPGQAPRLLINYASHRYTGVPDRFTGSGYGTEFTLTISSVQSEDFGVYYCQQDFSSPRTFGGGTKVEIK	None;None	None;None	5tru:HL/5xj3:DE/6jc2:HL/6rp8:hl;None	2020		CTLA4;PDCD1	TBC	TBC	TBC	TBC		
Vulinacimab	Whole mAb	-imab	G1	Kappa	Phase-I	Active	QVQLVQSGGGLVQPGGSLRLSCAASGFSFSTYAMSWVRQAPGKGLEWVSGISGSGGTTHYADSVKGRFTISRDNSKNTVNLQMNSLRAEDTAVYYCAKGLWFGEGLWGQGTLVTVSS	DVVMTQSPLSLPVTLGQPASISCRSSQSLYYRSGYTFLDWYVQKPGQSPQLLIYQSSKRDSGVPDRISGSGSGTDFTLRISRVEAEDVGVYYCFQGTHWPYTFGQGTKLEIK			None	None	None	2019		VEGFR2	Henlix		Solid tumours			
Vunakizumab	Whole mAb	-zumab	G1	Kappa	Phase-I/II	Active	EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEVHWVRQAPGQGLEWMGVIDPGTGGVAYNQKFEGRVTMTADTSTSTAYMELRSLRSDDTAVYYCTRYSLFYGSSPYAMDYWGQGTLVTVSS	EIVLTQSPDFQSVTPKEKVTITCSASSSVNYMHWFQQKPDQSPKLWIYRTSNLASGVPSRFSGSGSGTDYTLTINSLEAEDAATYYCQQRSSYPWTFGQGTKLEIK			None	None	None	2016	2017.0	IL17A	Atridia;Jiangsu Hengrui Medicine Co.		Plaque psoriasis;Psoriasis;Spondylarthritis	Autoimmune disorders		
Xentuzumab	Whole mAb	-zumab	G1	Lambda	Phase-II	Active	QVELVESGGGLVQPGGSLRLSCAASGFTFTSYWMSWVRQAPGKGLELVSSITSYGSFTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARNMYTHFDSWGQGTLVTVSS	DIVLTQPPSVSGAPGQRVTISCSGSSSNIGSNSVSWYQQLPGTAPKLLIYDNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCQSRDTYGYYWVFGGGTKLTVL			None	None	None	2015	2016.0	IGF1&IGF2	Boehringer Ingelheim;Eli Lilly		Breast cancer;Prostate cancer	Non-small cell lung cancer;Solid tumours	MorphoSys HuCAL Phage Display	
Zagotenemab	Whole mAb	-emab	G4	Kappa	Phase-II	Active	EVQLVQSGAEVKKPGESLKISCKGSGYTFSNYWIEWVRQMPGKGLEWMGEILPGSDSIKYEKNFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARRGNYVDDWGQGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCRSSQSLVHSNQNTYLHWYQQKPGQAPRLLIYKVDNRFSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCSQSTLVPLTFGGGTKVEIK			None	None	None	2019	2020.0	MAPT	Eli Lilly		Alzheimer's disease			
Zalifrelimab	Whole mAb	-imab	G1	Kappa	Phase-II	Active	EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVGLMGPFDIWGQGTMVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSRYLGWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK			None	None	None	2018		CTLA4	4-Antibody;Ludwig Institute for Cancer Research;Agenus;Recepta biopharma		Non-small cell lung cancer;Cervical cancer;Cancer			
Zalutumumab	Whole mAb	-umab	G1	Kappa	Phase-II	Discontinued	QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS	AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK			None	None	None	2005	2006.0	EGFR	Danish Head and Neck Cancer Group;Genmab			Head and neck cancer;Colorectal cancer;Non-small cell lung cancer		
Zampilimab	Whole mAb	-imab	G4	Kappa	Phase-I/II	Active	EVQLLESGGGLVQPGGSLRLSCAASGFTLSTHAMSWVRQAPGKGLEWVATISSGGRSTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARLISTYWGQGTLVTVSS	DITMTQSPSSLSASVGDRVTITCKASQDINSYLTWFQQKPGKAPKILIYLVNRLVDGVPSRFSGSGSGQDYALTISSLQPEDFATYYCLQYDDFPYTFGQGTKVEIK			None	None	None	2018	2019.0	TGM2	UCB		Autoimmune disorders			
Zanidatamab	Bispecific mAb	-amab	G1	Kappa;Kappa	Phase-II	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTFADYTMDWVRQAPGKGLEWVGDVNPNSGGSIYNQRFKGRFTFSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPATFGQGTKVEIK	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK	None;6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED	None;1fve:BA:DC/4x4x:AB:CD/6bgt:BA	1s78:FE:DC/4llu:AB:CD/1l7i:HL/4llw:CD:AB/5vsh:CD:EF:AB:HL/4lly:AB:CD;5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL	2019	2020.0	ERBB2;ERBB2	Zymeworks		Gastric cancer;Oesophageal cancer;Breast cancer;Solid tumours	Ovarian cancer		Biparatopic Bispecific
Zanolimumab	Whole mAb	-umab	G1	Kappa	Phase-III	Discontinued	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVINWFDPWGQGTLVTVSS	DIQMTQSPSSVSASVGDRVTITCRASQDISSWLAWYQHKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPYTFGQGTKLEIK			None	None	None	2004	2004.0	CD4	Emergent BioSolutions;Genmab			Cutaneous T-cell lymphoma;Peripheral T-cell lymphoma;Psoriasis;Rheumatoid arthritis	Medarex HuMAb Mouse	
Zatuximab	Whole mAb	-ximab	G1	Kappa	Phase-II	Active	EVQLQQPGSELVRPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGNIYPGSRSTNYDEKFKSKATLTVDTSSSTAYMQLSSLTSEDSAVYYCTRNGDYYVSSGDAMDYWGQGTSVTVSS	DIQMTQTTSSLSASLGDRVTISCRTSQDIGNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDFSLTINNVEQEDVATYFCQHYNTVPPTFGGGTKLEIK			None	None	None	2012	2013.0	EGFR	Symphogen;Merck		Colorectal cancer;Glioma;Non-small cell lung cancer	Head and neck cancer;Oesophageal cancer		Futuximab and Zatuximab are the same mAb
Zelminemab	Whole mAb	-emab	G1	Kappa	Phase-II	Active	QVQLVESGAEVVKPGASVKVSCKASGFTFSRFAMHWVRQAPGQGLEWMGVISYDGGNKYYAESVKGRVTMTRDTSTSTLYMELSSLRSEDTAVYYCARGYDVLTGYPDYWGQGTLVTVSS	DIQLTQSPSFLSASVGDRVTITCRASQSIGRSLHWYQQKPGKAPKLLIKYASQSLSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCHQSSRLPFTFGPGTKVDIK			None	None	None	2019		ADCYAP1R1	Amgen		Migraine			
Zenocutuzumab	Bispecific mAb	-zumab	G1	Kappa;Kappa	Phase-II	Active	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDHGSRHFWSYWGFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK	QVQLVQSGAEVKKPGASVKLSCKASGYTFTAYYINWVRQAPGQGLEWIGRIYPGSGYTSYAQKFQGRATLTADESTSTAYMELSSLRSEDTAVYFCARPPVYYDSAWFAYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK	5o4o:BA/5o7p:BA;5o4g:BA	None;None	None;None	2017	2018.0	ERBB3;ERBB2	Merus		Breast cancer;Colorectal cancer;Gastric cancer;Non-small cell lung cancer	Endometrial cancer;Ovarian cancer	GlymaxX Technology	
Ziltivekimab	Whole mAb	-imab	G1	Kappa	Phase-II	Active	EVQLVESGGGLVQPGGSLRLSCAASGFTISSNYMIWVRQAPGKGLEWVSDLYYYAGDTYYADSVKGRFTMSRDISKNTVYLQMNSLRAEDTAVYYCARWADDHPPWIDLWGRGTLVTVSS	DIQMTQSPSTLSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKVLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQSWLGGSFGQGTKLEIK			None	None	None	2019	2020.0	IL6	AstraZeneca;Corvidia		Cardiovascular disorders			
Zimberelimab	Whole mAb	-imab	G4	Lambda	Phase-II	Active	QLQLQESGPGLVKPSETLTLTCTVSADSISSTTYYWVWIRQPPGKGLEWIGSISYSGSTYYNPSLKSRVTVSVDTSKNQFSLKLNSVAATDTALYYCARHLGYNGRYLPFDYWGQGTLVTVSS	QSALTQPASVSGSPGQSITISCTGTSSDVGFYNYVSWYQQHPGKAPELMIYDVSNRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSISTWVFGGGTKLTVL			None	None	None	2020		PDCD1	Harbin Gloria Pharmaceuticals;WuXi Biologics;Arcus Biosciences;Beijing Cancer Hospital;Guangzhou Gloria Biosciences;Strata Oncology		Cervical cancer;Non-small cell lung cancer;Breast cancer;Cancer;Ovarian cancer;Pancreatic cancer;Solid tumours;Hodgkin's disease			
Zolbetuximab	Whole mAb	-ximab	G1	Kappa	Phase-III	Active	QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWINWVKQRPGQGLEWIGNIYPSDSYTNYNQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCTRSWRGNSFDYWGQGTTLTVSS	DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPFTFGSGTKLEIK			None	None	None	2017	2018.0	CLDN18	Ganymed Pharmaceuticals		Gastric cancer;Oesophageal cancer;Pancreatic cancer;Solid tumours			Zolbetuximab and Claudiximab are the same mAb
Zolimomab	Whole mAb	-omab	G2a	Kappa	Approved	Discontinued	QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS	QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEIN			1sy6:HL	None	None	1988	1989.0	CD3E	Cancer Research UK;Ortho-McNeil;XOMA			Diabetes mellitus;Graft-versus-host disease;Renal transplant rejection;Rheumatoid arthritis		Muromonab and Zolimomab are the same mAb. LC IMGT 127 is N not K as in Jain paper.
Zuberitamab	Whole mAb	-amab	G1	Kappa	Phase-II	Active	EVQLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDYSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSS	DIELSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLEIK			None	None	3bky:HL	2019		MS4A1	Zhejiang Hisun Pharmaceutical		Diffuse large B-cell lymphoma			Chimeric
